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The β2 adrenergic receptor (β2AR) regulates smooth muscle relaxation in the 
vasculature and airways. Long- and Short-acting β-agonists (LABAs/SABAs) are 
widely used in treatment of chronic obstructive pulmonary disorder (COPD) and 
asthma. Despite their widespread clinical use we do not understand well the dominant 
β2AR regulatory pathways that are stimulated during therapy and bring about 
tachyphylaxis, which is the loss of drug effects. Thus, an understanding of how the 
β2AR responds to various β-agonists is crucial to their rational use. Towards that end 
we have developed deterministic models that explore the mechanism of drug- induced 
β2AR regulation. These mathematical models can be classified into three classes; (i) 
Six quantitative models of SABA-induced G protein coupled receptor kinase (GRK)-
mediated β2AR regulation; (ii) Three phenomenological models of salmeterol (a 
LABA)-induced GRK-mediated β2AR regulation; and (iii) One semi-quantitative, 
unified model of SABA-induced GRK-, protein kinase A (PKA)-, and 
phosphodiesterase (PDE)-mediated regulation of β2AR signalling. The various models 
were constrained with all or some of the following experimental data; (i) GRK-mediated 
β2AR phosphorylation in response to various LABAs/SABAs; (ii) dephosphorylation of 
the GRK site on the β2AR; (iii) β2AR internalisation; (iv) β2AR recycling; (v) β2AR 
desensitisation; (vi) β2AR resensitisation; (vii) PKA-mediated β2AR phosphorylation in 
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response to a SABA; and (viii) LABA/SABA induced cAMP profile ± PDE inhibitors. 
The models of GRK-mediated β2AR regulation show that plasma membrane 
dephosphorylation and recycling of the phosphorylated β2AR are required to reconcile 
with the measured dephosphorylation kinetics. We further used a consensus model to 
predict the consequences of rapid pulsatile agonist stimulation and found that although 
resensitisation was rapid, the β2AR system retained the memory of prior stimuli and 
desensitised much more rapidly and strongly in response to subsequent stimuli. This 
could explain tachyphylaxis of SABAs over repeated use in rescue therapy of asthma 
patients. The LABA models show that the long action of salmeterol can be explained 
due to decreased stability of the arrestin/β2AR/salmeterol complex. This could explain 
long action of β-agonists used in maintenance therapy of asthma patients. Our 
consensus model of PKA/PDE/GRK-mediated β2AR regulation is being used to 
identify the dominant β2AR desensitisation pathways under different therapeutic 
regimens in human airway cells. In summary our models represent a significant 
advance towards understanding agonist-specific β2AR regulation that will aid in a 
more rational use of the β2AR agonists in the treatment of asthma. 
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Introduction 
1.1. GPCRs 
The G protein-coupled, seven-transmembrane receptors (GPCRs or 7TM 
receptors) are encoded by one of the largest gene families (Vroling, Sanders et al. 
2011).  They are targeted by > 25% FDA approved drugs (Flower 1999; 
Overington, Al-Lazikani et al. 2006). Based on hydropathy profiles and the crystal 
structure of bovine rhodopsin (Palczewski, Kumasaka et al. 2000) and human β2 
adrenergic receptor (β2AR) (Cherezov, Rosenbaum et al. 2007; Rasmussen, Choi 
et al. 2007; Rosenbaum, Cherezov et al. 2007) all GPCRs are thought to have the 
same molecular architecture, consisting of seven trans-membrane domains, three 
extra- and intra-cellular loops, an extracellular amino-terminal and an intracellular 
carboxyl-terminal domain. GPCRs are named thus due to their action as guanine-
nucleotide exchange factors at the heterotrimeric G proteins (comprising of an α-, 
β- and γ-subunit) leading to the exchange of GDP for GTP bound to the α-subunit 
post GPCR activation (Gilman 1987; Johnston and Siderovski 2007). The GTP-
bound α-subunit and the released βγ-dimer of the G protein can stimulate or inhibit 
effector molecules like adenylyl and guanylyl cyclases, phospholipases, 
phosphodiesterases and phosphoinositide 3-kinases (PI3Ks) (Rall and Sutherland 
1962; Sutherland, Rall et al. 1962; Jelsema and Axelrod 1987; Tang and Gilman 
1991; Camps, Carozzi et al. 1992). This in turn activates or inhibits the production 
of second messengers like cyclic adenosine monophosphate (cAMP), cyclic 
guanosine monophosphate (cGMP), diacylglycerol (DAG), inositol trisphosphate 
(IP3), phosphatidyl inositol trisphosphate (PIP3), arachidonic acid (AA) and 
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phosphatidic acid (PA), in addition to the opening or closing of a variety of ion 
channels (Sutherland and Robison 1966; Hardman, Robison et al. 1971; Goldberg, 
O'Dea et al. 1973; Lapetina and Michell 1973; Brindley and Waggoner 1996). 
GPCRs can be classified into six families based on functional similarity and 
sequence homology (Attwood and Findlay 1994; Kolakowski 1994; Bjarnadottir, 
Gloriam et al. 2006).  The similarity in 7TM topology across GPCR families is 
believed to be due to evolutionary convergence (Bockaert and Pin 1999). GPCR 
families have >20% amino acid sequence similarity within their trans-membrane 
helices (Kolakowski 1994; Kristiansen 2004). β2AR belongs to the family of 
Rhodospsin-like GPCRs. This Class A family is classified into 19 subgroups (A1-
A19) based on phylogenetic analysis of 241 sequences (Joost and Methner 2002), 
and the β2AR which is a Gαs-coupled GPCR belongs to subfamily A17.   
1.1.1. Adrenergic Receptor Classification 
Adrenergic receptors are a Class A GPCR that are targetted by 
catecholamines like norepinephrine and epinephrine. They can be classified 
into two groups, α and β, with subtypes in each group. The α receptors are 
either α1 or α3 where they are coupled to Gq and Gi respectively.  All three 
subtypes of β receptors – β1, β 2 and β3 are coupled to Gs and can activate 
adenylyl cyclases leading to cAMP-mediated downstream signalling. The major 
locale of β1AR is the cardiac muscle where it is involved in regulation of 
cardiac output by increasing speed and force of contraction. The β2AR is near 
ubiquitously expressed and regulates smooth muscle relaxation in uterus, GI 
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tract, bronchi and blood vessels. The β3AR is predominantly found in adipose 
tissue and regulates lipolysis and thermogenesis.  
1.1.2. Role of β2AR in Smooth Muscle Relaxation 
β2AR agonists increase cAMP levels in airway smooth muscle that is 
consistent with their relaxation response (Katsuki and Murad 1977; Wong and 
Buckner 1978; Rinard, Rubinfeld et al. 1979; Zhou, Newsholme et al. 1992). 
Phosphodiesterases degrade cAMP and abrogate cAMP-mediated signalling. 
Phosphodiesterase inhibitors (4,5-dihydro-6-[4-(1H-imidazol-1-yl)phenyl]-5-
methyl-3(2H)-pyridazinone (CI-930), 3-isobutyl-1-methylxanthine (IBMX), 4-(3-
Butoxy-4-methoxybenzyl)-2-imidazolidinone (Ro 20-1724), rolipram, 
siguazodan, SK&F 94120 and zaprinast) mimic and increase the response to 
β2AR agonists (Harris, Connell et al. 1989; Torphy, Zhou et al. 1991; Qian, 
Naline et al. 1993; Torphy, Undem et al. 1993). cAMP analogues (8-(4-
chlorophenylthio)-cAMP, 8-bromo-cAMP, 8-(6-aminohexylamino)-cAMP, N6-
benzoyl-cAMP, N6-2’-O-dibutyryl-cAMP and N6-monobutyryl cAMP) mimic the 
relaxation effect of β2AR agonists (Bresnahan, Borowitz et al. 1975; Napoli, 
Gruetter et al. 1980; Heaslip, Giesa et al. 1987; Francis, Noblett et al. 1988). 
β2AR agonists regulate cAMP-dependent protein kinase A (PKA) in airway 
smooth muscle consistent with the relaxation response (Torphy, Freese et al. 
1982; Giembycz and Diamond 1990; Zhou, Newsholme et al. 1992). Myosin 
Light Chain Phosphatase (MLCP) can be activated by cyclic GMP/AMP 
activated kinases (Janssen, Tazzeo et al. 2004). cAMP can also cross activate 
cyclic GMP activated kinase (PKG) in smooth muscle (Francis, Noblett et al. 
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1988). PKA phosphorylation of the IP3 receptor inhibits binding of IP3 to the 
receptor. This reduces release of calcium from internal pools in response to 
bronchioconstrictors (Schramm, Chuang et al. 1995).   
Bronchioconstrictors can activate kinases like ROCK which inactivate MYPT1 
a subunit of MLCP. This inhibitory phosphorylation on MYPT1 can be blocked 
by phosphorylation of MYPT1 by PKG/PKA (Wooldridge, MacDonald et al. 
2004). MLCK can be activated by ERK1(Morrison, Sanghera et al. 1996). 
MAPK Phosphatase 1 (MKP1) dephosphorylates and inactivates ERK1. MKP1 
can be activated by agonist activation of β2AR (Brondello, Brunet et al. 1997; 
Price, Chik et al. 2004). β2AR activation by agonists leads to membrane 
hyperpolarisation through activation of big conductance Ca2+ activated K 
channels (BKCa) in the plasma membrane counteracting electrical excitation 
and subsequent Ca2+ influx. Iberiotoxin mediated inhibition of BKCa prevents 
hyperpolarisation and β2AR mediated ASM relaxation (Jones, Charette et al. 
1993). The α subunit of BKCa has been shown to interact with β2AR and 
AKAP79 in ASM (Liu, Shi et al. 2004). PKA phosphorylation of the BKCa 
channel subunits has an activating or inactivating effect based on the splice 
isoform (Tian, Coghill et al. 2004). PKG also differentially activates various 
splice isoforms of the BKCa channel (Zhou, Arntz et al. 2001). All this (Figure 
1.1) provides compelling evidence that β2AR activation mediates smooth 
muscle relaxation through both cAMP-dependent and -independent signalling.  
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Figure 1.1 β2AR Agonist Induced ASM Relaxation/Contraction Pathways. 
The arrows indicate a direct or indirect effect; green arrows indicate an activating effect and 
the red arrows indicate an inhibitory effect.  
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In the light of the role of β2AR in ASM relaxation, β2AR agonists are used in 
the palliative treatment of inflammatorydiseases of the airways such as chronic 
obstructive pulmonary disease (COPD) and asthma (Connors, Dawson et al. 
1996; Celli and MacNee 2004; Donohue 2004). These include short-acting 
(SABA) and long-acting (LABA) β-agonists. SABAs are generally used as 
required for immediate relief in the treatment of acute asthma while LABAs are 
recommended for longer term use in combination with an inhaled steroid. β-
agonists have both bronchodilatory and bronchoprotective effects. 
Bronchodilation is the effect of lung inflation post airway smooth muscle 
relaxation. Bronchoprotection is the resistance to contraction on inhalation of a 
bronchioconstrictor like methacholine which acts on muscarinic receptors. 
Excessive and prolonged use of β2AR agonists leads to tachyphylaxis – which 
is the loss of both broncholdilatory and bronchoprotective effects of the drug 
(Keighley 1966; Van Metre 1969; Davis and Conolly 1980; Sears 2002; 
Abramson, Walters et al. 2003). It has been noted that repeated aerosolised 
administration of a β2AR agonist like salbutamol or isoproterenol leads to a 
decrease in spirometric measures like the forced vital capacity (FVC) and 
forced expiratory volume in 1 second (FEV1)in asthmatic patients within 180 
min (isoproterenol) and beyond 300 min (salbutamol) (Choo-Kang, Simpson et 
al. 1969). There is an increased rebound in bronchoconstriction in asthmatics 
following a prolonged isoproterenol treatment (Paterson, Evans et al. 1971) 
where rebound is defined as a fall in mean peak flow below baseline after 
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stopping treatment with β-agonists. Even healthy individuals show reduced 
bronchodilatory effects (as measured by specific airway conductance) over a 4 
week long exposure to a β-agonist like salbutamol (Holgate, Baldwin et al. 
1977). The tachyphylaxis to β-agonists has been attributed to desensitisation 
of the β2AR (Davis and Conolly 1980; Bruynzeel 1984; Bruynzeel, Meurs et al. 
1985). Thus understanding β2AR desensitisation mechanisms would help in 
rationale design of drug combinations that would allow for longer action of β-
agonists by inhibiting the agonist-specific dominant modes of β2AR 
desensitisation.   
1.1.3. β2AR Desensitisation 
β2AR desensitisation occurs in response to agonist-induced activation of the 
receptor. The major mechanisms by which desensitisation of β2AR signalling 
can occur are: (1) Phosphorylation of the receptor (Benovic, Kuhn et al. 1987; 
Kobilka, MacGregor et al. 1987; Bouvier, Hausdorff et al. 1988; Lohse, 
Lefkowitz et al. 1989; Roth, Campbell et al. 1991; Yuan, Friedman et al. 1994; 
Vaughan, Millman et al. 2006), (2) internalisation of uncoupled β2AR (Sher and 
Clementi 1985; Yu, Lefkowitz et al. 1993; Barak, Tiberi et al. 1994; Ferguson, 
Downey et al. 1996; January, Seibold et al. 1997; Conway, Minor et al. 1999; 
Seibold, Williams et al. 2000; Clark and Knoll 2002), and (3) 
phosphodiesterase activation and subsequent degradation of cAMP (Barber, 
Goka et al. 1992; Broadley 1999). The extent of activation of individual 
modules of desensitisation is dependent on the amount, duration, type of β-
agonist and amount of β2AR (Whaley, Yuan et al. 1994; Tran, Friedman et al. 
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2004). Figure 1.2 describes these overall reaction modules in β2AR 
desensitisation. 
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Figure 1.2 Modules of β2AR Regulation. 
The reactions involved in β2AR regulation are classified into G-protein independent and 
dependent pathways. The ‘+’ signs indicate a stimulatory effect of the modules along the 
direction of the arrow and a ‘-‘ sign indicates an inhibitory effect.  
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1.1.3.1. β2AR Phosphorylation 
Kinase-mediated phosphorylation of the βAR is a major mode of receptor 
desensitisation (Stadel, Nambi et al. 1983; Hertel and Perkins 1984; Sibley, 
Benovic et al. 1987; Clark, Kunkel et al. 1988; Krupnick and Benovic 1998). 
At low concentrations of hormones or β-agonists there is a high potency, 
cAMP-dependent protein kinase A mediated, heterologous desensitisation 
of β2AR signalling (Benovic, Pike et al. 1985; Clark, Friedman et al. 1987; 
Clark, Kunkel et al. 1988; Lohse, Benovic et al. 1990; Tran, Friedman et al. 
2004). In concurrence with this it was shown that mutation of putative PKA 
phosphorylation sites on β2AR led to marked reduction of desensitisation at 
low agonist concentrations (Hausdorff, Bouvier et al. 1989; Yuan, Friedman 
et al. 1994).  Our group has shown that PKA activation leads to 
phosphorylation of at least S262 (Seibold, Williams et al. 2000). Mass 
spectrometric analysis (Trester-Zedlitz, Burlingame et al. 2005) of a small 
peptide containing the S262 site showed a stoichiometry of phosphorylation 
of one, which is in agreement with our results with PKA-mediated 
phosphorylation. Desensitisation of the receptor is achieved by causing a 
reduction in coupling efficiency of the receptor to Gs by from ~20% (GRK) to 
~ 60% (PKA).   
At high agonist concentrations there is a low potency, receptor occupancy 
driven, G-protein receptor kinase (GRK) mediated receptor phosphorylation 
(Benovic, Strasser et al. 1986; Clark, Kunkel et al. 1988; Palczewski 1997; 
Tran, Friedman et al. 2004). GRK activation leads to the phosphorylation of 
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at least three serine residues on the carboxyl tail of the receptor, viz. S355, 
S356, and S364 (Seibold, Williams et al. 2000). Our group has further 
characterised the S-355,356 sites by the use of phosphosite-specific 
antibody directed against pS-355,356 (Tran, Friedman et al. 2004). Mass 
spectrometric analysis of a peptide (residues 349-372) containing the three 
GRK sites showed that it was phosphorylated in HEK293 cells (Trester-
Zedlitz, Burlingame et al. 2005). Stoichiometric analysis indicated that 
phosphorylation of S-355,356 was agonist-dependent, and S-364 was 
constitutively phosphorylated. Through siRNA studies it has been shown 
that GRK6 knockdown reduced S-355,356 phosphorylation by fivefold 
whereas GRK2 depletion increased isoproterenol-induced phosphorylation 
of these sites by 1.5 fold as detected by liquid chromatography–tandem 
mass spectrometry (Nobles, Xiao et al. 2011). In the same studies it has 
been suggested that GRK6-mediated phosphorylation of the β2AR is 
important for β-arrestin–dependent ERK1/2 activation, whereas GRK2 
phosphorylation of the receptor may inhibit β2AR signalling to ERK1/2 on 
account of differences in reduction of ERK1/2 phosphorylation by either 
isoproterenol or carvedilol. 
The GRK-mediated desensitisation of β2AR-mediated AC activation 
dominates only at higher agonist concentration due to the lack of significant 
amplification steps as compared to the PKA-mediated desensitisation at 
lower agonist concentrations. Our group has studied the effect of varying 
levels of β2AR expression on activation of adenylyl cyclase through Gαs 
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(Whaley, Yuan et al. 1994). We predicted the relationship between receptor 
number and EC50 of adenylyl cyclase activation. As the receptor density 
increased from 5 to 5000 fmol/mg of protein the EC50 for epinephrine 
activation of adenylyl cyclase decreased from 200 to 0.2 nM (Whaley, Yuan 
et al. 1994; Xin, Tran et al. 2008). The EC50s on treatment with isoproterenol 
for the PKA and GRK site phosphorylations respectively are 30 pM and 200 
nM in HEK 293 cells stably overexpressing the β2AR (Tran, Friedman et al. 
2004). Thus there is a large separation of the two pathways in cells with high 
β2AR levels as a function of agonist concentration. This large separation of 
the EC50s is not expected in HASMs where the receptor number is much 
lower and therefore the EC50s will approach the Kds. 
1.1.3.2. β2AR Internalisation 
PKA or GRK phosphorylation of β2AR by itself is insufficient to produce 
complete desensitisation (Lohse, Benovic et al. 1990). A cofactor called 
arrestin is required to completely desensitise the β2AR post GRK-
phosphorylation (Lohse, Benovic et al. 1990) since it completely uncouples 
the receptor from Gαs (Pan, Gurevich et al. 2003; Krasel, Bunemann et al. 
2005). Arrestins bind directly to most GRK-phosphorylated GPCRs, forming 
a stoichiometric complex that is precluded from further G protein coupling. A 
polar core located in the hinge region between the two globular domains of 
the arrestin interacts with both non-phosphorylated and GRK-
phosphorylated residues on the receptor tail (Hanson and Gurevich 2006). 
Receptor binding produces significant conformational changes in the 
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arrestin (Gurevich and Benovic 1993; Hirsch, Schubert et al. 1999; 
Vishnivetskiy, Paz et al. 1999; Vishnivetskiy, Schubert et al. 2000; 
Vishnivetskiy, Hirsch et al. 2002), whereas, conversely, arrestin binding 
stabilizes a receptor state with high agonist affinity, prompting some authors 
to characterise the receptor-arrestin complex as an alternative ternary 
complex analogous to the ternary complex of agonist-receptor-G protein in 
the absence of GTP (Gurevich, Pals-Rylaarsdam et al. 1997). 
Both GRK phosphorylation and agonist-induced β2AR activation are a 
prerequisite to arrestin binding the receptor (Krasel, Bunemann et al. 2005). 
β-arrestin binding leads to the internalisation of the receptor via recruitment 
of clathrin and protein AP-2 (Koenig and Edwardson 1997). The internalised 
receptor either recycles back to the plasma membrane in a fully sensitised 
state (Yu, Lefkowitz et al. 1993), is targetted to lysosomes for degradation 
(Williams, Barber et al. 2000) or is a scaffold for signalling proteins like 
MAPK (Pierce, Maudsley et al. 2000; Huang, Sun et al. 2004; Xu, Baillie et 
al. 2008). 
1.1.3.3. Phosphodiesterase Activity 
The PDE superfamily is grouped through functional and homology 
classification into 11 subfamilies (Soderling and Beavo 2000). Inspite of 
being encoded by just 21 genes close to 200 plus distinct PDEs are reported 
on account of extensive alternative RNA splicing and multiple promoters 
(Bingham, Sudarsanam et al. 2006). PDEs across families are functionally 
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distinguished on account of distinct combination of pharmacological 
inhibitory profiles and unique enzymatic charactersistics with individual 
families showcasing distinct allosteric modifiers of enzyme activity. Individual 
PDEs also have distinct distribution at the tissue, cellular and subcellular 
level. The PDE4A-D subfamily is subject to considerable pharmacological 
scrutiny on account of its role in various disease states like respiratory 
disease (Conti, Richter et al. 2003; Houslay, Baillie et al. 2007). Increase in 
cAMP levels is the major stimulant of airway smooth muscle relaxation 
pathways in human airway smooth mucle (HASM). In these cells, the 
physiological regulation of cAMP degradation is primarily through PDE4D 
isoforms, with minor contributions from PDE3/4B isoforms (Billington, 
Joseph et al. 1999; Le Jeune, Shepherd et al. 2002). Consistent with the 
HASM cell culture experiments PDE4D is the major phosphodiesterase in 
murine tracheal extracts and PDE4D knockout mice show reduced airway 
smooth muscle contractility (Hansen, Jin et al. 2000; Mehats, Jin et al. 
2003). In HASMs PDE4D5 seems most functionally relevant on account of 
its marked upregulation in response to elevated cAMP (Le Jeune, Shepherd 
et al. 2002; Hu, Nino et al. 2008). siRNA inhibition of PDE4D5  in HASMs 
causes a significant reduction in time required for cAMP-induced FRET to 
reach saturation in contrast to cells where PDE4D5 is uninhibited (Billington, 
Le Jeune et al. 2008).  PDE4D5 can be recruited to the β2AR by a β-arrestin 
dependent mechanism. This allows for the possibility that localised 
quenching of cAMP might happen and it would be coupled with arrestin-
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mediated desensitisation. Such a mechanism could be of significance in 
long-term regulation of the β2AR  (Perry, Baillie et al. 2002; Bolger, McCahill 
et al. 2003).  
Due to the importance of PDEs in regulating cAMP levels, PDE inhibitors 
like theophylline are used with glucocorticosteriods therapy as a second- or 
third-line treatment of asthma and COPD (Sullivan, Bekir et al. 1994; 
Weinberger and Hendeles 1996; Lim, Jatakanon et al. 2000; Rennard 2004; 
Spina 2008). Theophylline use is not favoured due to its narrow therapeutic 
index and its unwanted drug interactions with other drugs that lead to 
increase or decrease in serum concentrations of theophylline (Boswell-
Smith, Cazzola et al. 2006). It also blocks adenosine stimulation causing 
many off-target effects. Thus careful monitoring of plasma levels of 
theophylline is required while prescribing. Newer generation of PDE 
inhibitors are isoform specific like PDE4-inhibitors roflumilast and cilomilast. 
These inhibitors show promise in improving lung function and reducing 
exacerbations of respiratory distress (Rabe 2011) but they still show off-
target effects and longer term trials are needed to determine if these have 
an optimum place in COPD and asthma treatment (Cazzola, Picciolo et al. 
2011; Chong, Poole et al. 2011). 
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1.1.4. G-Protein Independent Arrestin Signalling 
A number of proteins bind arrestins and are recruited to agonist-occupied 
GPCRs, among them Src family tyrosine kinases (Luttrell, Ferguson et al. 
1999; Barlic, Andrews et al. 2000; DeFea, Vaughn et al. 2000), members of the 
c-Jun N-terminal kinase 3 (JNK3) and ERK1/2 mitogen-activated protein (MAP) 
kinase cascades (DeFea, Zalevsky et al. 2000; McDonald, Chow et al. 2000; 
Luttrell, Roudabush et al. 2001), Mdm2, an E3 ubiquitin ligase (Shenoy, 
McDonald et al. 2001), the cAMP phosphodiesterases (PDE), PDE4D3/5 
(Perry, Baillie et al. 2002), diacylglycerol kinase (Nelson, Perry et al. 2007), the 
inhibitor of nuclear factor (NF)κB, IκBα (Witherow, Garrison et al. 2004), the 
Ral-GDP dissociation stimulator (GDS), Ral-GDS (Bhattacharya, Anborgh et al. 
2002), and the Ser/Thr protein phosphatase (PP)2A (Beaulieu, Sotnikova et al. 
2005). It is via these interactions that arrestin binding to agonist-occupied 
GPCRs confers unique signalling properties, opening up a broad realm of 
previously unappreciated GPCR signal transduction.  
Since arrestin binding completely uncouples G protein from the receptor, the 
transmission of G protein-dependent and arrestin-dependent signals should be 
mutually exclusive, at least at the individual receptor level. Comparison of the 
ERK1/2 activation time course resulting from G protein signalling and from the 
arrestin-dependent formation of an ERK1/2 activation complex on the 
angiotensin AT1A, lysophosphatidic acid (LPA), type I parathyroid 
hormone/PTH-related peptide (PTH1), and β2 adrenergic receptors 
demonstrate that the onset of arrestin-dependent ERK1/2 activation coincides 
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with the waning of G protein signalling and persists as receptors internalise 
(Ahn, Shenoy et al. 2004; Gesty-Palmer, El Shewy et al. 2005; Gesty-Palmer, 
Chen et al. 2006; Shenoy, Drake et al. 2006). 
The arrestin-mediated and G-protein mediated signalling also tends to be 
spatially discrete. In the ERK1/2 cascade, it is clear that receptors that form 
stable complexes with arrestin, such as protease-activated receptor (PAR)-2, 
angiotensin AT1A, vasopressin V2, and neurokinin NK-1 receptors, activate 
ERK1/2 that accumulates in early endosomes along with the receptor (DeFea, 
Zalevsky et al. 2000; Luttrell, Roudabush et al. 2001; Tohgo, Pierce et al. 
2002). Unlike ERK1/2 activated by heterotrimeric G protein-mediated 
pathways, signalsome-associated ERK1/2 does not translocate to the cell 
nucleus and fails to induce a transcriptional response or stimulate cell 
proliferation (DeFea, Zalevsky et al. 2000; Tohgo, Pierce et al. 2002). This 
contrasts with receptors, such as the β2 adrenergic and LPA receptors, which 
form transient  complexes with arrestin that dissociate post internalisation 
(Oakley, Laporte et al. 2000; Wei, Ahn et al. 2004; Milano, Kim et al. 2006; 
Moore, Millman et al. 2007). Though, under physiologic conditions, arrestin-
mediated signalling commences concurrent with G protein activation, it is clear 
that at least some arrestin-mediated signals do not require heterotrimeric G 
protein activity. Data obtained using receptor mutants uncoupled from G-
proteins and arrestin pathway-selectiveligands have shown that arrestin-
dependent activation of ERK1/2 by the angiotensin AT1A, β2 adrenergic, and 
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PTH1 receptors is G protein-independent (Azzi, Charest et al. 2003; Wei, Ahn 
et al. 2003; Gesty-Palmer, Chen et al. 2006; Shenoy, Drake et al. 2006). 
Studies of mice lacking nonvisual arrestin isoforms suggest considerable 
functional redundancy among arrestin isoforms. Arrestin2- and arrestin3-null 
mice are grossly normal, with phenotypes that become apparent only upon 
treatment with pharmacological doses of GPCR agonists. Arrestin2-null mice 
exhibit exaggerated cardiac sensitivity to β adrenergic agonists (Conner, 
Mathier et al. 1997), whereas arrestin3-null mice demonstrate enhanced 
morphine-induced analgesia and attenuation of opiate tolerance (Bohn, 
Lefkowitz et al. 1999; Bohn, Lefkowitz et al. 2002). In each case, the 
phenotypes are consistent with impaired GPCR desensitisation rather than the 
loss of arrestin-mediated signalling. 
1.1.5. Differences in Desensitisation of β2AR and Other GPCRs 
Though β2AR is treated as a paradigm of GPCR desensitisation in textbooks 
there are differences in desensitisation mechanisms of other GPCRs. D2 is a 
dopaminergic GPCR. Locomotor hyperactivity induced by a D2 receptor agonist 
like apomorphine, is reduced in arrestin3 knockout mice (Beaulieu, Marion et al. 
2008). Likewise, the dopamine transporter knockout mice exhibit hyperactivity 
on account of increased synaptic dopamine concentration. This is reduced 
when these knockout mice are crossbred with arrestin3 knockouts, a 
paradoxical result, since GPCR-mediated responses ought to be potentitated by 
the loss of arrestin-dependent desensitisation. Similarly opioid peptides 
19 
 
stimulate rapid internalisation of the µ opioid receptors while in contrast these 
receptors fail to internalise  post-prolonged treatment with saturating 
concentrations of morphine, inspite of strong activation of receptor-mediated 
signalling via heterotrimeric G proteins (Keith, Murray et al. 1996). Morphine-
activated opioid receptors escape arrestin-dependent regulation via uncoupling 
from heterotrimeric G proteins and Dyn-dependent endocytosis (Whistler and 
von Zastrow 1998). Over expression of β-arrestin though causes increased 
receptor internalisation and desensitisation.  This suggests that under 
physiological conditions the role of arrestin in agonist-induced desensitisation 
could be different among GPCRs like D2 receptor, µ-opioid receptor and β2AR. 
1.1.6. Biased Signalling 
G protein-dependent and arrestin-dependent functions of many GPCRs can be 
dissociated pharmacologically by ligands that exhibit functional selectivity or 
“bias” favouring one pathway or the other (Kenakin 2002; Maudsley, Martin et 
al. 2005; Violin and Lefkowitz 2007; Gesty-Palmer and Luttrell 2008; Luttrell 
and Kenakin 2011). Conventional GPCR agonists and antagonists are believed 
to activate or inhibit all aspects of signalling equally, whereas “biased agonists” 
have the potential to change the signal output of a GPCR, thereby controlling 
not only the quantity but also the quality of efficacy.  A number of ligands have 
been characterised that exhibit paradoxical reversal of efficacy (e.g., acting as 
antagonists or inverse agonists of G protein signalling but behaving as agonists 
with respect to arrestin recruitment and arrestin-dependent signalling). For 
example, Sar1-Ile4-Ile8, an angiotensin AT1A receptor antagonist, promotes 
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arrestin-inducedreceptor sequestration in the absence of significant G protein 
activation (Holloway, Qian et al. 2002). Likewise, the PTH analog (D-
Trp12,Tyr34)PTH(7–34) is an inverse agonist for PTH1 receptor-Gs coupling 
but promotes arrestin-dependent receptor internalisation (Gardella, Luck et al. 
1996; Sneddon, Magyar et al. 2004). As a result, each is able to bring about 
ERK1/2 activation that is arrestin-dependent and under conditions in which G 
protein is not significantly activated (Gesty-Palmer, Chen et al. 2006). Likewise, 
(±)-1-[2,3-(dihydro-7-methyl-1H-inden-4-yl)oxy]-3-[(1-methylethyl)amino]-2-
butanol (ICI118551),  carvedilol and propranolol are β2AR ligands that show 
partial inverse agonism with respect to Gs activation, and partial agonism for 
the arrestin-mediated ERK1/2 activation (Azzi, Charest et al. 2003; Wisler, 
DeWire et al. 2007; Drake, Violin et al. 2008). Our group has shown that 
treatment of β2AR in HEK293 cells overexpressing receptor with saturating 
concentrations of salmeterol does not lead to significant internalisation (Moore, 
Millman et al. 2007). This phenomenon can be rescued by overexpression of 
arrestin. Through kinetic modeling we show that the most probable explanation 
for this is that salmeterol stabilizes a different β2AR state that in time shows 
equivalent GRK phosphorylation but has reduced affinity for arrestin, thereby 
reducing internalisation (Vayttaden, Friedman et al. 2010).  
Studies have reported that the phospholipase C (PLC)-mediated inositol 
phosphate (IP) accumulation and phospholipase A2(PLA2)-mediated 
arachidonic acid (AA) release varies based on the identity of agonists 
stimulating the human serotonin2A (5-HT2A) and 5-HT2C (Berg, Maayani et al. 
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1998; Kurrasch-Orbaugh, Watts et al. 2003). 2,5-dimethoxy-4-
methylphenylisopropylamine (DOM) and 2,5-Dimethoxyphenylisopropylamine 
(2,5-DMA) are examples of structurally close ligands. They differ only in the 
methyl group at C4. Inspite of these similarities in structure 2,5-DMA and DOM 
are good examples of biased agonists. For PLC-IP accumulation in 5-HT2C 
receptor, both ligands are partial agonistsbut, DOM is a full agonist for PLA2-
AA release, and in contrast 2,5-DMA does not have a significant PLA2-AA 
response. Taken together all these observations strongly suggest that the two-
state receptor activation model is too simplistic and one requires the invoking 
of multiple active states of the GPCRs that are differentially stabilized by 
various ligands.   
1.2. Modelling β2AR Regulation 
Given the background of β2AR regulation explained in previous sections it 
becomes increasingly clear that though the main features of β2AR desensitisation 
are GRK/PKA-mediated phosphorylation, arrestin recruitment and PDE activation, 
understanding which of these components is the dominant signalling module in 
clinically observed tachyphylaxis is not easily tractable by traditional experimental 
methods alone. This complication is because of 1) extensive use of different model 
systems for studying human β2AR desensitisation, wherein results from one model 
do not easily translate into another model; 2) simultaneous activation of various 
pathways, necessitating pharmacological or genetic manipulations to silence other 
signalling pathways; 3) isoform-specific differences of various signalling 
components in tissue distribution and signalling; and 4) G-protein independent 
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signalling. Thus it becomes necessary to first reduce all the complexities of β2AR 
signalling into a consensus mathematical model that is advised by experimental 
measurements of the system. 
Reduction of the complexities of β2AR signalling into a consensus model might 
seem counterintuitive but such model reduction has been helpful in physical 
sciences. Borrowing an example from the physical sciences, light is modeled both 
as a wave and as a particle because no one model can fully explain all the 
observable properties of light. So reducing the complexity and modeling light as a 
wave or a particle allows us to understand how light behaves under some 
experimental conditions as a wave and in other conditions as a particle. Similarly in 
order to understand β2AR desensitisation I will reduce the complexities of β2AR 
signalling into three modules viz. 1) GRK/Arrestin-mediated β2AR desensitisation; 
2) PKA-mediated β2AR desensitisation; and 3) PDE regulation. I will then test each 
module against a defined set of experimental readouts and see if a combined 
model can be created to explain β2AR desensitisation. In the process of model 
building we will understand better the different modules of β2AR desensitisation.  
My overall goal is to establish quantitatively the relevance of the major pathways of 
desensitisation with endogenous β2AR receptor in cells of human airway origin. 
Towards that end the work plan was to use HEK293 cells stably overexpressing 
β2AR and obtain rates for key steps in GRK-, PKA- and PDE-mediated β2AR 
desensitisation. Using these rates I would then develop a comprehensive model for 
these pathways and once developed extend the model to HASMs where some of 
the experimental measures are difficult to come by. A well validated and 
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constrained model could then be used to understand the agonist specific 
differences in signalling that allow differences in length of action of LABAs vs. 
SABAs. This would help in teasing out agonist specific desensitisation pathways 
that are responsible for tachyphylaxis in a clinical scenario.  
1.2.1. Other Models of β2AR 
The collision coupling model is one of the first βAR models, it suggests that 
ligand activated receptors and G-proteins can collide and transiently couple to 
activate the G-proteins (Tolkovsky and Levitzki 1981). More recent β2AR 
models simulate downstream effects of isoproterenol-induced receptor 
activation and match experimentally measured whole cell (Violin, DiPilato et al. 
2008) or near-membrane cAMP (Xin, Tran et al. 2008). Other βAR models are 
validated against more than one experimental readouts like isoproterenol 
induced -cAMP response, -PKA activation, -PLB phosphorylation in 
cardiomyocytes (Saucerman, Brunton et al. 2003) or - GRK 
phosphorylation/dephosphorylation, -receptor trafficking in HEK293s 
(Vayttaden, Friedman et al. 2010). Previous modelling work in the field has 
largely ignored the interplay between the PKA and GRK mediated β2AR 
desensitisation pathways. Our group in collaboration with Dr. Thomas Rich 
(University of South Alabama) examined the cAMP turnover profiles in HEK293 
cells expressing only endogenous β2AR. Their ordinary differential equation 
(ODE) model described the importance of receptor levels, basal AC activity, 
receptor desensitisation, and regulation of PDE activity in controlling cAMP 
signals (Xin, Tran et al. 2008). This study did not model the GRK pathway in its 
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full complexity, and examined desensitisation only at high agonist 
concentrations at which the PKA component of β2AR desensitisation is 
assumed to be not significant. Another limitation of the model was that there 
was no correlation between receptor phosphorylation and receptor 
desensitisation. 
Another modelling study (Violin, DiPilato et al. 2008) captured the cAMP 
profiles following β2AR activation as measured by using a fluorescent protein-
tagged EPAC sensor (ICUE2). This model did not include the PKA-mediated 
β2AR desensitisation or the arrestin binding sequelae. The model used a 
Monte Carlo method for simulating the kinetics of the cAMP profiles. In a Monte 
Carlo method one uses a computer algorithm to randomly sample a 
mathematical space. Since the Monte Carlo method is a statistical sampling 
method, one of the caveats of this method is that if the modeller is not careful 
the parameters used in the model might not necessarily match experimentally 
determined values. For example, in this Monte Carlo model the rate constants 
for PKA site phosphorylation and dephosphorylation were 0.0021 and 0.1103 
sec-1, values that are ~100 and 1000 fold greater respectively from our 
experimental values (Tran, Friedman et al. 2004; Tran, Friedman et al. 2007). 
One effect of artificially setting the PKA dephosphorylation rate very high is that 
the model will not be able to correctly capture the effects of PKA 
phosphorylation on the system. These differences might explain their 
conclusion that receptor inactivation by cAMP-dependent kinase is insignificant 
25 
 
which is at variance from what has been previously reported (Clark, Kunkel et 
al. 1988; Yuan, Friedman et al. 1994). 
A major limitation of both these modelling studies was that cAMP profiles were 
the only experimentally defined constraints on the model. In Chapter 3 I 
describe my ODE model of β2AR desensitisation (Vayttaden, Friedman et al. 
2010) that is constrained by six different types of experimental measurements 
viz. GRK phosphorylation, dephosphorylation, receptor internalisation, 
recycling, desensitisation and resensitisation. The model also describes the 
arrestin binding sequelae and the GRK pathway in its full complexity. The major 
conclusions of this modeling study will be discussed in Chapter 3. 
1.2.2. Partial Agonist Models 
Partial agonists are ligands that give sub-maximal receptor activation even at 
receptor saturation. For β2AR, isoproterenol (Isuprel®) and epinephrine 
(endogenous ligand) are examples of full agonists while salmeterol (Servent®) 
and albuterol (Ventolin®, Proventil®) are examples of partial agonists. Barring 
cyclopentylbutanephrine, the initial rate of GRK-mediated β2AR 
phosphorylation correlates with the coupling efficiency of partial agonists 
(January, Seibold et al. 1997; Tran, Friedman et al. 2004; Drake, Violin et al. 
2008). Given the extensive clinical use of partial agonists especially as long 
acting β-agonists I have extended my model (Vayttaden, Friedman et al. 2010) 
described in Chapter 3 to model GRK-mediated β2AR phosphorylation in 
response to a wide panel of partial agonists (Figure 4.1). Salmeterol (Figure 
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1.3) is a weak β-agonist widely used as a complement to steroid therapy in the 
treatment of asthma and COPD and available in the North American market as 
AdvairTM  which is the combination of a steroid (fluticasone propionate) and 
salmeterol (Spencer and Jarvis 1999; Markham and Jarvis 2000; Nelson 2001; 
Cowie, Boulet et al. 2007; McKeage and Keam 2009). It is equi-efficacious to 
strong β-agonists in reversing bronchoconstriction and improving clincial 
outcomes on chronic use.   
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Figure 1.3 Structural Formula of Salmeterol. 
Salmeterol has a salgenin head that binds the active site on the receptor and a hydrophobic 
tail. 
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Despite its clinical significance, salmeterol’s mechanism of β2AR activation and 
regulation of downstream signalling in HASMs is not well understood. Following the 
publication of salmeterol multicenter asthma research trial results (Nelson, Weiss 
et al. 2006) Federal Drug Administration mandated a black-box warning for 
salmeterol even though a salmeterol/steroid combination therapy was not part of 
this meta-analysis. The text of the Advair black-box warning is as follows “Long-
acting β2-adrenergic agonists, such as salmeterol, one of the active ingredients in 
ADVAIR DISKUS, may increase the risk of asthma-related death. Therefore, when 
treating patients with asthma, physicians should only prescribe ADVAIR DISKUS 
for patients not adequately controlled on other asthma-controller medications (e.g., 
low- to medium-dose inhaled corticosteroids) or whose disease severity clearly 
warrants initiation of treatment with 2 maintenance therapies. Data from a large 
placebo-controlled US study that compared the safety of salmeterol (Serevent® 
Inhalation Aerosol) or placebo added to usual asthma therapy showed an increase 
in asthma-related deaths in patient receiving salmeterol (13 deaths out of 13,176 
patients treated for 28 weeks on salmeterol versus 3 deaths out of 13,179 patients 
on placebo)” 
The 8-12 hour persistence of salmeterol is responsible for its clinical effectiveness 
(Beach, Young et al. 1992; Johnson, Butchers et al. 1993; Nials, Ball et al. 1994; 
Palmqvist, Persson et al. 1997). This is also the Achilles heel of mechanistic 
studies for salmeterol since it precludes washout experiments, and this too has 
contributed to many controversies and misconceptions in the field (Duringer, 
Grundstrom et al. 2009; Nino, Hu et al. 2009; Cooper, Kurten et al. 2011). A well 
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constrained and validated model of salmeterol action on β2AR could help in 
clarifying the mechanism of salmeterol action especially since it is possible to 
surmount difficulties of poor washout in silico. In Chapter 4 I discuss existing 
models of salmeterol action.  Briefly they are the microkinetic and exosite model. 
The microkinetic model posits that lipophilicity of salmetereol leads to membrane 
insertion of salmeterol and due to its delayed release there is a pool of salmeterol 
around the receptor microenvironment (Anderson, Linden et al. 1994). The exosite 
model posits that salmeterol binds the receptor to an exosite in addition to the 
active site. This exosite binding is quasi-irreversible and allows for continued 
retention of salmeterol near the receptor (Jack 1991). I combined the exosite and 
microkinetic models with my validated model of GRK-mediated β2AR 
desensitisation discussed in Chapter 3.  
1.2.3. Combined Models of PKA-/GRK-/PDE-Mediated β2AR Regulation 
In order to identify the dominant β2AR desensitisation pathways under different 
therapeutic regimens it becomes necessary to create a unified model of PKA-
/PDE-/GRK-/Arrestin-mediated regulation of β2AR signalling. In Chapter 5 I 
present very preliminary work towards this unified model. To create a 
consensus model I combined my model of the GRK/Arrestin modules 
(Vayttaden, Friedman et al. 2010) with that of the PKA/PDE modules that our 
group had published previously (Xin, Tran et al. 2008). The unified model thus 
created will be validated against experimental measurements of agonist-
induced GRK-mediated β2AR-phosphorylation, PKA-mediated β2AR-
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phosphorylation, β2AR-dephosphorylation, -trafficking, -desensitisation, -
resensitisation and -cAMP profile. 
1.3. Conclusion 
The β2AR activates smooth muscle relaxation through both cAMP-dependent and 
independent pathways. In order to understand why clinical tachyphylaxis happens 
in response to β-agonists it becomes necessary to understand agonist specific 
activation of the various β2AR desensitisation pathways. These studies are difficult 
and extremely time consuming to perform in vivo or in vitro on account of multiple 
isoforms and cross-reactions in signalling pathways. Towards that end I have 
developed various computational models that explore different desensitisation 
pathways and the effects of different β-agonists.  
One of the limitations of the work presented in this thesis is that it is geared 
towards understanding the effects of β-agonist mediated activation of β2AR in only 
airway smooth muscle. When a patient is treated for asthma more than one tissue 
type “sees” the β-agonist. β2AR is expressed in cells like mast cells, T cells etc. all 
which play a role in the inflammatory component of asthma (Sitkauskiene and 
Sakalauskas 2005; Anderson 2006; Deshpande and Penn 2006; Black, Oliver et al. 
2009; Loza and Penn 2010). Additionally the patient on maintenance therapy for 
asthma is treated with a combination of steroid and β-agonist so ideally the effect 
of β-agonists should be studied in the background of the effects steroid treatment. 
Inspite of the above described limitations as a first pass the models described here 
could be used as tools for high throughput hypothesis testing of the β2AR 
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regulatory components allowing us to select specific promising experiments to 
follow through in vivo or in vitro. 
Of most relevance to this thesis, the models described herein have resulted in 
some novel conclusions: (i) receptor dephosphorylation at the membrane and 
GRK-phosphorylated receptor recycling are required for proper β2AR kinetics 
(Chapter 3, Figure 3.9); (ii) discovery of latent memory in the β2AR signalling 
machinery (Chapter 3, Figures 3.11A, 3.12); (iii) realisation that receptor 
internalisation was not required for β2AR resensitisation (Chapter 3, Figure 3.12); 
(iv) salmeterol does not cause significant agonist-induced β2AR internalisation, 
probably by destabilising the salmeterol/β2AR/arrestin complex; (v) reduced 
stability of salmeterol/β2AR/arrestin complex might be the key property that 
explains long action of salmeterol (Chapter 4, Figure 4.10); and (vi) it follows from 
reduced arrestin binding to salmeterol/β2AR complex that salmeterol-induced  
β2AR desensitisation would be predominantly mediated by the PKA pathway (PKA-
mediated β2AR phosphorylation and PDE activation). The preliminary work 
towards modelling the combined effect of PKA-/GRK-/PDE-mediated regulation of 
β2AR signalling is discussed in Chapter 5. 
These models explain the basis of loss of efficacy during abuse of a rescue inhaler 
and the reason for long action of β-agonists used in maintenance therapy. The 
conclusions made herein reiterate the importance of modeling in studying β2AR 
regulation since many of the observations made through modeling would not have 
been easy to make solely by experiments.  
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2. Materials and Methods 
2.1. Experimental Methods 
Data used in this thesis comes predominantly from experiments performed using 
either HEK 293 cell lines with stable overexpression of β2AR at levels of 3–6 
pmoles/mg membrane protein or HASMs that have β2AR at levels of ~ 0.03 
pmoles/ mg membrane protein. Due to the low levels of β2AR in HASMs, receptor 
phosphorylation could not be detected with available phosphosite-specific 
antibodies. However, cAMP measurements could be performed in these cells. The 
stable overexpression of the WT β2AR comes in three “flavours” viz. a) an N-
terminal FLAG (DYKDDDDK) epitope tag (Tran, Friedman et al. 2007); b) an HA 
(YPYDVPDYA) tag on the N-terminus (Morrison, Moore et al. 1996); and c) both an 
HA (N-terminus) and a 6His (C-terminus) – Hβ2ARH (January, Seibold et al. 1997; 
Seibold, January et al. 1998). These tags do not significantly perturb the 
desensitisation parameters discussed in Tables 3.1 or 5.1 as measured by adenylyl 
cyclase in cell-free membrane preparations (Morrison, Moore et al. 1996; January, 
Seibold et al. 1997; Seibold, January et al. 1998; Iyer, Tran et al. 2006; Vaughan, 
Millman et al. 2006; Tran, Friedman et al. 2007), therefore in the discussion I refer 
to these stably expressing cell lines as expressing WT β2AR. Occasionally we 
have used epinephrine instead of isoproterenol, and found no changes in the 
desensitisation parameters at similar levels of receptor occupancy (Tran, Friedman 
et al. 2004). The overexpression does affect dramatically the basal levels of cAMP 
(much enhanced) and the time course and turnover of cAMP. Practically we find 
that cAMP levels do not decrease in time, paradoxically it appears that the 
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phosphodiesterase activity (as well as PKA activity – personal note from Peter 
Fishman) is markedly increased to compensate for constitutive activity. This 
problem is not discussed in any of the work by our group and others in the use of 
overexpression lines. Therefore, to model and simulate cAMP turnover it is best to 
use cells expressing either low or endogenous levels of receptor. On the other 
hand it will be a test of the models to simulate the effect of a 100 fold increase in 
receptors on cAMP turnover in the face of much higher PDE activity.  
An interesting further paradox is that our basal level of GRK site phosphorylation is 
almost undetectable (2-5% of the ISO stimulated levels, whereas the PKA site 
phosphorylation shows a marked basal level about 15-25% of the stimulated level. 
2.1.1. Intact Cell Membrane Dephosphorylation 
HEK 293 cells stably overexpressing the WT β2AR were grown to confluency in 
6-well plates. They were treated with 1µM isoproterenol dissolved in 
ascorbate/thiourea, pH 7 at a final concentration of 0.1 mM ascorbate/1 mM 
thiourea (AT) at 37°C for 30 secs. Post 30 sec saturating agonist challenge, the 
medium was removed and replaced with medium containing 1.0 µM propranolol 
(an antagonist). 30 sec of treatment with a saturating concentration of a full 
agonist should lead to negligible (<0.5%) internalisation but close to 75% 
maximal GRK phosphorylation. To stop all reactions, the medium was 
aspirated, and the cells were rapidly washed with 1 ml of ice-cold HE buffer (20 
mM HEPES and 1.0 mM EDTA, pH 7.7) and placed on ice. Cells were 
solubilised by addition of 200 µl of ice cold solubilisation buffer (20 mM HEPES, 
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pH 7.4, 150 mM NaCl, 0.9% dodecyl-β-maltoside, 20 mM tetrasodium 
pyrophosphate, 10 mM NaF, 0.1 µM okadaic acid, 10 µg/ml each of 
benzamidine, trypsin inhibitor, and leupeptin) to each well. The cells were 
scraped into the solubilisation buffer, transferred to 1.5-ml microcentrifuge 
tubes, and rocked for 30 min at 4°C. The solubilised extract was clarified by 
centrifugation for 15 min at 15,000 rpm and 4°C. Post centrifugation, the 
clarified supernatant of the cell extract was transferred to a new microcentrifuge 
tube and treated with 150 units of PNGase F (2 hours, 37°C) to allow for 
deglycosylation. Samples were then heated at 65°C for 15 min in SDS sample 
buffer (2% sodium dodecyl sulphate, 10% glycerol, 100 mM Tris, pH 6.8, 
bromphenol blue, and 10 mM dithiothreitol). 20 µL aliquots of samples were run 
on 12% SDS-polyacrylamide gel electrophoresis and transferred to 
nitrocellulose for immunoblotting. These nitrocellulose membranes were then 
probed with phosphoserine-specific antibodies, anti-pS(355,356) for the GRK 
sites on the β2AR. Post phosphoserine-specific antibody treatment the 
membranes were washed twice and incubated with suitable dilution of goat anti-
rabbit IgG horseradish peroxidase (Bio-Rad, Hercules, CA) and detected by 
SuperSignal reagent. In order to determine receptor levels the immunoblots 
were stripped and reprobed with a β2AR-specific rabbit anti-C-tail antibody. The 
blots were imaged using a camera system (GeneGnome; Syngene, Frederick, 
MD) or visualised on film using SuperSignal (Piercenet, Rockford, IL), and 
bands quantified using Syngene software. The signal from the anti-
pS(355,356)-specific antibodies were normalised to the corresponding signal 
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from anti-C-tail antibody. For averaging data across different dephosphorylation 
experiments, the results were calculated as a fraction of the control 
isoproterenol treatment followed by the means ± S.E.M. 
2.2. Computational Methods 
In this dissertation I have described 10 computational models of β2AR regulation. 
These have been developed using a suite of different simulators and mathematical 
solvers. The choice of simulators was motivated primarily by the extent of its use 
among collaborators to allow for ease of model sharing followed by the ease of 
model development. The choice of solvers was motivated by the ability to get an 
efficient mathematical solution. Efficiency is used loosely here to reflect the 
measure of the computational time invested in solving the system of equations to 
get a reproducible solution, the faster we get a solution the more efficient is the 
simulation. A reproducible solution won’t be significantly affected by change in time 
steps of the simulation (c.f. Figure 2.1 for discussion of time steps) and it will be a 
positive solution since negative concentrations is a physical impossibility. So an 
attempt is made to use the largest time step at which a stable solution is attained 
since the simulation time also tends to increase with the decrease in the time step, 
and the simulated solution is usually better approximated to the actual curves at 
smaller time steps. The point is to fix the time such that the simulation agrees as 
closely as time permits with the experimental data. 
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Figure 2.1 Effect of Choice of Time Step. 
A mockup of an experimentally determined time course is shown in grey. The polygonal 
approximation of the curve is shown in different colours for the choice of various time steps – 
green (large), orange (medium) and black (small). 
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Table 2.1 A List of Models with the Simulator and Solver Used. 
Model 
Numbers 
Model Description Simulator Solver 
1 – 6 
GRK-mediated 
regulation of β2AR 
MATLAB 
Runge-Kutta 4th 
Order 
GENESIS/ 
Kinetikit 
Euler  
7 – 9 
Salmeterol-induced 
GRK regulation of 
β2AR 
COPASI LSODE 
GENESIS/ 
Kinetikit 
Euler  
10 
GRK/PKA/PDE-
mediated regulation 
of β2AR signalling 
COPASI 
LSODE/ Hybrid 
LSODE/ Hybrid 
Runge Kutta (a 
variation of Runge-
Kutta 4th Order) 
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2.2.1.  Choice of Simulators  
2.2.1.1. MATLAB 
MATLAB® (MATrix LABoratory) is a proprietary numerical computing 
environment developed by MathWorks (Natick, MA). It can be used for 
matrix manipulations, data visualisation, algorithm development, data 
analysis, and numeric computation. I used MATLAB R2008 for developing 
the models described in Chapter 3 (models of GRK-mediated β2AR 
regulation) because of legacy issues since our group had previously 
implemented a model of PKA-/PDE-mediated β2AR regulation in MATLAB 
(Xin, Tran et al. 2008). Due to extensive toolboxes MATLAB allows one to 
perform numerical calculations and visualise results without the need for 
time consuming programming. And because MATLAB has been in use since 
1984 in academic research and industry, a wide online community is 
available to help with potential problems. However, since MATLAB is an 
interpreted language, it can be slow and poor programming practices would 
compound the problem further. Modifying a pre-existing model and adding 
new modules or removing old modules of reactions/equations is usually not 
trivial. Also with MATLAB, users are subject to vendor lock-in making 
sharing and viable reuse of models limited to the MATLAB language.  
2.2.1.2. GENESIS/Kinetikit 
Kinetikit (Schutter 2001; Bhalla 2002; Vayttaden and Bhalla 2004) is a 
graphical simulation environment that extends the capabilities of GENESIS 
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(GEneral NEural SImulation System) (Touretzky 1989; Bower and Beeman 
2007) to simulate large biochemical signalling pathways. Use of 
GENESIS/Kintekit does not require any product registration. I have used 
GENESIS/Kinetikit at the early stages of model development of all models 
described in this thesis dissertation. The biggest advantage for me was the 
ease of implementation of a variety of stimuli like paired pulses and agonist 
washouts post activation. Usability of GENESIS/Kinetikit requires 
experience to fully utilise the graphical user interface (GUI) and script 
language. Also Kinetikit is computationally reliable and efficient. The reason 
I didn’t use GENESIS/Kinetikit extensively beyond the initial model 
development was because of the difficulty in portability of the models across 
different operating systems. For the use of all features of GENESIS/Kinetikit, 
one is dependent on the Linux environment and since our laboratory is 
predominantly Windows rich this limited portability of the models. Also since 
the GUI required familiarisation it wasn’t easy for anybody other than the 
model author to follow the model development progress.  
2.2.1.3. COPASI 
COPASI a graphical program that allows the simulation of biochemical 
processes (Hoops, Sahle et al. 2006). COPASI can be downloaded freely 
and in addition to deterministic and stochastic simulations of reaction 
networks, it allows for flux analysis. I used COPASI due to its ease of use 
and large suite of modeling analysis tools. The biggest advantage was the 
ability to use the sliders feature that allowed for real-time, interactive 
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parameter changes during simulations. This enhanced the model 
development experience with experimentalists in our group settings. 
COPASI is not without its quirks that do affect its usability. Unlike 
GENESIS/Kinetikit COPASI does not have a very good network diagram 
visualisation. While modelling very large networks, network diagram 
visualization might not be “pretty” but it still is a very important tool in being 
able to zoom in and find a reaction or associated parameters. In COPASI 
one is limited to navigating a long table of alphanumeric characters to locate 
a reaction or parameter of interest. While this mode of access is useful in 
data entry it is not always efficient in data retrieval since model development 
rarely proceeds in a linear fashion and there are additions and deletions of 
reactions/species leading to “lack of order” in tables. Another drawback with 
COPASI is that if the model uses assignments, rules and global quantities, 
certain type of solvers cannot be used efficiently leading to extended 
calculation times. For example, in my models there are many global 
quantities like total GRK-phosphorylated receptor which is assigned the 
value of sum total of all GRK-phosphorylated receptor species. The 
simulated global quantity of total GRK-phosphorylated receptor is useful in 
matching simulation results with experimental results of GRK 
phosphorylation. Also combining parameter estimation with a variety of 
stimuli like paired pulses and agonist washouts post activation is difficult. 
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2.2.2. Choice of Solvers  
2.2.2.1. Euler 
The Euler integration method (in GENESIS/Kinetikit) is an explicit method 
for numerical integration of ordinary differential equations (ODEs) when 
given its initial value. The advantage of this method is that it is 
computationally simple. The disadvantage is that to reduce error in 
estimations for stiff equations one will have to use very small timesteps 
making it computationally inefficient. All models (1-10) were initially 
implemented using GENESIS/Kinetikit 10 (Vayttaden and Bhalla 2004) and 
an Euler solver on a PC running Red Hat Linux  (Red Hat Corp., Raleigh, 
NC). 
2.2.2.2. LSODE 
The LSODE (Livermore Solver for Ordinary Differential Equations) is an 
integration method for numerical integration of ODEs and can handle both 
stiff and non-stiff equations. It was written by Linda R. Petzold and Alan C. 
Hindmarsh and is the default method in COPASI to calculate timecourses. 
Models 7-9 (described in Chapter 4) and model 10 (described in Chapter 5) 
were implemented using COAPSI 4.6 and a Hybrid LSODE solver on a PC 
running Windows 7 (Microsoft Corp., Redmond, WA). 
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2.2.2.3. Runge-Kutta 
The Runge-Kutta methods are a group of implicit and explicit iterative 
methods used in estimating solutions of ODEs. Different implementations of 
Runge-Kutta methods are available in MATLAB, GENESIS/Kinetikit and 
COPASI. Models 1-6 (described in Chapter 3) were implemented using 
MATLAB R2008 and a 4th order Runge-Kutta solver on a PC running 
Windows XP (Microsoft Corp., Redmond, WA) and model 10 (described in 
Chapter 5) was implemented using COAPSI 4.6 and a Hybrid Runge-Kutta 
solver on a PC running Windows 7 (Microsoft Corp., Redmond, WA). 
2.2.3. Additional Model Details 
The reactions for all models were written per the Law of Mass-Action (Guldberg 
1864; Waage 1864; Waage and Guldberg 1864; Waage and Guldberg 2000 
(Translation)) considering the system to exist in equilibrium. All analyses were 
done using Microsoft Office Excel 2003/2007 (Microsoft Corp., Redmond, WA) 
and plots were generated using GraphPad Prism 4/5 (GraphPad Software, Inc., 
La Jolla, CA). 
2.2.4.  Partial Agonist Simulations  
2.2.4.1. Relative Efficacy  
Partial agonist-mediated activation of β2AR was simulated in Model 1 with 
coupling efficacies of each agonist set relative to epinephrine (α) (c.f. Table 
3.1, 4.1). The stated coupling efficacies/ efficiencies of various partial 
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agonists were from previous measurements in HEK 293s that stably 
overexpress WT β2AR (Tran, Friedman et al. 2004). The measurements of 
partial agonist-induced β2AR phosphorylation and internalisation were done 
at saturating agonist concentrations (Tran, Friedman et al. 2004; Moore, 
Millman et al. 2007). In simulations of partial agonists, concentrations were 
set equivalent to saturating epinephrine concentrations (10 µM) on account 
of the fact that efficacies/coupling efficiencies were set relative to 
epinephrine. 
2.2.4.2. Salmeterol Models  
In Model 1, differential coupling efficacies for salmeterol- vs. epinephrine-
induced β2AR activation was considered for salmeterol simulations. In 
Models 8-10 in addition to differential coupling efficacies, simulations for 
salmeterol mediated β2AR activation also invoked membrane accumulation 
of salmeterol in the microkinetic model (Model 7), or a salmeterol-binding 
exosite (Model 8), or both exosite and microkinetics (Model 9). The models 
were written using previously described mathematical formalism for 
salmeterol and competing agonist binding to β2AR (Szczuka, Wennerberg 
et al. 2009) and post agonist-induced GRK-mediated β2AR regulation 
(Vayttaden, Friedman et al. 2010).   
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2.2.5. Simulation of Receptor Number Variation and Perturbations of Rate 
Constants.  
In order to account for experiments such as overexpression or knockdowns of 
GRKs, phosphatases or arrestins, simulations of Models1-6 were performed by 
2 to 50 fold variations of the relevant rate constants. In Model 7 the 100 fold 
overexpression of β2AR in HEK293s as compared to HASMs is accounted for 
by arbitrarily changing receptor levels from 100 µM (stable overexpressions) to 
1µM (HASMs). The concentrations of receptor can also be estimated by 
calculations for an “ideal” HEK293 cell approximated to a sphere as given 
below. 
Equation 2.1 
Volume of an ideal HEK293 cell = 4/3 π R3 ~ 500 fL (when R = 5000 nm) 
Equation 2.2 
Volume of plasma membrane in an ideal HEK293 cell = 4/3 π (R3 - r3) ~ 3 fL 
(when R = 5000 nm and r = 4990 nm, assuming a membrane thickness of 10 
nm) 
The total protein yield from a 10 cm dish ~ 1 mg and β2AR concentration ~ 3 
pm/mg total protein. The approximate cell count in a confluent 10 cm dish is ~ 2 
X 106 cells. This leads to an approximation of β2AR concentration to 3.0× 10-6 
mole/L in a whole cell or 5.0× 10-4 mole/L in the membrane. This approximates 
to a receptor number of 1 X 105/ cell.  
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2.2.6. Sensitivity Analysis of Desensitisation and Resensitisation.  
A univariate sensitivity analysis was carried out for Model 1 to test the effect of 
variation in parameter values on the simulation results of desensitisation and 
resensitisation. Barring the ligand binding and unbinding rates (which were left 
unperturbed), all other rates were individually varied 2-, 5-, 10-, 20-fold around 
the default rates (Table 3.1).  
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3. GRK-Mediated β2AR Regulation  
This chapter is adapted from “Quantitative Modeling of GRK-Mediated β2AR 
Regulation.” Vayttaden SJ, Friedman J, Tran TM, Rich TC, Dessauer CW, Clark RB 
(2010) PLoS Comput Biol 6(1): e1000647. doi:10.1371/journal.pcbi.1000647 
I have modelled the GRK/Arrestin module of the β2AR regulation as it pertains to 
experimental measures of agonist-induced GRK-mediated β2AR-phosphorylation, 
β2AR-dephosphorylation, -trafficking, -desensitisation and -resensitisation (Figure 3.1). 
Our group has previously shown that stable overexpressions of the WT β2AR in HEK 
293 cells were suited for examining many aspects of the β2AR regulation process. 
Most importantly, the duration and amplitude of β2AR desensitisation in these cells is 
comparable with the endogenous receptor (Clark and Knoll 2002). In the stable 
overexpression system, the EC50 of PKA-mediated β2AR phosphorylation is ~ 1000-
fold lower than the EC50 for GRK-phosphorylation of the β2AR. This allows us to 
differentiate the GRK- and PKA-mediated β2AR desensitisation into separate 
modules. We have previously shown that at high agonist concentrations GRK 
accounts for the majority of β2AR desensitisation (Seibold, Williams et al. 2000). Table 
3.1 lists the parameters used to model and simulate the consensus GRK pathway in 
response to various agonists at different concentrations and durations. The data 
simulated were from 90+ independent experiments on our stable overexpressions of 
human β2AR in HEK 293 cells. Using a unique model to simulate the wide dataset 
provided good modelling constraints. This ensured that the model applicability 
extended over a wide repertoire of agonist-induced β2AR response.  
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Figure 3.1 Reaction Diagram of the GRK-Mediated β2AR Regulation. 
L is ligand; R* is active state of β2AR; Rs and Ri are surface/plasma membrane and 
internalised β2AR; Rg is GRK-phosphorylated β2AR; Arr is arrestin. This reaction diagram 
describes the default model for simulations using the rate constants as described in Table 3.1. 
Figure and Figure Legend Source: http://dx.doi.org/10.1371/journal.pcbi.1000647.g001 
“Quantitative Modeling of GRK-Mediated β2AR Regulation.” Vayttaden SJ, Friedman J, Tran 
TM, Rich TC, Dessauer CW, Clark RB (2010) PLoS Comput Biol 6(1): e1000647. 
doi:10.1371/journal.pcbi.1000647 
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Table 3.1 Parameters for GRK-Mediated β2AR Regulation Model 
Reaction Name Parameter (/min) Reference/Rationale 
Ligand (Agonist) On k1f = k4b = k5b = 500 Rates used to achieve rapid ligand 
binding so that it is not rate limiting.A Ligand (Agonist) Off k1b = k4f = k5f = 4 
Ligand (Agonist) On (in 
the presence of an 
antagonist) 
k1f = k4b = k5b = 0.005 
Antagonist is assumed to behave as a 
competitive inhibitor (Prichard and 
Tomlinson 1986) so the agonist binding 
rates are greatly reduced. 
Ligand (Agonist) Off (in 
the presence of an 
antagonist) 
k1b = k4f = k5f = 4 
Agonist off-rates are unaffected in the 
presence of an antagonist that behaves 
like a competitive inhibitor 
GRK Phosphorylation k2f = α[R*]1.4 
Initial rate of GRK phosphorylation on 
treatment with 10 µM epinephrine = 0.7-
1.4 /min (Tran, Friedman et al. 2004).B 
GRK Dephosphorylation k2b = k7f = k10f = 0.036 Phosphorylated receptor t1/2 = 18 min (Tran, Friedman et al. 2007). 
Arrestin On (to an 
agonist-bound receptor) k3f = 27.0 
Rate of arrestin binding = 26.6 ± 5.9 /min 
(Krasel, Bunemann et al. 2005) 
Arrestin Off (from an 
agonist-bound receptor) k3b = 4.0 
Rate of arrestin dissociation assumed to 
match measured Kd. 
Internalisation k8f = 0.22 kf = 0.22 /min (Tran, Friedman et al. 2004). 
Basal Internalisation k11b = k12f = k13b = 0.0085 
Rates used to match negligible basal 
internalisation (Morrison, Moore et al. 
1996). 
Arrestin Off (from an 
agonist-free receptor) k6f = k9f = 11.0 
Rate of arrestin dissociation = 10.86 ± 1.2 
/min (Krasel, Bunemann et al. 2005). 
Receptor Degradation k14f = k15f = k16f = 0.004 t1/2 ~ 3–4 hours (Liang, Hoang et al. 2008). 
Receptor Recycling k11f = k13f = 0.09 kf = 0.09 /min (Tran, Friedman et al. 2004). 
AOff-rates for isoproterenol ≥ 4 /min (Mueller, Motulsky et al. 1988), epinephrine > 100 /min 
(Krasel, Bunemann et al. 2005). For a Kd of 450 nM (epinephrine) and 283 nM (isoproterenol) 
the calculated on-rates are very fast. Slowing down the forward-rates to 500 /min does not 
affect the downstream events being simulated since they happen at a slower time scale. The 
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ligand off-rate is not set at lower than 4 /min in order to avoid making it rate limiting for arrestin 
dissociation. 
Bα = Coupling efficiency relative to epinephrine; Isoproterenol is assumed to have the same 
coupling efficiency as epinephrine since they are both full agonists. The relative coupling 
efficiencies for partial agonists are as follows, Epinephrine = Isoproterenol = 1, Fenoterol = 
0.66, Formoterol = 0.63, Terbutaline = 0.33, Zinterol = 0.33, Albuterol = 0.25, Salmeterol = 
0.13, Dobutamine = 0.04 and Ephedrine = 0.03. [R*] = ([Rtotal] [Agonist]/([Agonist]+(Kd agonist)); 
[Rtotal] = 1; Kd epinephrine = 450 nM; Kd isoproterenol = 283 nM. Simulated phosphorylation rate = α 
[R*]1.4 (for epinephrine); = α [R*]0.7 (for isoproterenol). 
Model 1: All rates are set as described above, for the default model. 
Model 2: k2b = k7f = 0 /min since this model disallows dephosphorylation at the plasma 
membrane. 
Model 3: k13f = 0 /min since this model disallows recycling of phosphorylated receptor. 
Model 4: k10f = 0 /min since this model disallows dephosphorylation of the internalised 
receptor. 
Model 5: k10f = k13f = 0 /min since this model does not allow neither dephosphorylation of the 
internalised receptor nor recycling of phosphorylated receptor. 
Model 6: k2b = k7f = k13f = 0 /min since this model does not allow neither dephosphorylation of 
the receptor at the plasma membrane nor recycling of phosphorylated receptor. 
Table Source: http://dx.doi.org/10.1371/journal.pcbi.1000647.t001 
“Quantitative Modeling of GRK-Mediated β2AR Regulation.” Vayttaden SJ, Friedman J, Tran 
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TM, Rich TC, Dessauer CW, Clark RB (2010) PLoS Comput Biol 6(1): e1000647. 
doi:10.1371/journal.pcbi.1000647 
  
51 
 
3.1. Assumptions  
3.1.1. Two State Model  
Since all parameters described in Table 3.1 were obtained using full agonists 
for the β2AR (epinephrine or isoproterenol), I assumed a simplified two state 
model for β2AR activation. Here the plasma membrane bound inactive β2AR is 
denoted by Rs and R*Ls denotes the agonist-induced active β2AR. I also 
assumed ligand-induced β2AR activation since basal GRK Phosphorylation of 
WT β2AR is negligible (Tran, Friedman et al. 2004; Vaughan, Millman et al. 
2006; Tran, Friedman et al. 2007; Drake, Violin et al. 2008). 
3.1.2. Ligand Binding  
The off-rate for isoproterenol from the β2AR is ≥4 /min (Mueller, Motulsky et al. 
1988) and for epinephrine >100 /min (Krasel, Bunemann et al. 2005). To 
achieve the Kds for isopreoterenol (283 nM) and epinephrine (450 nM), the on-
rates have to be very fast. These fast rates were slowed down to 500 /min for 
two reasons; (i) even at these reduced speeds ligand binding was about 18 fold 
faster than the next fastest reaction so it did not affect the time course of the 
downstream events being modelled; and (ii) at these reduced speeds very small 
step sizes were not required to solve the differential equations using the Runge-
Kutta solver (ODE23s) in MATLAB R2008 (MathWorks, Natick, MA).  
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3.1.3. Ligand Dissociation  
I assumed that the unbinding rates for agonist from β2AR were uninfluenced by 
its arrestin binding or GRK phosphorylation status (Reactions 1b, 4f, 5f in 
Figure 3.1).  This is a simplification of the kinetics since arrestin binding 
stabilizes a high-agonist affinity state of the receptor, prompting some authors 
to characterise the receptor-arrestin complex as an alternative ternary complex 
analogous to the ternary complex existing between agonist-receptor-G protein 
in the absence of GTP (Gurevich, Pals-Rylaarsdam et al. 1997). This 
simplification should not significantly affect the steady-state simulations of 
receptor phosphorylation, internalisation, desensitisation since the experimental 
measurements the simulations are constrained with are made under continuous 
presence of high agonist. The effect of assuming equivalent  ligand dissociation 
rates for naïve, GRK-phosphorylated  or arrestin bound receptor is that ligand 
dissociation rates from arrestin bound-receptor (Reaction 5f in Figure 3.1) end 
up being faster than normal leading to more rapid initial resensitisation post 
agonist removal. Since we did not have rates of ligand dissociation from arrestin 
bound receptor the model provided us a means to vary the ligand dissociation 
rate for arrestin bound species and compare the simulated results to the 
experimentally measured receptor resensitisation curve where the effects of this 
reaction would be most dominant. Through our simulations we showed that a 
ten-fold lower dissociation rate of ligand from arrestin-bound β2AR (Reaction 5f 
in Figure 3.1) is required to match the initial resensitisation rates correctly 
(Figure 3.3B). 
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3.1.4. Receptor Activity  
In the model I assumed that the GRK phosphorylated β2AR (Rgs, Rg*Ls in Figure 
3.1) has reduced activity (0.7) compared to naïve β2AR (Benovic, Kuhn et al. 
1987; Lohse, Andexinger et al. 1992; Tran, Friedman et al. 2007). This is a 
simplification since the receptor can exist in any conformation in a wide 
parameter space and each of the conformations would have its own activity. 
The effect of this simplification of assigning the same activities for all “flavours” 
of GRK-phosphorylated receptor is that the receptor activity profile would be 
dependent on both time and concentration of agonists, so a one-size-fits-all 
model would not easily match all data points. Thus the mismatches in simulated 
receptor desensitisation and experimentally measured desensitisation (Figure 
3.3A) could in part be because of this simplification. I also assumed that arrestin 
binding or internalisation completely uncouples the receptors therefore those 
species have no activity.  
3.1.5. GRK-Phosphorylation Kinetics  
I assumed that ligand activation of β2AR results in only a single event of GRK 
phosphorylation where both serines 355 and 356 are simultaneously 
phosphorylated. The anti-phosphosite antibody used in our β2AR 
phosphorylation studies detects only dual phosphorylation of serines 355, 356. 
Use of our antibody for studying GRK-mediated β2AR phosphorylation kinetics 
has been validated by various groups (Tran, Friedman et al. 2004; Shenoy, 
Drake et al. 2006; Violin, Ren et al. 2006; Pontier, Percherancier et al. 2008; 
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Woo, Wang et al. 2009). The assumption of a single phosphorylation event and 
equating Ser355,356 phosphorylation with “the” GRK phosphorylation event is a 
simplification since we do know that in our cells the phosphorylation of Ser364 
too is associated with GRK (Seibold, Williams et al. 2000). Also serine to 
alanine substitution of serines 355, 356, and 364 eliminated receptor-level 
desensitisation in the PKA- background (S261, 262A and S345, 346A) and 
caused ~ 90% reduction in phosphorylation as assessed by 32P-prelabeling. So 
there is at least a 10% receptor phosphorylation that cannot be attributed to the 
currently identified GRK phosphorylation sites. Inspite of these limitations the 
decision to assume a single event of GRK phosphorylation where both serines 
355 and 356 are simultaneously phosphorylated is justified because 1) there 
are no experimental readouts of individual phosphorylation sites available; 2) 
the dual phosphorylation of S365, 366 correlates well with both a dose 
response and time course of agonist treatment.  The disadvantage of this 
assumption is that it is no longer possible to project multi-phosphorylation states 
of the receptor that could play a role in receptor sorting post-internalisation 
selecting for recycling vs. receptor degradation. Also assuming a single 
phosphorylation event prevents assigning multiple phosphorylation site specific 
activities to the receptor, this could in turn affect the quality of simulation fits. 
In my models 1-6 the rate of GRK-mediated β2AR phosphorylation is 
dependent on the fraction of agonist-bound β2AR denoted by [R*], and coupling 
efficiency of the ligand denoted by α. We’ve measured epinephrine induced 
GRK-mediated β2AR phosphorylation to range from 0.7–1.4/min (Tran, 
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Friedman et al. 2004). I assume that isoproterenol induced β2AR 
phosphorylation rates will be in the same range since epinephrine and 
isoproterenol have comparable efficacies.  
We have previously shown that both the plasma membrane and endosomal 
fraction of β2AR can undergo dephosphorylation (Iyer, Tran et al. 2006; Tran, 
Friedman et al. 2007). Therefore I allow both plasma membrane and cytosolic 
dephosphorylation of β2AR in my model (c.f. Footnote of Table 3.1). 
3.1.6. Arrestin Kinetics   
The arrestin on/off rates were obtained from experiments on fluorescently 
tagged proteins (Krasel, Bunemann et al. 2005). I assumed that these 
fluorescent tags did not affect the measured kinetics. The arrestin off-rate from 
a ligand bound β2AR complex (Reaction 3b in Figure 3.1) was estimated to be 
~4.0/min from previous measurements of the Kd (Gurevich, Dion et al. 1995).  
3.1.7. Post-Internalisation Events  
Consistent with the rapid on/off-rates and high Kds of epinephrine or 
isoproterenol (Mueller, Motulsky et al. 1988; Devanathan, Yao et al. 2004) I 
assumed ligand dissociation post β2AR internalisation to be very rapid. We 
have previously shown negligible rates of basal β2AR internalisation (Morrison, 
Moore et al. 1996). Since both basal and agonist induced β2AR internalisation 
rates are slower than agonist dissociation I have collapsed β2AR internalisation 
and post-internalisation agonist dissociation into a single step. This assumption 
limits the usefulness of the model in simulating post-internalisation events on 
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treating with certain partial agonists like Salmeterol which don’t easily dissociate 
from the receptor (Jack 1991; Rong, Arbabian et al. 1999) and are postulated to 
have low affinity for arrestin (Moore, Millman et al. 2007; Vayttaden, Friedman 
et al. 2010). 
In the GRK-mediated β2AR regulation model I allow arrestin-free internalised 
β2AR to recycle independent of its phosphorylation status (Tran, Friedman et 
al. 2007).  Currently the precise mechanisms and pathways of β2AR 
downregulation are unclear even though we have shown it to be biphasic 
(Williams, Barber et al. 2000). Thus to simplify downregulation reactions in the 
model I assume that all internalised β2AR species can undergo downregulation 
(t1/2 = 3–4 hours) (Morrison, Moore et al. 1996; Williams, Barber et al. 2000; 
Liang, Hoang et al. 2008). 
3.1.8. Pseudo-First Order Kinetics  
In HEK293s GRK2/5/6 levels exceeds even overexpressed β2AR levels by 
approximately 100 fold (Tran, Jorgensen et al. 2007). We have also established 
that the level of desensitisation in both HEK 293 cells with endogenous (30 
fmol/mg) or overexpressed β2AR (3000 fmol/mg) is comparable. Arrestin levels 
therefore should be sufficiently high to allow complete desensitisation even on 
100 fold overexpression of β2AR. Others (Menard, Ferguson et al. 1997) have 
shown that in comparison to four cell lines HEK 293 cells have relatively the the 
highest levels of arrestin and GRK. In the light of the obvious excess of GRKs 
and arrestin over β2AR I represent the second order reactions of GRK-
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mediated β2AR phosphorylation and arrestin binding to the β2AR as pseudo-
first order reactions. These assumptions force us to use variation in rates of 
arrestin binding or GRK-phosphorylation as a proxy to the effects of variation in 
levels of arrestin and GRK. 
3.2. Model Validation  
My mathematical model of GRK-mediated β2AR regulation was validated against 
six types of biochemical measurements (~ 90+ distinct experiments) in HEK 293 
cells stably overexpressing the WT β2AR across a range of agonist concentrations 
(Figures 3.2, 3.3, 4.1). The model validation results are discussed below. 
3.2.1. GRK Phosphorylation 
 My model captured the main temporal features of GRK-mediated β2AR 
phosphorylation across a wide range of epinephrine concentrations wherein the 
stimulation was from 0–30 min (Figure 2.2A) and in response to a variety of 
partial agonists (Figure 4.1). GRK-mediated β2AR phosphorylation was 
measured in whole cell extracts as described here.  
GRK phosphorylations of the β2AR at residues Serine (355, 366) were 
determined using anti-phosphosite-specific antibodies (Santa Cruz 
Biotechnology, Inc., Santa Cruz, CA) (Tran, Friedman et al. 2004). HEK293s 
stably overexpressing WT β2AR were incubated with isoproterenol (Sigma, St. 
Louis, MO), through different treatment times. Post-treatment the whole cell 
protein was extracted with a solubilisation buffer and then incubated with 
Peptide N-glycosidase F (New England Biolabs, Ipswich, MA) to remove 
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glycosyl residues. This was followed by a treatment with SDS sample buffer 
prior to running on polyacrylamide gel electrophoresis. Following the gel 
transfer, the levels of GRK site phosphorylation were determined by western 
blots. First, the phosphorylation data was normalised to β2AR levels and then to 
allow inter-experimental comparison it was normalised to the maximum 
phosphorylation with saturating concentrations of epinephrine. 
GRK-mediated β2AR phosphorylation was simulated by selecting dosage and 
duration of ligand treatment corresponding to the experimental measurements. 
The sum total of Rgs, Rg*Ls, ArrRgs, ArrRg*Ls, ArrRgi and Rgi (Figure 3.1) 
was plotted as a percentage of total β2AR against the experimentally measured 
GRK phosphorylated β2AR (Figure 3.2A). 
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Figure 3.2. Comparisons of Experimental Results with Simulations of the Model. 
Panels A–D: Comparisons of simulations (continuous lines) of the model shown in Figure 2.1, 
with experimental data obtained in HEK 293 cells stably overexpressing FLAG WT β2AR 
(discrete data points). (A) Time course of GRK phosphorylation of the receptor on treatment 
with different concentrations of epinephrine (Tran, Friedman et al. 2004). (B) 
Dephosphorylation of the GRK phosphorylated site on the receptor after 5 min treatment with 
either 1.0 µM or 10 nM ISO (red bar) followed by addition of propranolol (blue bar) and 
measure of loss of GRK site phosphorylation. Phosphorylated receptor is expressed as a 
percent of phosphorylation achieved at the end of 5 min treatment with either agonist 
concentration (Tran, Friedman et al. 2007). (C) Recycling of the receptor after 20 min 
treatment with 1µM isoproterenol followed by rapid washout of agonist (Morrison, Moore et al. 
1996). (D) Internalisation of β2AR on treatment with various concentrations of isoproterenol as 
indicated. Surface receptor is measured by the loss of [3H]CGP-12177 (Tran, Friedman et al. 
2007). 
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Figure and Figure Legend Source: http://dx.doi.org/10.1371/journal.pcbi.1000647.g002 
“Quantitative Modeling of GRK-Mediated β2AR Regulation.” Vayttaden SJ, Friedman J, Tran 
TM, Rich TC, Dessauer CW, Clark RB (2010) PLoS Comput Biol 6(1): e1000647. 
doi:10.1371/journal.pcbi.1000647 
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3.2.2. Dephosphorylation  
Dephosphorylation of the GRK phosphorylated β2AR was simulated across a 
100 fold agonist concentration range as shown in Figure 3.2B. 
Dephosphorylation of the GRK-phosphorylated WT β2AR was measured in 
whole cell extract as described below.  
In dephosphorylation experiments HEK293s stably overexpressing WT β2AR 
were treated for 5 min with either 1.0 µM or 10 nM isoproterenol. Post agonist 
treatment the cells were washed and incubated with medium containing 0.1 µM 
propranolol (Sigma, St. Louis, MO) (Tran, Friedman et al. 2004). The loss of 
GRK site phosphorylations at Serine (355, 366) was then assayed using 
western blots as discussed in Section 3.2.1. In the dephosphorylation 
experiments, phosphorylation at 5 min with different agonist concentrations was 
normalised as maximum phosphorylation foreach concentration. 
The dephosphorylation simulations had two parts - the first part dealt with 
ligand-induced GRK-mediated β2AR phosphorylation, and the second part dealt 
with the antagonist treatment allowing for β2AR dephosphorylation. 
Concentrations of all species of β2AR for the second part of the simulation were 
initialised to the terminal state from the first simulation. During the second 
phase of the simulations the ligand on rates were reduced 100,000 fold (to 
mimic competitive binding with an antagonist). On completion of the 
simulations, the sum total of Rgs, Rg*Ls, ArrRgs, ArrRg*Ls, ArrRgi and Rgi 
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(Figure 3.1) was plotted as a percentage of total β2AR against the 
experimentally measured GRK phosphorylated β2AR (Figure 3.2B). 
3.2.3. Recycling  
β2AR recycling was measured by [3H]CGP-12177 binding, post a 20 min 
isoproterenol treatment followed by a wash as described here. HEK 293s stably 
overexpressing WT βAR were treated with 1 µM agonist (isoproternol) through 
20 min to maximise internalisation. Post ligand treatment, the cells were 
washed to remove ligand and incubated for the times indicated at 37°C to allow 
recycling. Surface β2AR levels were assayed using [3H]CGP-12177 binding as 
described in the previous section (Seibold, Williams et al. 2000). The measure 
of β2AR at the surface at time 0 was normalised as 100% surface βAR. 
Recycling was simulated similar to dephosphorylation as described in 3.2.2 
since both experiments involved two perturbations during the course of an 
experiment. On completion of the β2AR recycling simulations the sum total of 
Rs, R*Ls, Rgs, Rg*Ls, ArrRgs and ArrRg*Ls (Figure 3.1) was plotted against 
the experimentally measured surface β2AR with the surface receptor at time 
zero normalised to 100% (Figure 3.2C).  
3.2.4. Internalisation  
HEK 293s stably overexpressing WT βAR were treated with varying agonist 
(isoproterenol) concentrations through different treatment times. Post ligand 
treatment and washing, receptor internalisation was measured in intact cells 
using [3H]CGP-12177 (20 nM) binding (Tran, Friedman et al. 2007). [3H]CGP-
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12177 is a hydrophilic antagonist that binds only surface (plasma membrane) 
βAR at 0–4°C. The binding assay is conducted ±1µM alprenolol (Sigma, St. 
Louis, MO), a β2AR antagonist used to determine non-specific binding of 
[3H]CGP-12177. The measure of surface β2AR at time 0 was normalised as 
100% surface β2AR for different agonist concentrations.  
On completion of the internalisation simulations the sum total of Rs, R*Ls, Rgs, 
Rg*Ls, ArrRgs and ArrRg*Ls (Figure 3.1) was plotted against the experimentally 
measured surface β2AR with the surface receptor at time zero normalised to 
100% (Figure 3.2D).  
3.2.5. Desensitisation  
The β2AR desensitisation measurements (Figure 3.3A) were made in HEK 293 
cells that either stably overexpressed WT β2AR or a β2AR lacking the two PKA 
consensus sites (S261, 262A and S345, 346A termed PKA-). PKA- was used to 
eliminate the effects of PKA-mediated β2AR desensitisation (Seibold, Williams 
et al. 2000). Desensitisation of β2AR stimulation of AC was performed as 
described below.  
HEK 293s that stably overexpressed either WT βAR or a β2AR lacking the two 
PKA consensus sites (S261, 262A and S345, 346A) were treated with various 
concentrations of agonist (isoproterenol). Post washout of ligand, membrane 
fractions were separated using sucrose step gradients. Desensitisation was 
measured as the increase in EC50 for isoproterenol stimulation of AC relative to 
controls and the results were calculated as fraction activity remaining (Tran, 
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Friedman et al. 2007). Through our previous studies we have shown that there 
is a 35% decrease in Vmax from downstream effects, most likely on AC (Whaley, 
Yuan et al. 1994; Seibold, Williams et al. 2000). So in the model of receptor-
level GRK-mediated desensitisation described here we ignore these Vmax 
changes. The model described in Chapter 5 does address downstream effects 
due to PDE activity but even this model ignores Vmax effects due to 
postranscriptional modifications of AC.  
On completion of the simulation run, activity was calculated as the weighted 
sum of Rs, R*Ls, Rg*Ls and Rgs normalised to initial receptor activity. The 
weighting of the active β2AR species was decided as discussed above in 3.1.4.  
Simulated β2AR activity was plotted against the experimentally measured 
active β2AR (Figure 3.3A). Since the model lacked PKA-mediated β2AR 
regulation it underestimated early (first two minutes) desensitisation post-ligand 
treatment for the WTβ2AR, but there was significant concurrence with 
experimental data over longer treatment times.  
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Figure 3.3. Validation of the Model with Two Sets of Experimental Results. 
Validation of the simulations (continuous lines) of the model shown in Figure 3.1, with 
experimental data obtained in HEK 293 cells stably overexpressing the FLAG WT β2AR 
(discrete data points). (A) Desensitisation of β2AR stimulation of adenylyl cyclase after 
treatment with 10 µM isoproterenol. Inset shows β2AR desensitisation on stimulation with 30 
nM isoproterenol. Red – simulated results; Black – WT cells; Blue - cells stably overexpressing 
β2AR lacking PKA phosphorylation sites (PKA-). At lower concentrations the model matches 
PKA- desensitisation more closely since it does not include PKA-mediated β2AR 
desensitisation. (B) Resensitisation of the β2AR stimulation of adenylyl cyclase. WT β2AR 
were stimulated with 1µM isoproterenol for 15 min, followed by addition of metoprolol as 
described in 3.2.6. Dotted line shows simulated % activity of the β2AR when ligand 
dissociation from arrestin-bound receptor complex is reduced by ten-fold. 
Figure and Figure Legend Source: http://dx.doi.org/10.1371/journal.pcbi.1000647.g003 
“Quantitative Modeling of GRK-Mediated β2AR Regulation.” Vayttaden SJ, Friedman J, Tran 
TM, Rich TC, Dessauer CW, Clark RB (2010) PLoS Comput Biol 6(1): e1000647. 
doi:10.1371/journal.pcbi.1000647 
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3.2.6. Resensitisation  
The β2AR resensitisation experiments (Figure 3.3B) were done in HEK 293 
cells that stably overexpressed WT β2AR as described here.  
In order to measure resensitisation of WT β2AR, propranolol could not be used 
for the blockade of isoproterenol stimulation as described for desensitisation in 
Section 3.2.5, because its rate of dissociation from the receptor was too slow to 
allow for resensitisation time course measurements. To avoid this handicap we 
used a low affinity antagonist of the βARs like 100 µM metoprolol (240 nM Kd) 
(Sigma, St. Louis, MO) (Tran, Friedman et al. 2007).  Post different 
resensitisation times cells were washed free of metoprolol, and membranes 
were prepared and assayed for isoproterenol stimulation of AC (Tran, Friedman 
et al. 2007). The measure of membrane AC activity at time 0 is normalised as 
maximum activity in desensitisation and resensitisation experiments. 
β2AR resensitisation was simulated in two parts, as described previously for 
dephosphorylation (3.2.2) and recycling (3.2.3). At the end of the simulation run, 
activity was calculated as the weighted sum of Rs, R*Ls, Rg*Ls and Rgs 
normalised to the initial receptor activity. The weighting of the active β2AR 
species was decided as discussed above in 3.1.4.  As an artefact of the rates 
(Reaction 5f, Figure 3.1) used in the default model (Table 3.1, Model 1) there is 
initially a rapid increase in resensitisation. This artefactual spike can be 
removed on lowering the rate of agonist dissociation from an arrestin-bound 
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β2AR complex (Reaction 5f, Figure 3.1) by ten-fold which is in line with the 
increased apparent stability of this complex (Gurevich, Dion et al. 1995).  
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Figure 3.4. Correlation of Simulated Surface Arrestin with G Protein Independent 
ERK Activation.  
pERK data (Shenoy, Drake et al. 2006) matches initial accumulation of simulated surface 
arrestin (Arrs + ArrRg*Ls; Figure 2.1). The discrepancy in latter time points might be due to 
activation of ERK phosphatases which is not explicitly modelled. TYY mutants are uncoupled 
from G protein so the ERK phosphorylation seen is independent of G protein activation.  
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3.2.7. Arrestin-Dependent ERK Activation  
There have been a number of experiments demonstrating G protein-
independent signalling that appears to depend on arrestin scaffolding of MAPK 
cascades (Pierce, Luttrell et al. 2001; Song, Coffa et al. 2009). Since I did not 
use any arrestin signalling data to create the model, the ability to match 
arrestin-mediated ERK signalling data would be an independent validation of 
my model. I have compared the simulated time course of surface arrestin 
species viz. sum total of Arrs and ArrRg*Ls (Figure 3.1) with recent data 
(Shenoy, Drake et al. 2006) showing the G protein independent activation of 
ERK (Figure 3.4). For the early times of agonist stimulation there is good 
correlation of simulated surface arrestin with G protein independent ERK 
activation. The discrepancy in latter time points might be due to activation of 
ERK phosphatases which is not explicitly modelled. 
3.2.8. Sensitivity Analyses  
I subjected the model to a univariate sensitivity analyses by varying individual 
rates over a twenty-fold range and studying its effects on the simulated β2AR 
desensitisation and resensitisation under conditions described in 3.2.5 and 
3.2.6. The motivation to run sensitivity analyses on desensitisation and 
resensitisation were, 1) these were functional readouts of the signalling 
pathway; 2) these were experiments that validated the behaviour of the insilico 
β2AR signalling pathway; and 3) test for the robustness of the model by 
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checking for the dependence of modeled behavior on choice of reaction 
parameters.  
The simulations were carried out as described in Methods 2.2.6 and the results 
plotted as the difference from the average experimental value at each time 
point.  
In the simulated β2AR desensitisation experiments the model was significantly 
sensitive to perturbations of only three rates (Figure 3.5). Decreasing GRK-
mediated β2AR phosphorylation (k2f, Table 3.1) reduced the desensitisation at 
earlier time points. Reduction of arrestin affinity for the β2AR-agonist complex 
(k3f, k3b, Table 3.1) decreased desensitisation at later time points. These 
observations were consistent with the model design.  
The interpretation of the sensitivity analysis for β2AR resensitisation (Figure 
3.6) is not straightforward because I’d to first desensitise the system. The pre-
desensitisation affected the initial simulated values of resensitisation. Reducing 
ArrRg*Ls internalisation (k8f, Table 3.1) decreased β2AR desensitisation at 15 
min (see conditions in Figure 3.3B) leading to a higher baseline at the start of 
resensitisation causing an overestimate of initial resensitisation. Perturbing 
internalisation rates did not have any additional effects on latter time points of 
resensitisation. Increasing β2AR recycling (k11f, k13f, Table 3.1) reduced the 
internalised pool of β2AR and caused an overestimation of β2AR 
resensitisation. As a quality control measure the sensitivity analyses did not 
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reveal any unexpected surprises in the model behavior and it was robust over a 
wide range of perturbations. 
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Figure 3.5. Univariate Sensitivity Analyses of the Model for Desensitisation.  
Panels A–Q: Simulated isoproterenol (10 µM) induced β2AR desensitisation over a twenty-
fold variation of individual rates. Negative values indicate a simulated measurement higher 
than experimental measure.  
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Figure and Figure Legend Source: 
http://dx.doi.org/10.1371/journal.pcbi.1000647#pcbi.1000647.s002 
“Quantitative Modeling of GRK-Mediated β2AR Regulation.” Vayttaden SJ, Friedman J, Tran 
TM, Rich TC, Dessauer CW, Clark RB (2010) PLoS Comput Biol 6(1): e1000647. 
doi:10.1371/journal.pcbi.1000647 
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Figure 3.6. Univariate Sensitivity Analyses of the Model for Resensitisation.  
Panels A–Q: Simulated β2AR resensitisation post 15 min isoproterenol (1 µM) treatment over 
a twenty-fold variation of individual rates. Negative values indicate a simulated measurement 
higher than experimental measure.  
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Figure and Figure Legend Source: 
http://dx.doi.org/10.1371/journal.pcbi.1000647#pcbi.1000647.s003 
“Quantitative Modeling of GRK-Mediated β2AR Regulation.” Vayttaden SJ, Friedman J, Tran 
TM, Rich TC, Dessauer CW, Clark RB (2010) PLoS Comput Biol 6(1): e1000647. 
doi:10.1371/journal.pcbi.1000647 
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3.3. Model Description  
The ordinary differential equations for the GRK-mediated β2AR regulation based 
on the Laws of Mass Action are given below. 
Equation 3.1  
dRdt  	k  k	R  	k	RL  	k	R 
Equation 3.2  
dRLdt  	k  k	RL  	k	R  	kR L 
Equation 3.3  
dR Ldt  	k  k  kR L  	k	RL  	kArrR L  	kR  
Equation 3.4  
dArrR Ldt  	k  k  kArrR L  	kR L  	kArrR 
Equation 3.5  
dArrRdt  	k  k  kArrR  	kArrR L 
Equation 3.6  
dRdt  	k  k   kR  	kR L  	kR  
	kArrR  
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Equation 3.7  
dArrRdt  	k!  kArrR  	kArrR L  	kArrR  
Equation 3.8  
dRdt  	k"  k  kR  	k!ArrR  	kR 
Equation 3.9  
dRdt  	k  k	R  	k	R  	k"R 
Equation 3.10  
dR#$%&#$#dt  	kArrR  	kR  	k	R 
In the equations 3.1-3.10 kxf and kxb denote the forward and backward rates for 
the reaction number denoted by x. Rs = β2AR on the plasma membrane; R*Ls = 
Agonist bound β2AR on the plasma membrane; Rg*Ls = Agonist bound, GRK 
phosphorylated β2AR on the plasma membrane; ArrRg*Ls= Agonist and arrestin 
bound, GRK phosphorylated β2AR on the plasma membrane; ArrRgs = Arrestin 
bound, GRK phosphorylated β2AR on the plasma membrane; ArrRgi = Arrestin 
bound, GRK phosphorylated β2AR in the internalised compartments; Rgi = GRK 
phosphorylated β2AR in the internalised compartments; Ri = β2AR in the 
internalised compartments; Rdegraded = Degraded β2AR in the cytoplasm. 
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3.4. Model Results and Discussions  
GRK and arrestin isoforms have been frequently targeted for overexpression or 
knockdown in different cells types (Ahn, Nelson et al. 2003; Penela, Ribas et al. 
2003; Reiter and Lefkowitz 2006; Violin, Ren et al. 2006; Luo, Busillo et al. 2008). 
These proteins also differ in their overall expression levels and localisation (Zhang, 
Barak et al. 1997; Komori, Cain et al. 1998). They also undergo post-translational 
modifications which might affect its activity (Lin, Krueger et al. 1997; Lin, Chen et 
al. 2002; Penela, Ribas et al. 2003; Shenoy, Drake et al. 2006). Given that there is 
wide variability in the activity or level of theseβ2AR regulatory proteins in different 
cell types I was interested in the effect of this variability on the modelling results. I 
varied GRK-mediated β2AR phosphorylation and arrestin β2AR binding rates over 
a hundred-fold range around rates mentioned in Table 3.1 and plotted its effects on 
β2AR phosphorylation, desensitisation and internalisation over a 0–30 min time 
course.  
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Figure 3.7 Simulated Effects of Varying Rates of GRK Phosphorylation and 
Arrestin Binding. 
Panels A–C: Simulated effects of hundred-fold variation in GRK phosphorylation rates on (A) 
phosphorylation, (B) internalisation and (C) desensitisation. D–E: Simulated effects of 
hundred-fold variation in arrestin binding rates on (D) phosphorylation, (E) internalisation and 
(F) desensitisation. Experimental data as given in Figure 3.2A, C, and Figure 3.3A. 
Figure and Figure Legend Source: http://dx.doi.org/10.1371/journal.pcbi.1000647.g004 
“Quantitative Modeling of GRK-Mediated β2AR Regulation.” Vayttaden SJ, Friedman J, Tran 
TM, Rich TC, Dessauer CW, Clark RB (2010) PLoS Comput Biol 6(1): e1000647. 
doi:10.1371/journal.pcbi.1000647 
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3.4.1. Variation in GRK-Mediated β2AR Phosphorylation Rates 
Steady states of GRK phosphorylated β2AR were unaffected over hundred-fold 
variation in GRK phosphorylation rates (Figure 3.7 A-C) on treatment with 
saturating concentration (10 µM) of epinephrine. Initial GRK phosphorylation 
was significantly affected only by a decrease in the phosphorylation rates 
(Figure 3.7A). Since β2AR phosphorylation measurements in most GRK 
overexpression and knockdown studies are performed with saturating agonist 
concentrations at steady state, my model suggests that this would increase the 
risk of false negative results. A more exacting measure for the effects of GRK 
overexpression and knockdown experiments would be an estimate of the initial 
rates of GRK-mediated receptor phosphorylation at sub-saturating ligand 
concentrations. To test this assertion I simulated the effects of hundred-fold 
variations in rates of GRK-mediated β2AR phosphorylation following treatment 
with 50 nm epinephrine. Figure 3.8 clearly shows that effects of variations in 
GRK-mediated β2AR phosphorylation are more pronounced at subsaturating 
ligand concentrations.  
Since GRK phosphorylation of the β2AR is a pre-requisite for agonist-induced 
arrestin binding (Krasel, Bunemann et al. 2005)  and internalisation, only 
perturbations that markedly affected GRK phosphorylation affected 
internalisation. Therefore only lowering the GRK-mediated β2AR 
phosphorylation rates had any marked effect on the initial rates of 
internalisation, with little effect on the maximum internalisation (Figure 3.7B).  
The effects on desensitisation were similar to phosphorylation albeit they were 
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phase shifted on account of these being sequential events (Figure 3.7C).  
Therefore effects of variations in GRK-mediated β2AR phosphorylation on both 
internalisation and desensitisation are best studied at early time points with 
subsaturating ligand concentrations. 
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Figure 3.8 Simulated Effects of Varying Rates of GRK Phosphorylation.  
Effect of variations in GRK levels or activity on phosphorylation at subsaturating concentration 
of epinephrine (50 nM) is simulated by ten-fold up or down variations in GRK phosphorylation 
rates.  
Figure and Figure Legend Source:  
http://dx.doi.org/10.1371/journal.pcbi.1000647 #pcbi.1000647.s004 
“Quantitative Modeling of GRK-Mediated β2AR Regulation.” Vayttaden SJ, Friedman J, Tran 
TM, Rich TC, Dessauer CW, Clark RB (2010) PLoS Comput Biol 6(1): e1000647. 
doi:10.1371/journal.pcbi.1000647 
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3.4.2. Variation in Arrestin β2AR Binding Rates 
I varied the rates of arrestin binding β2AR over a hundred-fold range and 
studied the effect it had on GRK-mediated β2AR phosphorylation, 
internalisation and desensitisation (Figure 3.7D-F). Perturbing arrestin binding 
rates did not have significant effects on the initial maxima of GRK-mediated 
β2AR phosphorylation (Figure 3.7D). This was expected and served as a good 
sensitivity analyses since arrestin binding occurs only subsequent to GRK-
mediated β2AR phosphorylation. Reducing arrestin binding rates (Figure 3.7E) 
decreased internalisation by approximately 40% within 5-10 minutes post 
agonist treatment, whereas increasing these rates did not significantly increase 
the maximum internalisation at 30 minutes. The effect of variations in arrestin 
binding rates on β2AR desensitisation was similar to that of internalisation in 
that only a reduction in arrestin binding rates decreased desensitisation.  
3.4.3. Effects of β2AR Trafficking and the Cellular Location of 
Dephosphorylation  
The possibility of cell surface dephosphorylation of the GRK phosphorylated 
β2AR and the recycling of the phosphorylated β2AR has been a contentious 
issue (Yu, Lefkowitz et al. 1993; Pippig, Andexinger et al. 1995; Krueger, Daaka 
et al. 1997; Iyer, Tran et al. 2006; Kelly 2006). Our group has shown that 1) 
blocking internalisation does not prevent β2AR dephosphorylation (Iyer, Tran et 
al. 2006), and 2) that β2AR dephosphorylation can occur even at undetectable 
levels of internalisation (Tran, Friedman et al. 2007). I have determined GRK 
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site β2AR dephosphorylation rates at the membrane to be ~0.04/min per 
method described in 2.1.1. 
Other GPCRs such as f TRH receptors (Jones and Hinkle 2005) and D1 
dopamine receptors (Gardner, Liu et al. 2001) also undergo dephosphorylation 
at the plasma membrane. To investigate the effects of membrane 
dephosphorylation and phosphorylated receptor recycling I created six different 
models (Figure 3.9A-F) that vary different reactions as described in the footnote 
of Table 3.1. For ease of visualisation of the cellular distribution of the GRK 
phosphorylated β2AR, I plotted the total (black), the cytosolic (blue), and the 
surface (red) GRK phosphorylated β2AR.  
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Figure 3.9 Simulated Effects of Phosphatase Location and Recycling of 
Phosphorylated β2AR on Receptor Dephosphorylation.  
HEK 293 cells stably overexpressing WT β2AR were treated for 5 min with 1 µM ISO (red bar) 
followed by washout and addition of 1 µM propranolol (blue bar). Experimental data (Tran, 
Friedman et al. 2007) are shown as discrete points with standard errors and the simulations 
are shown as continuous lines. The black lines are the total phosphorylated receptor, red 
indicates the phosphorylated receptor on the plasma membrane and blue indicate internalised 
levels of phosphorylated β2AR. (A) Model 1 allows for dephosphorylation of both the 
internalised and plasma membrane bound receptor along with recycling of phosphorylated and 
dephosphorylated receptor. (B) Model 2 disallows plasma membrane dephosphorylation but 
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allows both dephosphorylation of the internalised receptor and recycling of phosphorylated 
receptor. (C) Model 3 allows for dephosphorylation of both the internalised and plasma 
membrane bound receptor but limits recycling to only dephosphorylated receptor. (D) Model 4 
allows for dephosphorylation only at the plasma membrane and also allows recycling of 
phosphorylated receptor. (E) Model 5 allows for dephosphorylation only at the plasma 
membrane and disallows recycling of phosphorylated receptor. (F) Model 6 allows for 
dephosphorylation only after internalisation and prevents recycling of phosphorylated receptor.  
Model 1: All rates are set as described in Table 3.1, for the default model. 
Model 2: k2b = k7f = 0 /min since this model disallows dephosphorylation at the plasma 
membrane. 
Model 3: k13f = 0 /min since this model disallows recycling of phosphorylated receptor. 
Model 4: k10f = 0 /min since this model disallows dephosphorylation of the internalised 
receptor. 
Model 5: k10f = k13f = 0 /min since this model does not allow neither dephosphorylation of the 
internalised receptor nor recycling of phosphorylated receptor. 
Model 6: k2b = k7f = k13f = 0 /min since this model does not allow neither dephosphorylation of 
the receptor at the plasma membrane nor recycling of phosphorylated receptor. 
Figure and Figure Legend Source adapted from: 
http://dx.doi.org/10.1371/journal.pcbi.1000647.g005 
“Quantitative Modeling of GRK-Mediated β2AR Regulation.” Vayttaden SJ, Friedman J, Tran 
TM, Rich TC, Dessauer CW, Clark RB (2010) PLoS Comput Biol 6(1): e1000647. 
doi:10.1371/journal.pcbi.1000647 
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In Figure 3.9A I modelled our default reaction topology that allowed for both 
receptor dephosphorylation at the cell surface and phosphorylated receptor 
recycling. I contrasted this with Figure 3.9F where I modelled a reaction 
topology that did not allow for both plasma membrane dephosphorylation and 
recycling of phosphorylated receptor. This was in keeping with the prevalent 
view around early 2000s (Krupnick and Benovic 1998; Billington and Penn 
2003). I showed that under these conditions the system failed to achieve more 
than 50% β2AR dephosphorylation which was discordant with our experimental 
measurements (Tran, Friedman et al. 2007). Increasing the cytosolic 
dephosphorylation rate did not help in rescuing the simulated 
dephosphorylation curves. Thus through modeling I was able to show that the 
prevalent model of early 2000s was not able to explain dephosphorylation 
measurements done in our lab. 
Since there were two reactions being contested viz. receptor dephosphorylation 
at the plasma membrane and phosphorylated receptor recycling, I decided to 
explore the effects of disallowing one of each reaction and cytosolic 
dephosphorylation in the remaining models to ensure that a random variation of 
these reaction topologies wouldn’t match our experimental data (Figure3.9B-E). 
Of the models tested Figure 3.9C and D showed that two models matched the 
measured dephosphorylation kinetics in addition to my default model. This 
therefore required additional testing of the two models to see if they matched 
other experimental measurements of our β2AR over expression system. 
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Preventing recycling of GRK phosphorylated β2AR did not skew the simulated 
rate of β2AR dephosphorylation (Figure 3.9C). I subjected Model 3 to further 
tests (Figure 3.10A-E) against other experimental measurements and showed 
that in the absence of GRK phosphorylated β2AR recycling, the model did not 
match the experimental measurements of internalisation (Figure 3.10B), 
recycling (Figure 3.10C) and resensitisation (Figure 3.10E). In the light of these 
observations it was clear that Model 3 could not represent the topology of 
reactions for β2AR in our over expression HEK293s. 
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Figure 3.10 Comparisons of Five Experimental Results with Simulations of 
Model 3 and 4.   
Through panels A–E I test alternate models 3 and 4 to see how well they match other 
experimental readouts of the β2AR signalling system besides dephosphorylation (c.f. Figure 
3.9C, D). Comparisons of simulations (continuous lines) of model 3 (A–E) and model 4 (F–J), 
with experimental data obtained in HEK 293 cells stably expressing the WT β2AR (discrete 
data points). (A, F) Time course of GRK phosphorylation of the receptor on treatment with 50 
nM isoproterenol (Tran, Friedman et al. 2004). (B, G) Internalisation of the β2AR on treatment 
with 1 µM isoproterenol. Surface receptor is measured by the loss of [3H]CGP-12177. (C, H) 
Recycling of the receptor after 20 min treatment with 1µM isoproterenol followed by rapid 
washout of agonist (Morrison, Moore et al. 1996). (D, I) Desensitisation of β2AR stimulation of 
adenylyl cyclase post treatment with 10 µM isoproterenol. (E, J) Resensitisation of the β2AR 
stimulation of adenylyl cyclase. WT β2AR were stimulated with 1µM isoproterenol for 15 min, 
followed by addition of metoprolol as described in 3.2.6.  
Figure and Figure Legend Source: 
http://dx.doi.org/10.1371/journal.pcbi.1000647#pcbi.1000647.s005                            
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“Quantitative Modeling of GRK-Mediated β2AR Regulation.” Vayttaden SJ, Friedman J, Tran 
TM, Rich TC, Dessauer CW, Clark RB (2010) PLoS Comput Biol 6(1): e1000647. 
doi:10.1371/journal.pcbi.1000647 
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There was a good match between the measured and simulated 
dephosphorylation rates in Figure 3.9D where I had allowed recycling of the 
GRK phosphorylated β2AR and dephosphorylation only at the plasma 
membrane.  I subjected Model 4 to further tests in Figure 3.10F-J. I showed that 
in the absence of cytoplasmic β2AR dephosphorylation, a 30 fold higher plasma 
membrane dephosphorylation rate is required to match the experimentally 
measured phosphorylation kinetics (Figure 3.10F). Absence of cytosolic β2AR 
dephosphorylation is at odds with experimental observations of the β2AR 
(Sibley, Strasser et al. 1986; Pippig, Andexinger et al. 1995; Tran, Friedman et 
al. 2007). In the light of these observations it was clear that Model 4 could not 
represent the topology of reactions for β2AR in our over expression HEK293s. 
This model cannot be summarily rejected for other GPCRs though where 
significant cytosolic dephosphorylation might not occur under physiological 
conditions.  
I allowed for solely plasma membrane dephosphorylation and prevented 
phosphorylated receptor recycling in Model 5 (Figure 3.9E). Under these 
conditions the dephosphorylation rates were significantly reduced. Thus of the 
six models designed, only one model viz. model 1 (Figure 3.1, Table 3.1, Figure 
3.9A) accounted for six different types of experimental measurements (Figures 
3.2, 3.3). This model was functionally unique and random variation in topologies 
of dephosphorylation and recycling reactions could not recapitulate all 
experimental measurements of our β2AR over expression system in HEK293s. 
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3.4.4. Frequency Coding 
Most of the studies discussed until now were performed in the presence of 
saturating agonist concentrations for long durations. Such a prolonged 
exposure rarely occurs under normal physiological conditions without 
pharmacological intervention. Rather based on the target tissue the β2AR 
“sees” different frequencies and amplitudes of stimuli. Synaptic β2AR “sees” 
high norepinephrine concentrations in a pulsatile fashion (Trendelenburg, 
Gaiser et al. 1999; Stjarne 2000) due to the small synaptic volumes, rapid 
removal and reuptake of norepinephrine. In contrast to the synaptic stimuli, the 
bloodstream concentrations of agonist post epinephrine secretion from the 
adrenal gland are much lower but for relatively longer periods. 
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Figure 3.11 Simulations of the Effects of Frequency Modulation.  
In these panels I describe the effect of varying the frequency of stimulation on surface (black), 
phosphorylated (red) and active (green) receptor species. (A) Rapid stimulation with a train of 
1 µM isoproterenol pulses for 0.5 min followed by a 0.5 min washout. Note that this achieves 
more than 80% desensitisation with only 20% internalisation. (B) This panels shows the 
results of a 5 min stimulation with 1.0 µM isoproterenol and a 5 min washout. (C) Simulation of 
30 min stimulation with 50 nM isoproterenol followed by washout of 30 min. This panel shows 
that even with low β2AR occupancy (15%) the prolonged stimulation time gives substantial 
desensitisation.  
Figure and Figure Legend Source: http://dx.doi.org/10.1371/journal.pcbi.1000647.g006 
“Quantitative Modeling of GRK-Mediated β2AR Regulation.” Vayttaden SJ, Friedman J, Tran 
TM, Rich TC, Dessauer CW, Clark RB (2010) PLoS Comput Biol 6(1): e1000647. 
doi:10.1371/journal.pcbi.1000647 
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I explored the effects of varying frequencies of agonist stimulation on my model. 
The first scenario shown here is that of stimuli at ~ 0.0167 Hz which is 
equivalent to 30 s bursts of agonist followed by 30 s washouts. I assumed that 
the washouts were perfect and allowed for instantaneous agonist dissociation 
from the receptor (Figure 3.11A). Under this stimulation pattern almost 100% 
GRK phosphorylation (red – GRK phosphorylated β2AR) is achieved with only 
20% internalisation (black – surface β2AR) but about 80% desensitisation 
(green – active β2AR). Post agonist washout, resensitisation was rapid due to 
fastdissociation of arrestin from the receptor. In spite of this near complete 
recovery, during subsequent pulsatile activation of the β2AR, the signalling 
machinery “remembers” previous agonist exposure and desensitises much 
more strongly on subsequent exposures. This memory of prior stimuli can be 
attributed to the accumulation of the GRK phosphorylated β2AR due to slower 
dephosphorylation. 
In Figure 3.11B I stimulate the system with a continuous 5 min long delivery of 
1µM isoproterenol followed by a 5 min wash and subsequent restimulation for 5 
min. Under this stimulus profile close to 95% β2AR is desensitised with ~ 50% 
β2AR internalised. In Figure 3.11C I tested the response of the β2AR system on 
prolonged exposure to sub-saturating levels of agonist. I simulated the 
response to 30 min delivery of 50 nM isoproterenol followed by 30 min wash 
and restimulation. Under longer periods of ligand treatment (Figure 3.11B, C) 
the resensitisation was biphasic (c.f Figure 3.3B). The rapid phase of 
resensitisation is dependent upon arrestin dissociation from the receptor while 
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the slower phase is dependent upon receptor recycling and dephosphorylation 
(Tran, Friedman et al. 2007). 
The phenomenon of latent memory that I described in Figure 3.11A was only 
observed at higher frequencies of agonist stimulation. For longer periods of 
stimulation (Figure 3.11C), as might be seen during treatment with a strong, 
stable agonist in diseases such as asthma, receptor recycling would play a 
significant role in resensitisation.  
3.4.5. Latent Memory 
Having previously shown in Figure 3.11A that the β2AR signalling machinery 
could “remember” previous stimuli I wanted to explore the effects of variation in 
inter-pulse duration (time between paired pulse stimulation), β2AR 
dephosphorylation and arrestin dissociation on this latent memory. I simulated a 
paired pulse pattern of β2AR activation with 1µM isoproterenol (Figure 3.12A). 
Even on rapid, near complete β2AR resensitisation, the system remembered 
previous stimuli and showed stronger desensitisation in response to 
subsequent stimuli (“active” β2AR- green lines, Figure 3.12A). The latent 
memory can be attributed to stockpiling of GRK phosphorylated β2AR on the 
surface (red). Pre-phosphorylation of the β2AR primes the system for faster 
arrestin binding to surface receptor (blue) on subsequent agonist activation, 
leading to increased desensitisation. Increasing the inter-pulse duration 
weakened the memory (Figure 3.12B), since it allowed the slow rate of 
dephosphorylation to catch up. The memory survived beyond 30 min post first 
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stimulus.  An extreme 50 fold increase in dephosphorylation rates was required 
to erode the memory of the previous stimuli (Figure 3.12C). 
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Figure 3.12 Basis for “Cellular Memory” in the β2AR Signalling Machinery.  
(A) Simulation of activation of β2AR by paired pulses of 1 µM isoproterenol. Higher 
desensitisation is obtained for the second and third pulse. Colours indicate simulated receptor 
species as indicated in the figure. (B) Decay in memory of prior stimuli on increase in inter-
pulse period from 1–120 min. (C) Effect of up to 50 fold increase in surface dephosphorylation 
rates on memory of prior stimuli. Default dephosphorylation rate is 0.036/min. (D) Effect of 
arrestin-β2AR complex stability on desensitisation time courses simulated by varying arrestin 
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dissociation rates from the ligand-free complex on the surface. Default arrestin surface 
dissociation rate from the ligand-free complex is 11/min.  
Figure and Figure Legend Source: http://dx.doi.org/10.1371/journal.pcbi.1000647.g007 
“Quantitative Modeling of GRK-Mediated β2AR Regulation.” Vayttaden SJ, Friedman J, Tran 
TM, Rich TC, Dessauer CW, Clark RB (2010) PLoS Comput Biol 6(1): e1000647. 
doi:10.1371/journal.pcbi.1000647 
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Figure 3.13 Sensitivity of Simulated “Cellular Memory” to the Stability of 
Arrestin-Receptor/Ligand Complex.   
Simulation of activation of β2AR by paired pulses of 1 µM Isoproterenol. Higher 
desensitisation is obtained for the second and third pulse even on 100 fold increased stability 
of the arrestin-receptor/ligand complex.  
Figure and Figure Legend Source: 
http://dx.doi.org/10.1371/journal.pcbi.1000647#pcbi.1000647.s006                             
“Quantitative Modeling of GRK-Mediated β2AR Regulation.” Vayttaden SJ, Friedman J, Tran 
TM, Rich TC, Dessauer CW, Clark RB (2010) PLoS Comput Biol 6(1): e1000647. 
doi:10.1371/journal.pcbi.1000647 
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Some GPCRs have a higher affinity for arrestin than β2AR causing a slower 
release of arrestin from the receptor post internalisation (Moore, Milano et al. 
2007). To investigate the effects of slow arrestin release from β2AR on latent 
memory I decreased the dissociation rate of arrestin from the β2AR (Figure 3.1, 
Table 3.1; k3b, k6f, k9f) thereby mimicking a high affinity complex. The time 
required for resensitisation was directly proportional to the affinity of arrestin for 
the β2AR (Figure 3.12D). Next I increased the stability of the ligand/β2AR 
/arrestin complex by a 100 fold reduction in the ligand off-rate (Figure 3.1, Table 
3.1; k5f). This did not diminish the extent of memory, but it did increase the 
recovery time between each paired pulse (Figure 3.13). In summary, the 
predicted latent memory was due to (i) slow β2AR dephosphorylation (0.036 
/min); and (ii) rapid arrestin dissociation from ligand free β2AR (11.0 /min).  
3.4.6. Model Limitations 
My model ignores effects of adenylyl cyclase or PDE regulation and PKA 
mediated β2AR phosphorylation. In the absence of the PKA/PDE module the 
current model fails to capture the behaviour of the β2AR signalling machinery at 
low agonist concentrations as shown in Figure 3.3A inset (red bar graphs). Our 
group has shown that at high agonist concentrations GRK phosphorylation 
appears to decrease PKA site phosphorylation of the β2AR (Vaughan, Millman 
et al. 2006). Prestimulation of PKA mediated β2AR phosphorylation with 
forskolin on the other hand does not affect GRK mediated β2AR 
phosphorylation (Tran, Friedman et al. 2004). So clearly there is some interplay 
between PKA and GRK phosphorylation of the β2AR and this cannot be 
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explored in the current model. I have modelled only receptor-level 
desensitisation and as a consequence omitted downstream regulatory events 
like adenylyl cyclase regulation. 
On account of lack of relevant kinetic data my model ignores multi-site 
phosphorylation of the receptor in that it considers phosphorylation and 
dephosphorylation of S365, 366 as a single event and ignores phosphorylation 
at other sites by GRK or PKA. As a consequence of this simplification this 
model cannot be used to explore effects of phosphosignature on receptor 
sorting and varied receptor activity. 
In this model I collapse internalisation of arrestin-bound, GRK-phosphorylated 
ligand-bound β2AR and post-internalisation ligand dissociation into the same 
step since internalisation is slower than ligand dissociation rates for full agonists 
like epinephrine/isoproterenol. This model in its current state cannot be used to 
simulate post-internalisation effects on treatment with a partial agonist like 
salmeterol that quasi-irreversibly bind to the β2AR. 
The simplistic ligand-induced two-state receptor activation model used here can 
be used to credibly simulate a variety of biochemical events that the receptor 
undergoes like GRK phosphorylation/dephosphorylation, receptor trafficking, 
desensitisation/resensitisation. This representation of receptor activation is not 
amenable to studying biased signalling of the receptor on account of lack of 
representation of other signalling states of the receptor and lack of downstream 
signalling proteins like the elements of the MAPK cascade. 
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Due to the use of pseudo-first order reactions to simulate ligand -, arrestin- and 
GRK-binding the receptor the model in its current form cannot be used to study 
the effects of prolonged membrane accumulation of lipophilic ligands like 
salmeterol and formoterol that could persist even after internalisation of the 
receptor. This model also cannot explore effects of agonist treatment on GRK 
and arrestin trafficking and recruitment to the plasma membrane bound 
receptor. 
I have shown that preventing plasma membrane receptor dephosphorylation 
and recycling of the GRK phosphorylated receptor is antithetical with my 
modeling and our previous experimental results. A point to note is that my 
model does not have a significant basal internalisation. Agonist-independent 
internalisation does occur in GPCRs like the melanocortin MC4 receptor 
(Mohammad, Baldini et al. 2007) and cannabinoid CB1 receptor (McDonald, 
Henstridge et al. 2007). Our group has shown that in HEK293s there is no 
detectable basal internalisation of the β2AR (Morrison, Moore et al. 1996). 
Others have detected agonist-independent internalisation in HeLa cells 
transiently transfected with M3R or β2AR (Scarselli and Donaldson 2009). It 
needs to be examined if agonist-independent β2AR internalisation occurs in 
other cell lines, and if it does the current model would hold true only for β2AR 
signalling in HEK293s. 
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4. Partial Agonist Models 
Agonist-induced activation of a GPCR leads to a change in the relative orientations of 
the transmembrane helices leading to induction of a signal transduction function. The 
efficiency with which these ligands induce the downstream signal transduction is called 
coupling efficiency.  Partial agonists are ligands that give sub-maximal receptor 
activation on account of lower coupling efficiency even at receptor saturation. For 
β2AR, isoproterenol (Isuprel®) and epinephrine (endogenous ligand) are examples of 
full agonists while salmeterol (Servent®) and albuterol (Ventolin®, Proventil®) are 
examples of partial agonists. Except for cyclopentylbutanephrine, the initial rate of 
GRK-mediated β2AR phosphorylation is proportional to the coupling efficiency of 
partial agonists (January, Seibold et al. 1997; Tran, Friedman et al. 2004; Drake, Violin 
et al. 2008).  
4.1. Relative Efficacies  
I used the GRK-mediated β2AR regulation model developed in Chapter 3 to model 
partial agonist induced GRK-mediated β2AR phosphorylation. To do this I set the 
coupling efficiencies of the partial agonist relative to epinephrine/isoproterenol (α in 
Table 2.1 for parameter k2f). The relative coupling efficiencies for partial agonists 
are given in Table 4.1. 
Figure 4.1A shows that the simulated time course of salmeterol and albuterol 
induced GRK-mediated β2AR phosphorylation matches experimental data over 30 
minutes. In figure 4.1B I show that the simulation results match well the GRK-
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mediated β2AR phosphorylation at 2 min normalised to 10 µM epinephrine. These 
results are additional validation for Model 1 presented in Chapter 3. 
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Table 4.1. Relative Coupling Efficiencies and Kds of β-Agonists  
Agonist 
Coupling Efficiencies 
Relative to Epinephrinea 
Kd (nM) b 
Epinephrine 1 450 
Isoproterenol 1 283 
Fenoterol 0.66 133 
Formoterol 0.63 5 
Terbutaline 0.33 1835 
Zinterol 0.33 8.6 
Albuterol 0.25 420 
Salmeterol 0.13 < 2 
Dobutamine 0.04 589 
Ephedrine 0.03 2674 
a
 The relative coupling efficiencies are calculated as described by our group 
previously (Tran, Friedman et al. 2004). 
b
 Kds as estimated in HEK293 cells stably overexpressing β2AR. 
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Figure 4.1 Comparison of Simulated Time Course of GRK Site Phosphorylation 
with Experimentally Measured Phosphorylation in Response to Various 
Agonists. 
 (A) The simulated time course of GRK site phosphorylation of the β2AR in response to 
various agonists is compared with experimentally measured phosphorylation (Tran, Friedman 
et al. 2004). (B) Comparison of simulated and experimentally measured GRK-mediated β2AR 
phosphorylation at 2 min of agonist treatment normalised to phosphorylation achieved with 10 
µM epinephrine (Tran, Friedman et al. 2004).  
Figure and Figure Legend Source: 
http://dx.doi.org/10.1371/journal.pcbi.1000647#pcbi.1000647.s001 
“Quantitative Modeling of GRK-Mediated β2AR Regulation.” Vayttaden SJ, Friedman J, Tran 
TM, Rich TC, Dessauer CW, Clark RB (2010) PLoS Comput Biol 6(1): e1000647. 
doi:10.1371/journal.pcbi.1000647 
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4.2. Previous Models of Salmeterol Action on the Receptor 
Salmeterol is a partial agonist that is extensively used clinically in maintenance 
therapy of asthma along with a steroid. Due to the clinical importance of salmeterol 
there have been a few phenomenological models of salmeterol. All models of 
salmeterol action must reconcile with two important phenomena of salmeterol 
action, viz. (i) long action (8-12 hours) as described in the section above; and (ii) 
reassertion of salmeterol action following first treatment with antagonist (that fully 
inhibits salmeterol action), and second, washout of antagonist without addition of 
new salmeterol (Ball, Brittain et al. 1991; Anderson 1993). Additionally clinical 
models of salmeterol must also explain the reason for delayed onset of salmeterol 
action (Ball, Brittain et al. 1991; Johnson, Butchers et al. 1993; Nials, Coleman et 
al. 1993). In contrast to slow onset of salmeterol action in patients and tissue 
explants, salmeterol shows no noticeable lag in monolayer cell culture experiments 
(McCrea and Hill 1993; Clark, Allal et al. 1996; McCrea and Hill 1996). Therefore, 
we have not attempted to model the torturous path of salmeterol to the relevant 
sites of action on the receptor. 
A detailed discussion of the merits of the different models of salmeterol action can 
be found elsewhere (Anderson, Linden et al. 1994; Szczuka, Wennerberg et al. 
2009). Briefly, salmeterol action has been explained by three models. Salmeterol 
is lipohilic and reversibly incorporates in the plasma membrane, resulting in a 
partition of drugs between a membrane and an aqueous phase (Rhodes, Newton 
et al. 1992). Due to membrane partitioning of salmeterol, the membrane can act as 
a salmeterol reservoir and this forms the basis of the microkinetic model (MM) 
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(Anderson, Linden et al. 1994) (Figure 4.2). Due to the high membrane partitioning 
of salmeterol and its slow rate of release from the membrane, t1/2 = 25 mins 
(synthetic membranes) – 3 hours (tracheal strips) (Rhodes, Newton et al. 1992; 
Austin, Barton et al. 2003) it is posited that salmeterol reaches the receptor by 
lateral diffusion through the membrane (Anderson, Linden et al. 1994) since by the 
time salmeterol traverses the length of the airways to reach the target bronchii it 
would have  bound to the membrane on account of its lipophilicity. 
Per the exosite model (EM) (Figure 4.4) the saligenin head of salmeterol (Figure 
1.2) and the hydrophobic phenylalkoxyalkyl side chain binds the β2AR at two 
spatially distinct sites. The site of saligenin head binding is identified as the active 
site and the site of hydrophobic phenylalkoxyalkyl side chain binding is called an 
exosite. In the exosite model tethering of the phenylalkoxyalkyl chain to the exosite 
is quasi-irreversible while the binding of the saligenin head to the active site is 
rapidly reversible. This model also allows agonist or antagonist binding to the 
active site when the exosite is occupied by salmeterol’s hydrophobic tail (Figure 
6.1). To allow the flipping in and out of the saligenin head from the active site, the 
exosite has been posited to be in the central core of the β2AR (Jack 1991). Both 
site directed mutagenesis studies involving replacement of β2AR central domains 
with β1AR (Green, Spasoff et al. 1996; Isogaya, Yamagiwa et al. 1998) and 
photoaffinity labeling with [125I]iodoazido-salmeterol (Rong, Arbabian et al. 1999) 
lend credence to the idea that the exosite is further into the transmembrane 
domains toward the cytosol than the active site. 
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 The rebinding model posits that a high local concentration of salmeterol is 
maintained on account of rapid rebinding (Szczuka, Wennerberg et al. 2009). This 
model wouldn’t be able to explain the reassertion phenomenon when a competing 
ligand is present without invoking another mechanism to retain salmeterol in the 
proximity of the receptor.  
Given the importance of salmeterol in treating asthma and COPD (as discussed in 
Section 1.3) I developed phenomenological models to describe the effects of 
membrane retention of salmeterol, exosite binding or a composite of the two 
(combined model - CM). I then coupled these models to an adaptation of the 
GRK-mediated β2AR regulation model developed in Chapter 3 and then tested 
them to see if properties of salmeterol long action and reassertion still held true.  
4.2.1. Model Assumptions 
4.2.1.1. Isoproterenol Partitioning (Valid for MM/EM/CM) 
I presume that isoproterenol “sees” the plasma membrane as an inert 
substratum for the β2AR. As a consequence of this there is no partitioning of 
isoproterenol from the aqueous phase into the plasma membrane. Washout 
of isoproterenol from the aqueous phase results in no lingering free 
isoproterenol concentration in the plasma membrane. To mimic addition of 
isoproterenol in an in silico experiment I initialise free isoproterenol 
concentration in the aqueous phase to the concentration used in the in vitro 
experiment. To mimic washout of isoproterenol in an in silico experiment I 
buffer free isoproterenol concentration in the aqueous phase to zero.  
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4.2.1.2. Salmeterol Partitioning (Valid for MM/CM) 
I have modelled salmeterol partitioning into the plasma membrane as a first 
order reaction. Partitition coefficient for a molecule is defined as the ratio of 
concentrations of a molecule in the phases of a mixture of immiscible 
solvents at equilibrium. Membrane based partition coefficient (Kp(mem)) for 
salmeterol has been determined to be 22500 from unilamellar liposomes 
(Rhodes, Newton et al. 1992; Lombardi, Cuenoud et al. 2009). Using 
dioleoyl phosphatidylcholine it has been estimated that under ideal 
conditions the association coefficient (Ka) would be ~ 1.24 X Kp(mem)(Rhodes, 
Newton et al. 1992). Thus the Ka of salmeterol would be ~ 27900.  
The t1/2 for salmeterol release from membranes ranges between ~ 60 min 
from unilamellar liposomes to ~ 180 min from multilamellar liposomes 
(Rhodes, Newton et al. 1992). I used the t1/2 of 180 min to calculate a rate of 
salmeterol release from the membrane because (i) the t1/2 is comparable to 
that from tracheal strips (Austin, Barton et al. 2003), and (ii) partition 
coefficients for other systems are not affected by lamellarity of membranes 
(Rhodes, Newton et al. 1992). Using a t1/2 of 180 min the rate of release of 
salmeterol from the plasma membrane (krel) is approximated to 0.004 /min. 
Once krel is known the rate of plasma membrane association for salmeterol 
(kin) can be approximated to 107 /min from Ka. 
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4.2.1.3. Salmeterol Exosite Binding (Valid for EM/CM) 
I have assumed that the rate of salmeterol binding to the exosite is same as 
the rate of plasma membrane association for salmeterol and hence both are 
denoted by kin with a t1/2 ~ 0.006/min. This is a simplification since based on 
the rate of appearance of the increase in basal adenylyl cylase activity in 
washed membranes after salmeterol treatment of intact cells we have 
estimated a t1/2 ~ 0.14/min. (Clark, Allal et al. 1996) 
Also I have assumed that the rate of release of salmeterol from the exosite 
is the same as the rate of salmeterol release from the plasma membrane, 
and hence both are denoted by krel. This too is a gross oversimplification 
since while we do know that the t1/2 of release of salmeterol from synthetic 
liposomes is ~180 min (Rhodes, Newton et al. 1992) krel from the exosite is 
quasi-irreversible making a measure of release of salmeterol from the 
exosite difficult (Clark, Allal et al. 1996). Further this rate is inextricably 
mixed in with release from the membranes. As a consequence of these 
simplifications it is possible to run the simulations for a shorter period of time 
and it is possible to compare the microkinetic and exosite models on the 
same timescales. 
Salmeterol can bind either the active site or the exosite of a naïve receptor. 
Again for ease of simulations I have ignored the receptor state that has 
salmeterol bound to the active-site alone (c.f.Figure 4.4. Reactions 6 and 7). 
Since I am exploring the effects of long term salmetereol action, at the time 
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courses being simulated, both active and exo-site of the receptor will be 
occupied.  
4.2.1.4. Ligand Binding (Valid for MM/EM/CM) 
Since we had an estimate of Kd for epinephrine to be ~ 450 nM (Vayttaden, 
Friedman et al. 2010) the off-rates were calculated to give the appropriate 
Kd. The on-rates of isoproterenol were assumed to be similar to epinephrine 
and then using a Kd of ~ 283 nM (Vayttaden, Friedman et al. 2010) 
appropriate off-rates were calculated. I assumed that salmeterol binds β2AR 
on the active site at the same rate as isoproterenol. Based upon the Kd for 
salmeterol (2 nM) (Rong, Arbabian et al. 1999), off-rates were calculated. In 
the exosite model Sal:REam (salmeterol bound only to the exosite) can 
transition into Sal:REAm (salmeterol bound to both active site and exosite on 
the β2AR). This transition is a first order reaction and its rate must match the 
second order rate for salmeterol binding β2AR (8.4e+08 /M.min). I estimated 
the first order transition rates to be ~ 20 /min by matching the t1/2 for both 
reactions at saturating agonist concentration. Using this calculation we note 
that the off rate for salmeterol is about 1400 times slower that for 
isopreoterenol/epinephrine. 
4.2.1.5. Ligand Dissociation (Valid for MM/EM/CM) 
I ignored ligand dissociation from membrane bound, GRK phosphorylated 
β2AR with or without arrestin in the larger models that have microkinetics or 
exosite binding introduced into the GRK-mediated β2AR regulation. This 
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was done to reduce the number of receptor states and reactions. The 
reactions that I have ignored have negligible fluxes under saturating agonist 
concentrations since under these conditions GRK phosphorylation and 
arrestin binding are favoured. Therefore I’ve validated the model only to 
GRK phosphorylation under saturating levels of agonist. Due to these 
modifications, under washout conditions there will be an exaggeration of 
membrane retention of agonists and residual receptor activity on account of 
accumulation of ligand bound GRK-phosphorylated β2AR. Arrestin kinetics 
will be unaffected by these modifications. It is not known if the assumption of 
saturating concentration of salmeterol might bear out under pharmacological 
conditions.  The recommended dose of Advair HFA gives 42 µg of 
salmeterol base which amounts to 60.90 µg of salmeterol xinafoate 
(GlaxoSmithKline 2008). Peak plasma concentrations from 21 µg  of 
salmeterol base is about 510 pg/mL but due to the lipophilicity of salmeterol 
it is anybody’s guess what the actual concentrations are in the plasma 
membranes. 
4.2.2. Microkinetic Model (MM) 
The hallmark of the microkinetic model (Figure 4.2) is the partitioning of salmeterol 
into the plasma membrane which then serves as a reservoir for prolonged 
salmeterol action (Anderson, Linden et al. 1994). Table 4.2 lists the parameters 
used in my representation of the microkinetic model. Figure 4.3 shows that this 
representation of the microkinetic model can recapitulate both long action and 
reassertion of salmeterol post treatment with a competing ligand. 
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Figure 4.2 Reaction Diagram of the Microkinetic Model (MM) 
The membrane acts as depot for salmeterol (Salm) from where it is steadily released. Salo = 
Sal outside the cell; Rm = membrane bound β2AR; Sal:Rm = salmeterol bound to β2AR on the 
membrane; Isoo = isoproterenol in the aqueous phase; Iso:Rm = isoproterenol bound to β2AR 
on the membrane. 
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Table 4.2 Parameters of the Microkinetic Model 
Reaction Name Parameter Reference/Rationale 
Salmeterol association 
rate (to plasma 
membrane) 
kin= 107 min-1 Kp(mem) = 22500 (Rhodes, Newton et al. 1992) 
Salmeterol release rate 
(from plasma membrane) krel = 0.004 min
-1
 
t1/2 ~  180 min (Rhodes, Newton et 
al. 1992; Austin, Barton et al. 
2003) 
Salmeterol On kSal on = 8.4e+07 M-1.min-1 Rate of salmeterol binding β2AR assumed to similar to isoproterenol 
Salmeterol Off kSal off = 0.168 min-1 Kd ~ 2 nM (Rong, Arbabian et al. 1999) 
Isoproterenol On kIso on = 8.4e+07 M-1.min-1 
Kf set to achieve ~ 47 msec τ for 
10µM isoproterenol binding 
(Reiner, Ambrosio et al. 2010) 
Isoproterenol Off kIso off = 235.2 min-1 Kd ~ 283 nM (Vayttaden, Friedman et al. 2010) 
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Figure 4.3 Microkinetic Model – Salmeterol Long Action and Reassertion 
Simulations based on Figure 4.2 and Table 4.2. Long Action – Salmeterol bound active β2AR 
(black line) persists after 2 min treatment. Reassertion – Salmeterol bound active β2AR 
(black line) reappears even after 20 min washout and 20 min isoproterenol treatment followed 
by a 20 min second washout. 
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4.2.3. Exosite Model (EM) 
The exosite model (Figure 4.4) is characterised by the binding of salmeterol on the 
receptor at a site that is by necessity adjacent to the saligenin site. This exosite 
binding enables preferable partitioning of salmeterol into the plasma membrane 
which then serves as a reservoir for prolonged salmeterol action (Jack 1991). A 
key difference between the exosite and microkinetic model is that in the 
microkinetic model partitioning of salmeterol into the plasma membrane is driven 
by the drug’s lipophilicity whereas in the exosite model it is dependent upon the 
receptor concentration. 
Table 4.3 lists the parameters used in my representation of the exosite model. 
Figure 4.5 shows that this representation of the exosite model can recapitulate both 
long action and reassertion of salmeterol post treatment with a competing ligand.  
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Figure 4.4 Reaction Diagram of the Exosite Model (EM) 
The β2AR has an exosite to which salmeterol is bound and retained in the membrane. The 
subscript m denotes that the species is retained on the plasma membrane and the subscript o 
denotes that the species is in the aqueous phase. R denotes the β2AR and it is followed by 
subscripts eam, EAm, Eam and eAm where e/E and a/A denote the exosite and active site 
respectively and the case denotes whether these sites are empty or occupied. A lower case 
denotes that the site is empty and an upper case denotes that the site is occupied. Thus Ream 
=  β2AR with empty active- and exo-sites; Sal:REAm =  Salmeterol bound to both active- and 
exo-site on the β2AR; Sal:REam =  Salmeterol bound to only exo-site on the β2AR; Sal:ReAm =  
Salmeterol bound to only active-site on the β2AR; Iso:ReAm =  Isoproterenol bound to active-
site on the β2AR; Sal:Iso:ReAm =  Isoproterenol bound to active-site on the β2AR. Reactions 6 
and 7 are ignored in the simulations since at longer treatments active site should be occupied 
and exosite should be quasi-irreversibly occupied.  
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Table 4.3 Parameters of the Exosite Model 
Reaction Name Parameter Reference/Rationale 
Salmeterol association 
rate (to β2AR exosite) kin= 8e+07 M
-1
.min-1 
Set to match τ (at 4e-07 M 
salmeterol and 3e-07 M naïve 
β2AR) for membrane association 
of salmeterol in microkinetic model  
Salmeterol release rate 
(from β2AR exosite) kexo = 0.004 min
-1
 
t1/2 ~  180 min (Rhodes, Newton et 
al. 1992; Austin, Barton et al. 
2003) 
Salmeterol On                  
(to β2AR active site) kSal on = 20 min
-1
 
Set to match τ (at 4e-07 M 
salmeterol and 3e-07 M naïve 
β2AR) for salmeterol binding β2AR 
in microkinetic model 
Salmeterol Off             
(from β2AR active site) kSal off = 0.168 min
-1
 
Kd ~ 2 nM (Rong, Arbabian et al. 
1999) 
Isoproterenol On kIso on = 8.4e+07 M-1.min-1 
Kf set to achieve ~ 47 msec τ for 
10µM isoproterenol binding 
(Reiner, Ambrosio et al. 2010) 
Isoproterenol Off kIso off = 235.2 min-1 Kd ~ 283 nM (Vayttaden, Friedman et al. 2010) 
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Figure 4.5 Exosite Model – Salmeterol Long Action and Reassertion 
Simulations based on Figure 4.4 and Table 4.2. Long Action – Salmeterol bound active β2AR 
(black line) persists after 2 min treatment. Reassertion – Salmeterol bound active β2AR 
(black line) reappears even after 20 min washout and 20 min isoproterenol treatment. 
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4.2.4.  Combined Model (CM) 
The third model proposed for salmeterol action was the rebinding model (Szczuka, 
Wennerberg et al. 2009). This model explains long action of salmeterol by rapid 
rebinding of the released salmeterol to an adjacent receptor. As recognised by the 
proponents of this model, rebinding cannot by itself explain reassertion properties 
of salmeterol when a competing ligand is present. It is now generally accepted that 
the properties of salmeterol are due to a combination of microkinetics, exosite 
binding to the receptor and rebinding. I have thus made a composite model that 
allows for all three events to occur. The combined model is shown in Figure 4.6 
and its ability to capture long action and reassertion properties of salmeterol is 
shown in Figure 4.7. Table 4.4 lists the parameters used in my representation of 
the combined model. 
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Figure 4.6 Reaction Diagram of the Combined Model (CM) 
The β2AR has an exosite to which salmeterol is bound and retained in the membrane. The 
membrane also acts as depot for salmeterol (Salm) from where it is steadily released. R 
denotes the β2AR and it is followed by subscripts eam, EAm, Eam and eAm where e/E and 
a/A denote the exosite and active site respectively and the case denotes whether these sites 
are empty or occupied. A lower case denotes that the site is empty and an upper case denotes 
that the site is occupied. Thus Ream =  β2AR with empty active- and exo-sites; Sal:REAm =  
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Salmeterol bound to both active- and exo-site on the β2AR; Sal:REam =  Salmeterol bound to 
only exo-site on the β2AR; Sal:ReAm =  Salmeterol bound to only active-site on the β2AR; 
Iso:ReAm =  Isoproterenol bound to active-site on the β2AR; Sal:Iso:ReAm =  Isoproterenol 
bound to active-site on the β2AR. Reactions 9 - 11 are ignored in the simulations since at 
longer treatments active site should be occupied and salmeterol exosite binding is quasi-
irreversible. Isoo = isoproterenol in the aqueous phase  
  
124 
 
 
  
Table 4.4 Parameters of the Combined Model 
Reaction Name Parameter Reference/Rationale 
Salmeterol association 
rate (to β2AR exosite) kin’ = 8e+07 M
-1
.min-1 
Set to match τ (at 4e-07 M 
salmeterol and 3e-07 M naïve 
β2AR) for membrane association 
of salmeterol in microkinetic model  
Salmeterol association 
rate (to plasma 
membrane) 
kin= 107 min-1 Kp(mem) = 22500 (Rhodes, Newton et al. 1992) 
Salmeterol release rate 
(from β2AR exosite or 
from plasma membrane) 
kexo = krel = 0.004 min-1 
t1/2 ~  180 min (Rhodes, Newton et 
al. 1992; Austin, Barton et al. 
2003) 
Salmeterol On (to β2AR 
active site) kSal on’ = 20 min
-1
 
Set to match τ (at 4e-07 M 
salmeterol and 3e-07 M naïve 
β2AR) for salmeterol binding β2AR 
in microkinetic model (see below) 
Salmeterol On (to β2AR 
active site) kSal on = 8.4e+07 M
-1
.min-1 Rate of salmeterol binding β2AR 
assumed to similar to isoproterenol 
Salmeterol Off             
(from β2AR active site) kSal off = 0.168 min
-1
 
Kd ~ 2 nM (Rong, Arbabian et al. 
1999) 
Isoproterenol On kIso on = 8.4e+07 M-1.min-1 
Kf set to achieve ~ 50 msec τ for 
10µM isoproterenol binding 
(Reiner, Ambrosio et al. 2010) 
Isoproterenol Off kIso off = 235.2 min-1 Kd ~ 283 nM (Vayttaden, Friedman et al. 2010) 
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Figure 4.7 Combined Model – Salmeterol Long Action and Reassertion 
Simulations based on Figure 4.6 and Table 4.4. Long Action – Salmeterol bound active β2AR 
(black line) persists after 2 min treatment. Reassertion – Salmeterol bound active β2AR 
(black line) reappears even after 20 min washout and 20 min isoproterenol treatment. 
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4.2.5. Salmeterol β2AR Binding Models Coupled to the GRK Model 
Since all the three salmeterol models presented thus far in Section 4.2 deal only 
with events at the receptor ligand interaction level it is necessary to follow up these 
models to see if the simulated behaviour of salmeterol action holds true when 
downstream signalling events are introduced. Towards that end I created three 
new models (Figure 4.8, Models 8-10) that looked at the effects of coupling GRK-
mediated β2AR regulation to the existing models (MM/EM/CM). Since the 
Combined Model coupled to the GRK model encompasses both exosite and 
microkinetics I have discussed only that variation of the model in detail below. The 
exosite model and the microkinetic model coupled by itself to the GRK model 
showed similar results (data not shown). 
To validate these phenomenological models I simulated isoproterenol- and 
salmeterol-induced GRK-mediated β2AR phosphorylation at saturating agonist 
concentrations. All three models (8-10) have a general match to the 
phosphorylation kinetics. Figure 4.9 shows results from only the combined model.  
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Figure 4.8 Reaction Diagram of the MM/EM/CM Coupled to GRK-Mediated β2AR 
Regulation 
L is ligand (salmeterol/isoproterenol); the blue box with the letterings MM/EM/CM denotes the 
microkinetic, exosite and combined models for ligand receptor interactions presented above; 
Reaction numbers are as described in Table 3.1 (c.f. Chapter 3). Isoo = isoproterenol outside 
the cell; Salo = salmeterol outside the cell, Arr = arrestin; surface species are denoted with a 
subscript s; internalised species are denoted with a subscript i, GRK phosphorylated species 
are denoted with a subscript g. 
  
 Figure 4.9 Simulated Time Course of GRK Site Phosphorylation
Simulations of GRK phosphorylation on treatment with 10
0.4µM salmeterol (orange lines) in the
results are shown as discrete points.
 
 
µM epinephrine (brown lines) or 
 Combined-GRK (Model 10) model. The expe
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rimental 
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These validated models were then tested for salmeterol properties of long action 
and reassertion. All three models show reassertion capabilities but none of them 
were now able to show considerable long action. Figure 4.10A shows the results 
for the Combined-GRK model. This can be explained by the simulated rapid 
arrestin binding to the ligand bound phosphorylated β2AR as measured for 
isoproterenol (Krasel, Bunemann et al. 2005). In the absence of information to the 
contrary I had assumed that salmeterol-induced recruitment of arrestin would be as 
rapid as isoproterenol-induced arrestin recruitment. When I now used the 
Combined-GRK model to simulate salmeterol induced receptor internalisation 
(Figure 4.10B) I see that arrestin affinity for the salmeterol-bound receptor had to 
be reduced 100 fold to match experimentally measured salmeterol-induced 
receptor internalisation.  
We had previously shown that contrary to isoproterenol behaviour, there is 
negligible β2AR internalisation on treating with saturating salmeterol 
concentrations. This negligible salmeterol-induced internalisation can be rescued 
by overexpression of arrestin without affecting internalisation induced by other 
agonists (Moore, Millman et al. 2007). I had previously shown that a 100-fold 
reduction in arrestin affinity for salmeterol/β2AR complex was needed to simulate 
the negligible internalisation, and this did not affect the simulated phosphorylation 
kinetics (Vayttaden, Friedman et al. 2010). This supports our idea that salmeterol 
stabilises an alternate conformation of the receptor where eventually the GRK 
phosphorylation matches the levels attained by full agonists but arrestin affinity of 
the salmeterol/β2AR complex is markedly reduced. In the light of this I modified 
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models 8-10 by a ten-fold reduction of arrestin on rate and a ten-fold increase of 
arrestin on rate to salmeterol/β2AR complex. These modified models were all able 
to now recapitulate both long action and reassertion effects of salmeterol. Figure 
4.10C shows the results of only the Combined-GRK model with the abrogation of 
internalisation.  
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Figure 4.10 Simulated Salmeterol Long Action, Reassertion and Salmeterol-
Induced Internalisation 
Simulations based on Figure 4.8 and Tables 2.1and 4.1-3. Long Action – Salmeterol bound 
active β2AR (black line) persists after 2 min treatment only in C. Reassertion – Salmeterol 
bound active β2AR (black line) reappears even after 20 min washout and 20 min in A and C.  
(A) Combined-GRK models with default arrestin kinetics; (B) Sal-induced internalisation, with 
varying arrestin kinetics and (C) Combined-GRK model with 100 fold lower arrestin affinity for 
salmeterol/ β2AR complex with internalisation inhibited. 
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In summary, all existing models of salmeterol action deal solely with receptor ligand 
events. When we consider downstream signalling events none of these models can 
effectively explain salmeterol long action. It becomes necessary to invoke reduced 
arrestin affinity for the salmeterol/β2AR complex in order to simulate experimentally 
measured salmeterol-induced β2AR internalisation (Vayttaden, Friedman et al. 
2010) and to rescue loss of long action (Section 4.2 of this thesis). 
4.3. Model Limitations 
For ease of comparison of microkinetic and exosite models on the same time 
scales I assumed that the two mechanisms have the same rates even though we 
know that the t1/2 for salmeterol release from synthetic membranes is ~ 3 hrs 
(Rhodes, Newton et al. 1992) and for exosite binding is possibly 2-3 fold longer. In 
spite of these assumptions the models described herein can be used to provide 
important proof-of-concept simulations about the necessity of reduced arrestin 
affinity for salmeterol bound β2AR complex.  
Figure 4.11 shows experimental measures of cyclic AMP on both short term (30 
mins) and long term (12 hrs) treatment with salmeterol in the presence of IBMX to 
inhibit PDE activity. The experimental data clearly shows that in spite of lower 
coupling efficiency of salmeterol activated β2AR it is still able to activate significant 
amount of adenylyl cyclases to show measureable cAMP in the presence of PDE 
inhibitors. Inspite of the use of IBMX the PDE inhibition is not complete, so by 30 
minutes we see a drop in cAMP levels in human airways smooth muscle (HASM) 
cells treated with saturating isoproterenol (Figure 4.11B). Our data also shows that 
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a 12 hour pre-treatment with salmeterol does bring about significant desensitisation 
of the cAMP synthesis machinery. My models of salmeterol action encompass only 
the G-protein independent GRK-mediated β2AR regulation and so cannot explain 
the experimental measurements shown in Figure 4.11. From my simulations 
(Section 4.2 of this thesis) and our experimental data (Moore, Millman et al. 2007) 
it is clear that the GRK-mediated β2AR regulation does not bring about significant 
receptor desensitisation on account of weak arrestin affinity so the reduction in 
cAMP synthesis seen in Figure 4.11B is due to other parts of the signaling 
machinery. Therefore to better capture the dynamics of salmeterol-induced β2AR 
desensitisation it is necessary to include PKA- and PDE-mediated regulatory 
components in the model.  
Since salmeterol association and dissociation kinetics from both the active- and 
exo-site are difficult to measure it is necessary to do a thorough analysis on the 
effects of variations in these rates on the simulated properties of salmeterol long 
action and reassertion in models 8-10, although only varying the exosite release is 
of real consequence over the long treatment periods since we could get good 
measures of active site on/off from the Kd. Also it would be necessary to include 
salmeterol dissociation from the GRK phosphorylated β2AR species with or without 
arrestin so that dephosphorylation and recycling experiments can be simulated. 
This would have predictive value on account of the difficulties in washing out 
salmeterol in an experiment. In the next chapter I show very preliminary work 
towards creating a model that is aimed at explaining the effects of GRK-/PKA-
/Arrestin-/PDE-mediated regulation of β2AR signaling.  
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 Figure 4.11 cAMP Measured in HASMs in Response to Salmeterol and 
Isoproterenol Treatment* 
(A) cAMP measured in response to 1 µM Isoproterenol or 50 nM Salmeterol treatment for 30 
minutes when the cells have been pre-treated with IBMX for 30 mins to inhibit PDE activity. (B) 
cAMP measured in response to 100 µM Isoproterenol treatment ± 12 hour pre-treatment with 
20 nM Salmeterol. Sal-induced internalisation, with varying arrestin kinetics and (C) 
Combined-GRK model with100 fold lower arrestin affinity for salmeterol/ β2AR complex. 
*
 Experiments performed by Ms.Jacqueline Friedman 
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5. Unified Model for PKA-/PDE-/GRK-Mediated Regulation of β2AR 
Signalling 
This chapter presents preliminary work towards combining models from 
 “Quantitative Modeling of GRK-Mediated β2AR Regulation.” Vayttaden SJ, Friedman 
J, Tran TM, Rich TC, Dessauer CW, Clark RB (2010) PLoS Comput Biol 6(1): 
e1000647. doi:10.1371/journal.pcbi.1000647and “Roles of GRK and PDE4 activities in 
the regulation of beta2 adrenergic signaling” Xin W, Tran TM, Richter W, Clark RB, 
Rich TC J Gen Physiol. 2008 Apr;131(4):349-64. 
My work presented in Chapter 4 suggests that arrestin-mediated desensitisation 
cannot be the major mode of desensitisation for partial agonists like salmeterol. My 
work presented in Chapter 3 shows that the rapid arrestin-mediated desensitisation 
with transient levels of high concentrations of a full agonist like isoproterenol is fully 
reversible on washout of the agonists and that there is increased desensitisation on 
repeated agonist delivery inspite of near complete resensitisation during washouts. To 
understand the effects of prolonged salmeterol maintenance treatment and 
isoproterenol rescue treatment and to identify the dominant β2AR desensitisation 
pathways under these different therapeutic regimens it then becomes necessary to 
follow PKA-/PDE-/GRK-/Arrestin-mediated regulation of β2AR signaling in HASMs.  
Due to the low receptor number of HASMs the measure of GRK- and PKA-mediated 
β2AR phosphorylation and β2AR internalisation in HASMs is inherently noisy. These 
measurements can be made in our stable β2AR overexpressions in HEK293 cells. It is 
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possible to measure cAMP profiles in HASMs in response to treatment with various β-
agonists in the presence or absence of PDE inhibitors. The use of PDE inhibitors is not 
without difficulties in that inhibitors like IBMX do not completely inhibit all PDE activity 
in the cells (Figure 5.1).  In our stable β2AR overexpressions in HEK293s the basal 
PDE activity is up regulated to compensate for the β2AR overexpression. Thus due to 
the difficulties in obtaining experimental readouts of  PKA-/PDE-/GRK-/Arrestin 
signaling modules in β2AR regulation in a single cell line, it becomes necessary to 
pool experimental data from both HASMs and stable β2AR overexpressions in 
HEK293s. 
A mathematical representation of the β2AR regulation involving PKA-/PDE-/GRK-
/Arrestin signaling modules working together in a single model can then be used to 
simulate the behaviour of the modules for which data is missing in either HEKs or 
HASMs. The individual signalling modules of the model can be validated against 
appropriate data sets while varying receptor number in the model depending on 
whether HASM data or HEK293 data is being used. This combination of experiments 
across different cell lines and modeling is expected to yield insight into which of the 
signalling modules plays a major role in β2AR desensitisation during various treatment 
regimens. 
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Figure 5.1 cAMP in Response to Isoproterenol Treatment.* 
cAMP measured in response to 1 µM isoproterenol ± IBMX pretreatment for 30 mins to inhibit 
PDE activity. At 10 mins post isoproterenol treatment 0.1 µM propranolol is added to displace 
isoproterenol and abrogate β2AR activated adenylyl cyclase activity. If IBMX inhibition of 
PDEs were 100% then the cAM levels post propranolol treatment wouldn’t have deacayed 
significantly. 
 *
 Experiments performed by Ms.Jacqueline Friedman in HASMs. 
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Some of the weaknesses of this approach are; 1) there will always be unknown 
variability from one cell line to the other, this will make creating a unique model to 
explain all datasets very challenging; 2) the number of species and reactions in this 
model will be higher than any of the previously discussed models which could result in 
longer computation times; 3) there will also be an increase in unknown parameter 
values which will require parameter estimation; 4) the large model size will require 
multiple iterations of the model building exercise before we can settle on the simplest 
model that can simulate the behavior of all the signalling modules that we are 
interested in. To create a consensus model I combined my model of the GRK/Arrestin 
modules (Vayttaden, Friedman et al. 2010) with that of the PKA/PDE modules that our 
group had published previously (Xin, Tran et al. 2008). The reaction diagram for the 
unified model as it pertains to experimental measurements of agonist-induced GRK-
mediated β2AR-phosphorylation, PKA-mediated β2AR-phosphorylation, β2AR-
dephosphorylation, -trafficking, -desensitisation, -resensitisation and -cAMP profile is 
given in Figures 5.2-5.5 and Table 5.1 lists its parameters.   
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Figure 5.2 Reaction Diagram of β2AR Level Regulation at the Plasma Membrane. 
This reaction diagram describes the β2AR level regulation modules at the plasma membrane 
as highlighted in red in the inset. L is ligand; β2AR* is active state of β2AR; β2ARg is GRK-
phosphorylated β2AR; β2ARp is PKA-phosphorylated β2AR; Arr is arrestin; C is catalytic 
subunit of PKA. The reaction numbers in green correspond to rate constants described in 
Table 5.1. 
 
 
 
140 
 
 
 
 
 
 
 
 
Figure 5.3 Reaction Diagram of Gs/PKA/PDE Activation Modules in β2AR 
Regulation. 
This reaction diagram describes the Gs/PKA/PDE activation modules in β2AR regulation at the 
plasma membrane as highlighted in red in the inset. Gs is G protein αs; null indicates an 
implicit substrate or product; R is the regulatory subunit of PKA; C is catalytic subunit of PKA; 
PDEp indicates PKA phosphorylated PDE. The reaction numbers in green correspond to rate 
constants described in Table 5.1. 
  
141 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.4 Reaction Diagram of β2AR-Trafficking and Degradation. 
This reaction diagram describes the β2AR-trafficking and degradation modules in β2AR 
regulation as highlighted in red in the inset. β2ARi indicates an internalised β2AR; Li indicates 
an internalised ligand; null indicates an implicit product; β2AR* is active state of β2AR; β2ARg 
is GRK-phosphorylated β2AR; β2ARp is PKA-phosphorylated β2AR; Arr is arrestin. The 
reaction numbers in green correspond to rate constants described in Table 5.1. 
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Figure 5.5 Reaction Diagram of Post-Internalisation Events in β2AR Regulation. 
This reaction diagram describes the post-internalisation events of β2AR regulation as 
highlighted in red in the inset. β2ARi indicates an internalised β2AR; Li indicates an 
internalised ligand; β2AR* is active state of β2AR; β2ARg is GRK-phosphorylated β2AR; 
β2ARp is PKA-phosphorylated β2AR; Arr is arrestin. The reaction numbers in green 
correspond to rate constants described in Table 5.1. 
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Table 5.1 Parameters for the Unified PKA-/GRK-/PDE-Mediated β2AR Regulation 
Model 
No. Parameter Name Value Reference/Rationale Fig. No. 
1 R1f: β2AR Activation 40 /sec Rates adjusted to achieve 
appropriate levels of basal 
active β2AR. 
5.2 
2 R1r: β2AR* Inactivation 200 /sec 
3 R2f: L On β2AR* 14 µM-1.sec-1 Rates adjusted to achieve 
appropriate τ (Reiner, Ambrosio 
et al. 2010) and Kds (Vayttaden, 
Friedman et al. 2010). 
5.2 
4 R2r: L Off L:β2AR* 6.3 sec-1 
5 R3f: Gs Activation Kc = 15 µM; 
kact = 15 sec-
1; kh = 0.8 
sec-1 
(Kc) Equilibrium constant for 
activated β2AR and Gs; (kact) 
Rate constant of Gs activation 
by active β2AR; (kh) Rate 
constant of GTP hydrolysis 
(Xin, Tran et al. 2008). 
5.3 
6 R3r: Gs:GTP Hydrolysis 
'(: '*+   -./0 1 		23456789 :567;< =2:? 1 '(: '@+ A/⁄   -C 1 '(: '*+ 
Adapted from equations 2, 5 and 6 (Xin, Tran et al. 2008). 
7 R4: cAMP Production 
ACsyn = 10 
µM.sec-1; 
KGsAC = 315 
µM 
(ACsyn) cAMP synthesis rate; 
(KGsAC) Equilibrium constant for 
Gs:GTP and AC (Xin, Tran et 
al. 2008).  
5.3 
-   :D(EF  1  '(: '*+ AG(HI⁄  ; Adapted from equation 8 (Xin, Tran et al. 2008). 
8 R5f: cAMP On R2:C2 0.4 µM
-1
.sec-
1
 
(Xin, Tran et al. 2008) 5.3 
9 R5r: cAMP Off 
cAMP:R2:C2 0.2 sec
-1
 (Xin, Tran et al. 2008) 5.3 
10 R6f: cAMP On 
cAMP:R2:C2 
0.4 µM-1.sec-
1
 
(Xin, Tran et al. 2008) 5.3 
11 R6r: cAMP Off 
cAMP2:R2:C2 0.2 sec
-1
 (Xin, Tran et al. 2008) 5.3 
12 R7f: cAMP On 
cAMP2:R2:C2 5 µM
-1
.sec-1 (Xin, Tran et al. 2008) 5.3 
13 R7r: cAMP Off 
cAMP3:R2:C2 1 sec
-1
 (Xin, Tran et al. 2008) 5.3 
14 R8f: cAMP On 
cAMP3:R2:C2 5 µM
-1
.sec-1 (Xin, Tran et al. 2008) 5.3 
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Table 5.1 (contd.) Parameters for the Unified PKA-/GRK-/PDE-Mediated β2AR 
Regulation Model 
No. Parameter Name Value Reference/Rationale Fig. No. 
15 R8r: cAMP Off 
cAMP4:R2:C2 1 sec
-1
 (Xin, Tran et al. 2008) 5.3 
16 R9f: 2C Off cAMP4:R2:C2 70 sec-1 (Xin, Tran et al. 2008) 5.3 
17 R9r: 2C On cAMP4:R2 0.75 µM
-
2
.sec-1 
(Xin, Tran et al. 2008) 5.3 
18 R10f: PKA Phosphorylation β2AR 
[Fraction 
Active 
PKA]*83 sec-
1
 
(Tran, Friedman et al. 2004) 5.2 
19 R10r: PKA Dephosphorylation β2ARp 0.036 sec
-1
 
Phosphorylated receptor t1/2 = 
18 min (Tran, Friedman et al. 
2004; Tran, Friedman et al. 
2007) 
5.2 
20 R11f: PKA Phosphorylation β2AR* 
[Fraction 
Active 
PKA]*83 sec-
1
 
(Tran, Friedman et al. 2004) 5.2 
21 
R11r: PKA 
Dephosphorylation 
β2AR*p 
0.036 sec-1 
Phosphorylated receptor t1/2 = 
18 min (Tran, Friedman et al. 
2004; Tran, Friedman et al. 
2007) 
5.2 
22 R12f: β2ARp Activation 40 /sec Rates adjusted to achieve 
appropriate levels of basal 
active β2AR. 
5.2 
23 R12r: β2AR*p Inactivation 200 /sec 
24 R13f: L On β2AR* 14 µM-1.sec-1 Rates adjusted to achieve 
appropriate τ (Reiner, Ambrosio 
et al. 2010) and Kds (Vayttaden, 
Friedman et al. 2010). 
5.2 
25 R13r: L Off L:β2AR* 6.3 sec-1 
26 R14f: PKA Phosphorylation L:β2AR* 
[Fraction 
Active 
PKA]*83 sec-
1
 
(Tran, Friedman et al. 2004) 5.2 
27 
R14r: PKA 
Dephosphorylation 
L:β2AR*p 
0.036 sec-1 
Phosphorylated receptor t1/2 = 
18 min (Tran, Friedman et al. 
2004; Tran, Friedman et al. 
2007) 
5.2 
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Table 5.1 (contd.) Parameters for the Unified PKA-/GRK-/PDE-Mediated β2AR 
Regulation Model 
No. Parameter Name Value Reference/Rationale Fig. No. 
28 R15f: PKA Phosphorylation PDE 
[Fraction 
Active 
PKA]*0.015 
sec-1 
Rates need to be adjusted for 
my system (Xin, Tran et al. 
2008) 
5.3 
29 R15r: PKA Dephosphorylation PDEp 0.005 sec
-1
 
Rates need to be adjusted for 
my system (Xin, Tran et al. 
2008) 
5.3 
30 R16: PDE Activity 
kPDE =0.15 
µM.sec-1; 
kPDEp =2.5 X ( 
kPDE); I 
=Appropriate 
PDE inhibitor 
concentration 
as used in 
experiment ; 
KI=0.1 µM 
(for 
Rolipram) 
(Xin, Tran et al. 2008) 5.3 
-J   +@K 1 5:L+ 1 -MNO5:L+  PAQ MNO 1 R1  TAU VW
 +@KX 1 5:L+ 1 -MNOX
5:L+  PAQ MNOX 1 R1  TAU VW
 
Adapted from equation 9 (Xin, Tran et al. 2008). 
31 R17f: GRK Phosphorylation L:β2AR* 8.4 sec
-1
 (Tran, Friedman et al. 2004) 5.2 
32 
R17r: GRK 
Dephosphorylation 
β2AR*g 
0.036 sec-1 
Phosphorylated receptor t1/2 = 
18 min (Tran, Friedman et al. 
2004; Tran, Friedman et al. 
2007) 
5.2 
33 R18f: GRK Phosphorylation L:β2AR*p 8.4 sec
-1
 (Tran, Friedman et al. 2004) 5.2 
34 
R18r: GRK 
Dephosphorylation 
L:β2AR*pg 
0.036 sec-1 
Phosphorylated receptor t1/2 = 
18 min (Tran, Friedman et al. 
2004; Tran, Friedman et al. 
2007) 
5.2 
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Table 5.1 (contd.) Parameters for the Unified PKA-/GRK-/PDE-Mediated β2AR 
Regulation Model 
No. Parameter Name Value Reference/Rationale Fig. No. 
35 R19f: PKA Phosphorylation L:β2AR*g 
[Fraction 
Active 
PKA]*83 sec-
1
 
(Tran, Friedman et al. 2004) 5.2 
36 
R19r: PKA 
Dephosphorylation 
L:β2AR*pg 
0.036 sec-1 
Phosphorylated receptor t1/2 = 
18 min (Tran, Friedman et al. 
2004; Tran, Friedman et al. 
2007) 
5.2 
37 R20f: Arrestin On L:β2AR*g 1620 sec
-1
 
Rate of arrestin binding = 26.6 
± 5.9 /min (Krasel, Bunemann 
et al. 2005) 
5.2 
38 R20r: Arrestin Off Arr:L:β2AR*g 240 sec
-1
 
Rate of arrestin dissociation 
assumed to match measured 
Kd. 
5.2 
39 R21f: Arrestin On L:β2AR*pg 1620 sec
-1
 
Rate of arrestin binding = 26.6 
± 5.9 /min (Krasel, Bunemann 
et al. 2005) 
5.2 
40 R21r: Arrestin Off Arr:L:β2AR*pg 240 sec
-1
 
Rate of arrestin dissociation 
assumed to match measured 
Kd. 
5.2 
41 R22f: L On Arr:β2AR*g 14 µM-1.sec-1 Rates adjusted to achieve 
appropriate τ (Reiner, Ambrosio 
et al. 2010) and Kds (Vayttaden, 
Friedman et al. 2010). 
5.2 
42 R22r: L Off Arr:L:β2AR*g 6.3 sec-1 
43 R23f: L On Arr:β2AR*pg 14 µM-1.sec-1 Rates adjusted to achieve 
appropriate τ (Reiner, Ambrosio 
et al. 2010) and Kds (Vayttaden, 
Friedman et al. 2010). 
5.2 
44 R23r: L Off Arr:L:β2AR*pg 6.3 sec-1 
45 R24: Arrestin Off Arr: 
β2AR*g 660 sec
-1
 
Rate of arrestin dissociation = 
10.86 ± 1.2 /min (Krasel, 
Bunemann et al. 2005). 
5.2 
46 R25: Arrestin Off Arr: 
β2AR*pg 660 sec
-1
 
Rate of arrestin dissociation = 
10.86 ± 1.2 /min (Krasel, 
Bunemann et al. 2005). 
5.2 
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Table 5.1 (contd.) Parameters for the Unified PKA-/GRK-/PDE-Mediated β2AR 
Regulation Model 
No. Parameter Name Value Reference/Rationale Fig. No. 
47 R26f: Arr:β2ARg Activation 40 /sec Rates adjusted to achieve 
appropriate levels of basal 
active β2AR. 
5.2 
48 R26r: Arr:β2AR*g Inactivation 200 /sec 
49 R27f: Arr:β2ARpg Activation 40 /sec Rates adjusted to achieve 
appropriate levels of basal 
active β2AR. 
5.2 
50 R27r: Arr:β2AR*pg Inactivation 200 /sec 
51 R28: Arrestin Off Arr: 
β2AR*g 660 sec
-1
 
Rate of arrestin dissociation = 
10.86 ± 1.2 /min (Krasel, 
Bunemann et al. 2005). 
5.2 
52 R29: Arrestin Off Arr: 
β2AR*pg 660 sec
-1
 
Rate of arrestin dissociation = 
10.86 ± 1.2 /min (Krasel, 
Bunemann et al. 2005). 
5.2 
53 R30f: PKA Phosphorylation β2ARg 
[Fraction 
Active 
PKA]*83 sec-
1
 
(Tran, Friedman et al. 2004) 5.2 
54 
R30r: PKA 
Dephosphorylation 
β2ARpg 
0.036 sec-1 
Phosphorylated receptor t1/2 = 
18 min (Tran, Friedman et al. 
2004; Tran, Friedman et al. 
2007) 
5.2 
55 R31f: β2ARg Activation 40 /sec Rates adjusted to achieve 
appropriate levels of basal 
active β2AR. 
5.2 
56 R31r: β2AR*g Inactivation 200 /sec 
57 R32f: β2ARpg Activation 40 /sec Rates adjusted to achieve 
appropriate levels of basal 
active β2AR. 
5.2 
58 R32r: β2AR*pg Inactivation 200 /sec 
59 R33f: PKA Phosphorylation β2AR*g 
[Fraction 
Active 
PKA]*83 sec-
1
 
(Tran, Friedman et al. 2004) 5.2 
60 
R33r: PKA 
Dephosphorylation 
β2AR*pg 
0.036 sec-1 
Phosphorylated receptor t1/2 = 
18 min (Tran, Friedman et al. 
2004; Tran, Friedman et al. 
2007) 
5.2 
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Table 5.1 (contd.) Parameters for the Unified PKA-/GRK-/PDE-Mediated β2AR 
Regulation Model 
No. Parameter Name Value Reference/Rationale Fig. No. 
61 R34: GRK Dephosphorylation β2ARg 0.036 sec
-1
 
Phosphorylated receptor t1/2 = 
18 min (Tran, Friedman et al. 
2004; Tran, Friedman et al. 
2007) 
5.2 
62 
R35: GRK 
Dephosphorylation 
β2ARpg 
0.036 sec-1 
Phosphorylated receptor t1/2 = 
18 min (Tran, Friedman et al. 
2004; Tran, Friedman et al. 
2007) 
5.2 
63 R36: GRK Dephosphorylation β2ARg 0.036 sec
-1
 
Phosphorylated receptor t1/2 = 
18 min (Tran, Friedman et al. 
2004; Tran, Friedman et al. 
2007) 
5.2 
64 
R37: GRK 
Dephosphorylation 
β2ARpg 
0.036 sec-1 
Phosphorylated receptor t1/2 = 
18 min (Tran, Friedman et al. 
2004; Tran, Friedman et al. 
2007) 
5.2 
65 R38f: L On β2AR*g 14 µM-1.sec-1 Rates adjusted to achieve 
appropriate τ (Reiner, Ambrosio 
et al. 2010) and Kds (Vayttaden, 
Friedman et al. 2010). 
5.2 
66 R38r: L Off L:β2AR*g 6.3 sec-1 
67 R39f: L On β2AR*pg 14 µM-1.sec-1 Rates adjusted to achieve 
appropriate τ (Reiner, Ambrosio 
et al. 2010) and Kds (Vayttaden, 
Friedman et al. 2010). 
5.2 
68 R39r: L Off L:β2AR*pg 6.3 sec-1 
69 R40f: β2AR Basal Internalisation 0.51 sec
-1
 
Rates used to match negligible 
basal internalisation (Morrison, 
Moore et al. 1996). 
5.4 
70 R40r: β2ARi Recycling 5.4 sec-1 kf = 0.09 /min (Tran, Friedman 
et al. 2004). 5.4 
71 R41f: β2ARg Basal Internalisation 0.51 sec
-1
 
Rates used to match negligible 
basal internalisation (Morrison, 
Moore et al. 1996). 
5.4 
72 R41r: β2ARgi Recycling 5.4 sec-1 kf = 0.09 /min (Tran, Friedman 
et al. 2004). 5.4 
73 R42f: β2ARp Basal Internalisation 0.51 sec
-1
 
Rates used to match negligible 
basal internalisation (Morrison, 
Moore et al. 1996). 
5.4 
149 
 
Table 5.1 (contd.) Parameters for the Unified PKA-/GRK-/PDE-Mediated β2AR 
Regulation Model 
No. Parameter Name Value Reference/Rationale Fig. No. 
74 R42r: β2ARpi Recycling 5.4 sec-1 kf = 0.09 /min (Tran, Friedman 
et al. 2004). 5.4 
75 R43f: β2ARpg Basal Internalisation 0.51 sec
-1
 
Rates used to match negligible 
basal internalisation (Morrison, 
Moore et al. 1996). 
5.4 
76 R43r: β2ARpgi Recycling 5.4 sec-1 kf = 0.09 /min (Tran, Friedman 
et al. 2004). 5.4 
77 R44f: β2AR* Basal Internalisation 0.51 sec
-1
 
Rates used to match negligible 
basal internalisation (Morrison, 
Moore et al. 1996). 
5.4 
78 R44r: β2AR*i Recycling 5.4 sec-1 kf = 0.09 /min (Tran, Friedman 
et al. 2004). 5.4 
79 R45f: β2AR*g Basal Internalisation 0.51 sec
-1
 
Rates used to match negligible 
basal internalisation (Morrison, 
Moore et al. 1996). 
5.4 
80 R45r: β2AR*gi Recycling 5.4 sec-1 kf = 0.09 /min (Tran, Friedman 
et al. 2004). 5.4 
81 R46f: β2AR*p Basal Internalisation 0.51 sec
-1
 
Rates used to match negligible 
basal internalisation (Morrison, 
Moore et al. 1996). 
5.4 
82 R46r: β2AR*pi Recycling 5.4 sec-1 kf = 0.09 /min (Tran, Friedman 
et al. 2004). 5.4 
83 R47f: β2AR*pg Basal Internalisation 0.51 sec
-1
 
Rates used to match negligible 
basal internalisation (Morrison, 
Moore et al. 1996). 
5.4 
84 R47r: β2AR*pgi Recycling 5.4 sec-1 kf = 0.09 /min (Tran, Friedman 
et al. 2004). 5.4 
85 R48f: L:β2AR* Basal Internalisation 0.51 sec
-1
 
Rates used to match negligible 
basal internalisation (Morrison, 
Moore et al. 1996). 
5.4 
86 R48r: L:β2AR*i Recycling 5.4 sec-1 kf = 0.09 /min (Tran, Friedman 
et al. 2004). 5.4 
  
150 
 
Table 5.1 (contd.) Parameters for the Unified PKA-/GRK-/PDE-Mediated β2AR 
Regulation Model 
No. Parameter Name Value Reference/Rationale Fig. No. 
87 R49f: L:β2AR*g Basal Internalisation 0.51 sec
-1
 
Rates used to match negligible 
basal internalisation (Morrison, 
Moore et al. 1996). 
5.4 
88 R49r: L:β2AR*gi Recycling 5.4 sec-1 kf = 0.09 /min (Tran, Friedman 
et al. 2004). 5.4 
89 R50f: L:β2AR*p Basal Internalisation 0.51 sec
-1
 
Rates used to match negligible 
basal internalisation (Morrison, 
Moore et al. 1996). 
5.4 
90 R50r: L:β2AR*pi Recycling 5.4 sec-1 kf = 0.09 /min (Tran, Friedman 
et al. 2004). 5.4 
91 R51f: L:β2AR*pg Basal Internalisation 0.51 sec
-1
 
Rates used to match negligible 
basal internalisation (Morrison, 
Moore et al. 1996). 
5.4 
92 R51r: L:β2AR*pgi Recycling 5.4 sec
-1
 
kf = 0.09 /min (Tran, Friedman 
et al. 2004). 5.4 
93 R52f: Arr:β2ARg Basal Internalisation 0.51 sec
-1
 
Rates used to match negligible 
basal internalisation (Morrison, 
Moore et al. 1996). 
5.4 
94 R52r: Arr:β2ARgi Recycling 5.4 sec
-1
 
kf = 0.09 /min (Tran, Friedman 
et al. 2004). 5.4 
95 R53f: Arr:β2ARpg Basal Internalisation 0.51 sec
-1
 
Rates used to match negligible 
basal internalisation (Morrison, 
Moore et al. 1996). 
5.4 
96 R53r: Arr:β2ARpgi Recycling 5.4 sec
-1
 
kf = 0.09 /min (Tran, Friedman 
et al. 2004). 5.4 
97 R54f: Arr:β2AR*g Basal Internalisation 0.51 sec
-1
 
Rates used to match negligible 
basal internalisation (Morrison, 
Moore et al. 1996). 
5.4 
98 R54r: Arr:β2AR*gi Recycling 5.4 sec
-1
 
kf = 0.09 /min (Tran, Friedman 
et al. 2004). 5.4 
99 R55f: Arr:β2AR*pg Basal Internalisation 0.51 sec
-1
 
Rates used to match negligible 
basal internalisation (Morrison, 
Moore et al. 1996). 
5.4 
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Table 5.1 (contd.) Parameters for the Unified PKA-/GRK-/PDE-Mediated β2AR 
Regulation Model 
No. Parameter Name Value Reference/Rationale Fig. No. 
100 R55r: Arr:β2AR*pgi Recycling 5.4 sec
-1
 
kf = 0.09 /min (Tran, Friedman 
et al. 2004). 5.4 
101 R56f: Arr:L:β2AR*g Internalisation 13.2 sec
-1
 
kf = 0.22 /min (Tran, Friedman 
et al. 2004). 5.4 
102 R56r: Arr:L:β2AR*gi Recycling 5.4 sec
-1
 
kf = 0.09 /min (Tran, Friedman 
et al. 2004). 5.4 
103 R57f: Arr:L:β2AR*pg Internalisation 13.2 sec
-1
 
kf = 0.22 /min (Tran, Friedman 
et al. 2004). 5.4 
104 R57r: Arr:L:β2AR*pgi Recycling 5.4 sec
-1
 
kf = 0.09 /min (Tran, Friedman 
et al. 2004). 5.4 
105 R58: Li Degradation 100 sec-1 
Catecholamine group should 
degrade rapidly. Arbitrarily set 
high to prevent persistent 
ligand rebinding post 
internalisation 
5.4 
106 R59: β2ARi Degradation 0.24 sec-1 t1/2 = 3-4 hours (Liang, Hoang 
et al. 2008) 5.4 
107 R60: β2ARgi Degradation 0.24 sec-1 t1/2 = 3-4 hours (Liang, Hoang 
et al. 2008) 5.4 
108 R61: β2ARpi Degradation 0.24 sec-1 t1/2 = 3-4 hours (Liang, Hoang 
et al. 2008) 5.4 
109 R62: β2ARpgi Degradation 0.24 sec-1 t1/2 = 3-4 hours (Liang, Hoang 
et al. 2008) 5.4 
110 R63: β2AR*i Degradation 0.24 sec-1 t1/2 = 3-4 hours (Liang, Hoang 
et al. 2008) 5.4 
111 R64: β2AR*gi Degradation 0.24 sec-1 t1/2 = 3-4 hours (Liang, Hoang 
et al. 2008) 5.4 
112 R65: β2AR*pi Degradation 0.24 sec-1 t1/2 = 3-4 hours (Liang, Hoang 
et al. 2008) 5.4 
113 R66: β2AR*pgi Degradation 0.24 sec
-1
 
t1/2 = 3-4 hours (Liang, Hoang 
et al. 2008) 5.4 
114 R67: L:β2AR*i Degradation 0.24 sec
-1
 
t1/2 = 3-4 hours (Liang, Hoang 
et al. 2008) 5.4 
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Table 5.1 (contd.) Parameters for the Unified PKA-/GRK-/PDE-Mediated β2AR 
Regulation Model 
No. Parameter Name Value Reference/Rationale Fig. No. 
115 R68: L:β2AR*gi Degradation 0.24 sec
-1
 
t1/2 = 3-4 hours (Liang, Hoang 
et al. 2008) 5.4 
116 R69: L:β2AR*pi Degradation 0.24 sec
-1
 
t1/2 = 3-4 hours (Liang, Hoang 
et al. 2008) 5.4 
117 R70: L:β2AR*pgi Degradation 0.24 sec
-1
 
t1/2 = 3-4 hours (Liang, Hoang 
et al. 2008) 5.4 
118 R71: Arr:β2ARgi Degradation 0.24 sec
-1
 
t1/2 = 3-4 hours (Liang, Hoang 
et al. 2008) 5.4 
119 R72: Arr:β2ARpgi Degradation 0.24 sec
-1
 
t1/2 = 3-4 hours (Liang, Hoang 
et al. 2008) 5.4 
120 R73: Arr:β2AR*gi Degradation 0.24 sec
-1
 
t1/2 = 3-4 hours (Liang, Hoang 
et al. 2008) 5.4 
121 R74: Arr:β2AR*pgi Degradation 0.24 sec
-1
 
t1/2 = 3-4 hours (Liang, Hoang 
et al. 2008) 5.4 
122 R75: Arr:L:β2AR*gi Degradation 0.24 sec
-1
 
t1/2 = 3-4 hours (Liang, Hoang 
et al. 2008) 5.4 
123 R76: Arr:L:β2AR*pgi Degradation 0.24 sec
-1
 
t1/2 = 3-4 hours (Liang, Hoang 
et al. 2008) 5.4 
124 R77f: β2ARi Activation 40 /sec Rates adjusted to achieve 
appropriate levels of basal 
active β2AR. 
5.5 
125 R77r: β2AR*i Inactivation 200 /sec 
126 R78f: L On β2AR*i 14 µM-1.sec-1 Rates adjusted to achieve 
appropriate τ (Reiner, Ambrosio 
et al. 2010) and Kds (Vayttaden, 
Friedman et al. 2010). 
5.5 
127 R78r: L Off L:β2AR*i 6.3 sec-1 
128 
R79: GRK 
Dephosphorylation 
L:β2AR*gi 
0.036 sec-1 
Phosphorylated receptor t1/2 = 
18 min (Tran, Friedman et al. 
2004; Tran, Friedman et al. 
2007) 
5.5 
129 R80f: Arrestin On L:β2AR*gi 1620 sec
-1
 
Rate of arrestin binding = 26.6 
± 5.9 /min (Krasel, Bunemann 
et al. 2005) 
5.5 
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Table 5.1 (contd.) Parameters for the Unified PKA-/GRK-/PDE-Mediated β2AR 
Regulation Model 
No. Parameter Name Value Reference/Rationale Fig. No. 
130 R80r: Arrestin Off Arr:L:β2AR*gi 240 sec
-1
 
Rate of arrestin dissociation 
assumed to match measured 
Kd. 
5.5 
131 R81f: L On Arr:β2AR*gi 14 µM-1.sec-1 Rates adjusted to achieve 
appropriate τ (Reiner, Ambrosio 
et al. 2010) and Kds (Vayttaden, 
Friedman et al. 2010). 
5.5 
132 R81r: L Off Arr:L:β2AR*gi 6.3 sec-1 
133 R82f: Arr:β2ARgi Activation 40 /sec Rates adjusted to achieve 
appropriate levels of basal 
active β2AR. 
5.5 
134 R82r: Arr:β2AR*gi Inactivation 200 /sec 
135 R83: Arrestin Off Arr:β2ARgi 660 sec
-1
 
Rate of arrestin dissociation = 
10.86 ± 1.2 /min (Krasel, 
Bunemann et al. 2005). 
5.5 
136 R84: Arrestin Off Arr:β2AR*gi 660 sec
-1
 
Rate of arrestin dissociation = 
10.86 ± 1.2 /min (Krasel, 
Bunemann et al. 2005). 
5.5 
137 R85f: L On β2AR*gi 14 µM-1.sec-1 Rates adjusted to achieve 
appropriate τ (Reiner, Ambrosio 
et al. 2010) and Kds (Vayttaden, 
Friedman et al. 2010). 
5.5 
138 R85r: L Off L:β2AR*gi 6.3 sec-1 
139 R86f: β2ARi Activation 40 /sec Rates adjusted to achieve 
appropriate levels of basal 
active β2AR. 
5.5 
140 R86r: β2AR*i Inactivation 200 /sec 
141 R87: GRK Dephosphorylation β2ARgi 0.036 sec
-1
 
Phosphorylated receptor t1/2 = 
18 min (Tran, Friedman et al. 
2004; Tran, Friedman et al. 
2007) 
5.5 
142 
R88: GRK 
Dephosphorylation 
β2AR*gi 
0.036 sec-1 
Phosphorylated receptor t1/2 = 
18 min (Tran, Friedman et al. 
2004; Tran, Friedman et al. 
2007) 
5.5 
143 R89f: β2ARpi Activation 40 /sec Rates adjusted to achieve 
appropriate levels of basal 
active β2AR. 
5.5 
144 R89r: β2AR*pi Inactivation 200 /sec 
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Table 5.1 (contd.) Parameters for the Unified PKA-/GRK-/PDE-Mediated β2AR 
Regulation Model 
No. Parameter Name Value Reference/Rationale Fig. No. 
145 R90f: L On β2AR*pi 14 µM-1.sec-1 Rates adjusted to achieve 
appropriate τ (Reiner, Ambrosio 
et al. 2010) and Kds (Vayttaden, 
Friedman et al. 2010). 
5.5 
146 R90r: L Off L:β2AR*pi 6.3 sec-1 
147 
R91: GRK 
Dephosphorylation 
L:β2AR*pgi 
0.036 sec-1 
Phosphorylated receptor t1/2 = 
18 min (Tran, Friedman et al. 
2004; Tran, Friedman et al. 
2007) 
5.5 
148 R92f: Arrestin On L:β2AR*pgi 1620 sec
-1
 
Rate of arrestin binding = 26.6 
± 5.9 /min (Krasel, Bunemann 
et al. 2005) 
5.5 
149 R92r: Arrestin Off Arr:L:β2AR*pgi 240 sec
-1
 
Rate of arrestin dissociation 
assumed to match measured 
Kd. 
5.5 
150 R93f: L On Arr:β2AR*pgi 14 µM-1.sec-1 Rates adjusted to achieve 
appropriate τ (Reiner, Ambrosio 
et al. 2010) and Kds (Vayttaden, 
Friedman et al. 2010). 
5.5 
151 R93r: L Off Arr:L:β2AR*pgi 6.3 sec-1 
152 R94f: Arr:β2ARpgi Activation 40 /sec Rates adjusted to achieve 
appropriate levels of basal 
active β2AR. 
5.5 
153 R94r: Arr:β2AR*pgi Inactivation 200 /sec 
154 R95: Arrestin Off Arr: 
β2ARpgi 660 sec
-1
 
Rate of arrestin dissociation = 
10.86 ± 1.2 /min (Krasel, 
Bunemann et al. 2005). 
5.2 
155 R96: Arrestin Off Arr: 
β2AR*pgi 660 sec
-1
 
Rate of arrestin dissociation = 
10.86 ± 1.2 /min (Krasel, 
Bunemann et al. 2005). 
5.2 
156 R97f: L On β2AR*pgi 14 µM-1.sec-1 Rates adjusted to achieve 
appropriate τ (Reiner, Ambrosio 
et al. 2010) and Kds (Vayttaden, 
Friedman et al. 2010). 
5.5 
157 R97r: L Off L:β2AR*pgi 6.3 sec-1 
158 R98f: β2ARpgi Activation 40 /sec Rates adjusted to achieve 
appropriate levels of basal 
active β2AR. 
5.5 
159 R98r: β2AR*pgi Inactivation 200 /sec 
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Table 5.1 (contd.) Parameters for the Unified PKA-/GRK-/PDE-Mediated β2AR 
Regulation Model 
No. Parameter Name Value Reference/Rationale Fig. No. 
160 
R99: GRK 
Dephosphorylation 
β2ARpgi 
0.036 sec-1 
Phosphorylated receptor t1/2 = 
18 min (Tran, Friedman et al. 
2004; Tran, Friedman et al. 
2007) 
5.5 
161 
R100: GRK 
Dephosphorylation 
β2AR*pgi 
0.036 sec-1 
Phosphorylated receptor t1/2 = 
18 min (Tran, Friedman et al. 
2004; Tran, Friedman et al. 
2007) 
5.5 
162 
R101: PKA 
Dephosphorylation 
β2ARpgi 
0.036 sec-1 
Phosphorylated receptor t1/2 = 
18 min (Tran, Friedman et al. 
2004; Tran, Friedman et al. 
2007) 
5.2 
163 R102: PKA Dephosphorylation β2ARpi 0.036 sec
-1
 
Phosphorylated receptor t1/2 = 
18 min (Tran, Friedman et al. 
2004; Tran, Friedman et al. 
2007) 
5.2 
164 
R103: PKA 
Dephosphorylation 
β2AR*pi 
0.036 sec-1 
Phosphorylated receptor t1/2 = 
18 min (Tran, Friedman et al. 
2004; Tran, Friedman et al. 
2007) 
5.2 
165 
R104: PKA 
Dephosphorylation 
β2AR*pgi 
0.036 sec-1 
Phosphorylated receptor t1/2 = 
18 min (Tran, Friedman et al. 
2004; Tran, Friedman et al. 
2007) 
5.2 
166 
R105: PKA 
Dephosphorylation 
L:β2AR*pi 
0.036 sec-1 
Phosphorylated receptor t1/2 = 
18 min (Tran, Friedman et al. 
2004; Tran, Friedman et al. 
2007) 
5.2 
167 
R106: PKA 
Dephosphorylation 
L:β2AR*pgi 
0.036 sec-1 
Phosphorylated receptor t1/2 = 
18 min (Tran, Friedman et al. 
2004; Tran, Friedman et al. 
2007) 
5.2 
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Table 5.1 (contd.) Parameters for the Unified PKA-/GRK-/PDE-Mediated β2AR 
Regulation Model 
No. Parameter Name Value Reference/Rationale Fig. No. 
168 β2ARt=0; HASMs 1µM 
Arbitrarily set (Xin, Tran et al. 
2008). Need to lower to 
0.003µM per my calculations 
5.2 
169 β2ARt=0; HEK293s (over expression) 100µM 
Arbitrarily set (Xin, Tran et al. 
2008). Need to lower to 0.3µM 
per my calculations 
5.2 
170 PDEt=0; HASMs / HEK293s (over 
expression) 
1µM Arbitrarily set (Xin, Tran et al. 2008).  5.3 
171 R2:C2t=0; HASMs / HEK293s (over 
expression) 
1µM (Xin, Tran et al. 2008).  5.3 
172 Gs:GDPt=0; HASMs / HEK293s (over 
expression) 
4µM (Xin, Tran et al. 2008).  5.3 
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5.1. Assumptions  
5.1.1. Receptor Activation  
I assumed a ligand-induced stabilisation model for β2AR activation. Here β2AR 
denotes the inactive receptor on the plasma membrane, β2AR* the 
spontaneously active receptor and L:β2AR, the agonist-induced stable active 
receptor. This was done to accommodate the differences in basal activity with 
varying receptor levels. The limitations of the two-state model are that it cannot 
account for ligand induced differential signalling or bias wherein a wide 
spectrum of receptor conformations is stabilised by different agonists to varying 
extents and thereby capable of differential signalling. 
5.1.2. Ligand On/Off  
The ligand binding rates were set in COPASI (COmplex PAthway SImulator) 
(Hoops, Sahle et al. 2006) to achieve appropriate t1/2 of 47 msec for 10 µM 
epinephrine (Reiner, Ambrosio et al. 2010). Since we had an estimate of Kd for 
epinephrine to be ~ 450 nM (Vayttaden, Friedman et al. 2010) the off-rates 
were calculated to give the appropriate Kd. The on-rates of isoproterenol were 
assumed to be similar to epinephrine and then using a Kd of ~ 283 nM 
(Vayttaden, Friedman et al. 2010) appropriate off-rates were calculated.  
5.1.3. Receptor Activity  
In the current version of the model I have assumed only two receptor states – 
active or inactive. Contrary to the GRK-mediated β2AR regulation model 
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presented in chapter 3, I haven’t considered intermediate receptor activity levels 
dependent on phosphorylation status. In its current version the model will not be 
able to capture the effects of PKA phosphorylation of the β2AR on 
desensitisation. This simplification was done to reduce the complexity of the 
model to capture first the effects of PKA-mediated PDE activation on treatment 
with 1 – 100 µM isoproterenol (c.f. Figure 4.11) since at these concentrations 
PKA phosphorylation of the β2AR would be saturated (Tran, Friedman et al. 
2004). The effects of phosphorylation dependent variable receptor activity will 
have to be explored in later versions of the model. I also assume that arrestin 
binding and/or internalisation completely uncouples the receptor from Gαs and 
therefore these species have no activity. 
5.1.4. β2AR-Phosphorylation Kinetics  
In my model the rate of PKA phosphorylation is dependent on [C] which is the 
fraction of activated PKA. We’ve measured 0.01 – 100 nM epinephrine-induced 
PKA-mediated β2AR phosphorylation t1/2 to ~ range from 1–2/min (Tran, 
Friedman et al. 2004). I assume that isoproterenol induced β2AR 
phosphorylation rates will be in the same range since epinephrine and 
isoproterenol have comparable efficacies. 
I assumed that ligand activation of β2AR results in only a single event of GRK 
phosphorylation where both serines 355 and 356 are simultaneously 
phosphorylated. The anti-phosphosite antibody used in our β2AR 
phosphorylation studies detects only dual phosphorylation of serines 355, 356. 
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Use of our antibody for studying GRK-mediated β2AR phosphorylation kinetics 
has been validated by various groups (Tran, Friedman et al. 2004; Shenoy, 
Drake et al. 2006; Violin, Ren et al. 2006; Pontier, Percherancier et al. 2008; 
Woo, Wang et al. 2009). The disadvantage of this assumption is that it is no 
longer possible to project multi-phosphorylation states of the receptor that could 
play a role in receptor sorting post-internalisation selecting for recycling vs. 
receptor degradation. Also assuming a single phosphorylation event prevents 
assigning multiple phosphorylation site specific activities to the receptor, this 
could in turn affect the quality of simulation fits. 
We’ve measured epinephrine-induced GRK-mediated β2AR phosphorylation to 
range from 0.7–1.4/min (Tran, Friedman et al. 2004). I assume that 
isoproterenol induced β2AR phosphorylation rates will be in the same range 
since epinephrine and isoproterenol have comparable efficacies.  
We have previously shown that both the plasma membrane and endosomal 
fraction of β2AR can undergo dephosphorylation (Iyer, Tran et al. 2006; Tran, 
Friedman et al. 2007). Therefore I allow both plasma membrane and cytosolic 
dephosphorylation of β2AR in my model (c.f. Footnote of Table 3.1).  
5.1.5. PKA Activation Kinetics  
Generic PKA activation is modelled here through a series of 10 reactions. The 
kinetics of cAMP binding/unbinding to the PKA regulatory subunit  and the rate 
of release and rebinding of catalytic subunit binding to the regulatory subunit of 
PKA in HASMs is assumed to match the rates determined using purified dimer 
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of regulatory subunit of PKA I from rabbit skeletal muscle (Doskeland and 
Ogreid 1984). These rates will have to be adjusted to match PKA activation in 
our cell lines as measured by PKA phosphorylation of the β2AR. 
5.1.6. PDE Activation Kinetics  
Generic PKA-mediated activation of PDE is modelled here through PKA 
phosphorylation of PDE and PDE dephosphorylation. The kinetics of these two 
reactions is arbitrarily set to match the cAMP kinetics observed in HEK293 cells 
overexpressing the C460W/E583M CNG channel (Xin, Tran et al. 2008). These 
rates will have to be adjusted to match cAMP levels in our cell lines in the 
presence and absence of PDE inhibitors. 
5.1.7. Post-Internalisation Events  
I have assumed that there is no PKA or GRK activity post-internalisation so no 
new phosphorylation is achieved post-internalisation. Consistent with the rapid 
on/off-rates and high Kds of epinephrine or isoproterenol (Mueller, Motulsky et 
al. 1988; Devanathan, Yao et al. 2004) I assumed ligand dissociation post 
β2AR internalisation to be very rapid. We have previously shown negligible 
rates of basal β2AR internalisation (Morrison, Moore et al. 1996).  
I allow arrestin-free internalised β2AR to recycle independent of its 
phosphorylation status (Tran, Friedman et al. 2007).  Currently the precise 
mechanisms and pathways of β2AR downregulation are unclear even though 
we have shown it to be biphasic (Williams, Barber et al. 2000). Thus to simplify 
downregulation reactions in the model I assume that all internalised β2AR 
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species can undergo downregulation (t1/2 = 3–4 hours) (Morrison, Moore et al. 
1996; Williams, Barber et al. 2000; Liang, Hoang et al. 2008). 
 
5.2. Model Validation  
My unified model of GRK-/PKA-/PDE-mediated β2AR regulation has 167 reactions 
and 4 initial species. The model has currently been subjected to only 
phenomenological validation; extensive quantitative validation is required for this 
model as part of future works.  Figure 5.6A shows the simulated results of 1 µM 
isoproterenol stimulation and figure 5.6B shows cAMP profile in HASMs on 
treatment with 1 µM isoproterenol. 
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Figure 5.6 1 µM Isoproterenol Stimulation of HASMs 
This reaction diagram shows the effect of treatment of HASM with 1 µM isoproterenol. A) 
Simulated profiles of: total PKA phosphorylated β2AR (red line); active β2AR (green line); free 
cAMP (grey line); PKA-activated PDE (blue line); free catalytic subunit of PKA (black line); 
β2ARt0=1µM. B) cAMP in HASMs normalised to maximum levels obtained with 0-300 sec of 1 
µM isoproterenol treatment. 
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The model shows that receptor activation is near instantaneous and transient. After 
a minute of stimulation, active receptor levels reach a steady state of roughly 50 % 
of maximal active levels. This is likely a modelling artifact on account of not 
considering intermediate receptor activity levels dependent on phosphorylation 
status and ignoring arrestin binding. Figure 3.2D clearly shows that 1µM 
isoproterenol treatment causes internalisation of close to 40 % of surface β2AR 
after minutes. Had I considered arrestin binding in these simulations then the active 
β2AR levels would have dropped close to zero within the first five minutes of 
treatment with 1µM isoproterenol. This simplification was done to reduce the 
complexity of the model to capture first the effects of β2AR-mediated AC activation 
on treatment within the first 5 minutes. We know that there is both a high-potency 
PKA-mediated desensitisation, and an occupancy-dependent desensitisation 
mediated by GRKs (Clark, Knoll et al. 1999). Seeing that we have maximal PKA 
phosphorylation of the receptor in a minute, there would be significant PKA-
mediated desensitisation at the receptor level which is currently being ignored. 
Incorporating partial receptor activities based on phosphorylation status should 
lower the high steady state receptor activities. The fact that PKA phosphorylation 
reaches steady state within 1 minute is congruent with experimental observations 
that PKA phosphorylation of receptor reaches near steady state within 1-2 mins on 
treatment with 100 nM epinephrine (Tran, Friedman et al. 2004). The simulated 
PKA-phosphorylated PDE follows PKA activation. We don’t have an experimental 
measure of PKA-phosphorylated PDE in our cell lines. The time course of PKA-
phosphorylated β2AR and PKA-phosphorylated PDE don’t match on account of the 
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different phosphorylation rates used in the model. The rate of PKA phosphorylation 
of the β2AR in our HEK293 cells that stably overexpress the β2AR is ~ 83/sec 
(Tran, Friedman et al. 2004). The rate of PKA phosphorylation of PDE in our cells 
is unknown. I used a rate of ~ 0.015/sec based on our previous models for the 
HEK293 cells (Xin, Tran et al. 2008). The rates of PDE phosphorylation will have to 
be adjusted to help match the experimental measured cAMP in response to varying 
concentrations of isoproterenol. The simulated cAMP profile reaches maximal 
levels in ~ 1 minute and the experimentally measured cAMP profile reaches 
maximal levels after about 2 minutes. The fact that simulated cAMP levels rise 
faster than our experimental measures could be because of one of two reasons (i) 
very high AC activity; and (ii) low basal PDE activity. This will have to be fine-tuned 
in future simulations.  Inspite of this divergence from measured behaviour 
simulated cAMP levels at 5 min can be used to study the effects of varying receptor 
concentrations to mimic differences between HASMs and HEK293s that stably 
over express the β2AR. 
5.3. Effect of Varying β2AR Levels   
There is ~ 100-fold difference in β2AR levels between stable overexpressions in 
HEK293s and endogenous levels in HASMs (Clark and Knoll 2002). I’ve simulated 
in Figure 5.7 the effect of variation in receptor levels and of inhibiting GRK-/PKA-
/PDE-modules when the GRK/arrestin modules are functioning properly.  
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Figure 5.7 Effect of [β2AR] Variation in Unified Model Under Different Inhibition 
Protocols 
This reaction diagram shows the simulated profiles of normalised cAMP in HASMs (β2ARt=0 = 
1 µM; green triangle/line) and HEK293s (β2ARt=0 = 100 µM; black square/line). (A) Parameters 
as per Table 3.1; (B) PDEt=0 = 0 µM; (C) R2:C2t=0 = 0 µM; (D) GRK Phosphorylation Rate = 0 
sec-1. 
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As expected from Figure 5.6 basal PDE activity is very low in the model. Therefore 
inhibiting PDE by setting initial PDE concentrations to 0 µM does not affect cAMP 
at 5 min, hence Figure 5.7A and Figure 5.7B are same. Due to ignoring PKA 
effects on the receptor any PKA-mediated desensitisation is through PDE 
activation. Figure 5.6 shows that there is a delay in accumulation of catalytic 
subunit of PKA and PKA-phosphorylated PDE, because of this there won’t be any 
significant effect of inhibiting PKA on the cAMP profile in the first 5 mins post-
stimulus. Therefore Figure 5.7C will be same as Figure 5.7A. Post ligand treatment 
GRK phosphorylation of the receptor is a prerequisite for arrestin binding the 
receptor (Krasel, Bunemann et al. 2005). Arrestin binding to the receptor is rapid 
and assumed to completely uncouple the receptor from Gαs. Therefore in the 
absence of GRK phosphorylation there won’t be any arrestin binding and arrestin-
mediated desensitisation. Figure 5.7D shows that GRK-/arrestin-mediated β2AR 
desensitisation is the dominant mode of β2AR desensitisation in the over 
expression system.  
5.4. Model Limitations 
My model currently ignores effects of PKA mediated β2AR phosphorylation. 
Incorporation of variable receptor activity dependent upon phosphorylation status 
of the receptor is necessary to capture better the behaviour of the β2AR signaling 
machinery at low agonist concentrations. At high agonist concentrations GRK-
phosphorylation of the β2AR leads to arrestin recruitment and complete uncoupling 
of the Gαs from the β2AR thereby reducing the β2AR coupling efficieny for Gs to 
zero 
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Currently the simulated AC activity is too high and basal PDE activity is too low and 
this leads to a faster peak in cAMP production. AC activity and basal PDE activity 
can be corrected while validating the model to cAMP profile ± PDE inhibitors. 
The model of PDE-mediated β2AR regulation previously developed by our group 
(Xin, Tran et al. 2008) used arbitrary concentrations for β2AR levels in HASMs (1 
µM) and HEK293s (100 µM). Estimates of local concentrations of membrane bound 
proteins are error-prone. One needs an estimate of the plasma membrane volume 
and assume point distribution of the protein of interest. My crude estimates (c.f. 
Equations 5.1 and 5.2) based on an ideal spherical cell and measured total protein 
levels in our cells put the receptor concentration at the ball park range of 0.003 µM 
for HASMs and 0.3 µM for HEK293s. I’ll have to validate the model for cAMP 
profile ± PDE inhibitors for a range of receptor concentrations and verify if the 
simulated properties of overexpression are a function of absolute receptor 
concentrations or they are dependent upon the ratio of concentrations. 
Given the preponderance of reactions (167!) in this model it is necessary to do a 
sensitivity analysis to help prune the model. Stoichiometric analysis will also help in 
reducing the number of receptor states in the model.  
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6. Conclusions and Future Work 
The β2AR is a G-protein coupled receptor that activates smooth muscle relaxation 
through both cAMP-dependent and independent pathways (Katsuki and Murad 1977; 
Wong and Buckner 1978; Rinard, Rubinfeld et al. 1979; Zhou, Newsholme et al. 
1992). Asthma is a chronic disease characterised by; 1) bronchial hyper-
responsiveness which leads to increased contraction of the airway smooth muscles; 2) 
inflammation; and 3) airway remodelling.  Due to its role in smooth muscle relaxation 
β-agonists are used in treatment of asthma and COPD (Connors, Dawson et al. 1996; 
Celli and MacNee 2004; Donohue 2004). Short acting β-agonists are used as a rescue 
agent to bring about immediate airway smooth muscle relaxation to relieve airway 
distress. Long acting β-agonists are used in combination with inhaled corticosteroids 
on a daily basis as a maintenance therapy to avoid recurrence of asthmatic episodes. 
The hallmark of these treatments is that they are only palliative and so they alleviate 
the symptom of airway distress and don’t cure the underlying cause of the symptoms. 
Due to this, during asthma treatment regimen a patient is repeatedly exposed to the 
drugs. Excessive and prolonged use of β-agonists leads to tachyphylaxis – which is 
characterised by a tolerance or subsensitivity to the drug leading to the loss of both 
broncholdilatory (lung inflation post airway smooth muscle relaxation) and 
bronchoprotective (resistance to contraction on inhalation of a bronchioconstrictor) 
effects of the drug (Keighley 1966; Van Metre 1969; Davis and Conolly 1980; Sears 
2002; Abramson, Walters et al. 2003). For β-agonists, tachyphylaxis occurs due to β-
desensitisation and downregulation. In order to understand why clinical tachyphylaxis 
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happens in response to β-agonists it becomes necessary to understand agonist 
specific activation of the various β2AR desensitisation pathways. These studies are 
difficult and extremely time consuming to perform in vivo or in vitro on account of 
multiple isoforms and cross-reactions in signalling pathways. Our group’s long-term 
goal has been to understand the regulatory mechanisms of the β2AR machinery in 
response to both short- and long-acting β-agonists. The ten models that I have 
developed and described in the previous chapters represent a significant advance 
toward this goal.  
In Chapter 3 I have modelled the GRK/Arrestin module of the β2AR regulation as it 
pertains to experimental measures of agonist-induced GRK-mediated β2AR-
phosphorylation, β2AR-dephosphorylation, -trafficking, -desensitisation and -
resensitisation (Figure 3.1). Table 3.1 lists the parameters used to model and simulate 
the consensus GRK pathway in response to various agonists at different 
concentrations and durations. The data simulated were from 90+ independent 
experiments on our stable overexpressions of human β2AR in HEK 293 cells.  
GRK and arrestin isoforms have been frequently targeted for overexpression or 
knockdown in different cells types (Ahn, Nelson et al. 2003; Penela, Ribas et al. 2003; 
Reiter and Lefkowitz 2006; Violin, Ren et al. 2006; Luo, Busillo et al. 2008). These 
proteins also differ in their overall expression levels and localisation (Zhang, Barak et 
al. 1997; Komori, Cain et al. 1998). They also undergo post-translational modifications 
(Lin, Krueger et al. 1997; Lin, Chen et al. 2002; Penela, Ribas et al. 2003; Shenoy, 
Drake et al. 2006). Given that there is wide variability in the level or activity of these 
two β2AR regulatory proteins in different cell types I was interested in the effect of this 
170 
 
variability on the modelling results. In Figure 3.7 I explored the effects of varying GRK 
phosphorylation and arrestin binding over a hundred-fold range around rates 
mentioned in Table 3.1 and plotted its effects on β2AR phosphorylation, 
desensitisation and internalisation over a 0–30 min time course.  
The major discoveries from these computational analyses were that steady states of 
GRK phosphorylated β2AR were unaffected over hundred-fold variation in GRK 
phosphorylation rates (Figure 3.7 A-C) on treatment with saturating concentration (10 
µM) of epinephrine. This pointed out a flaw in how most GRK overexpression and 
knockdown studies are performed. These usually tend to measure β2AR 
phosphorylation at steady state with saturating agonist concentrations; my model 
suggests that this would increase the risk of false negative results. A more exacting 
measure for the effects of GRK overexpression and knockdown experiments would be 
an estimate of the initial rates of GRK-mediated receptor phosphorylation at sub-
saturating ligand concentrations.  
I presented models to test various reaction topologies for GRK-mediated β2AR 
regulation. This was done since the possibility of cell surface dephosphorylation of the 
GRK phosphorylated β2AR and the recycling of the phosphorylated β2AR has been a 
contentious issue (Yu, Lefkowitz et al. 1993; Pippig, Andexinger et al. 1995; Krueger, 
Daaka et al. 1997; Iyer, Tran et al. 2006; Kelly 2006). Our group has shown that 1) 
blocking internalisation does not prevent β2AR dephosphorylation (Iyer, Tran et al. 
2006), and 2) that β2AR dephosphorylation can occur even at undetectable levels of 
internalisation (Tran, Friedman et al. 2007). I have determined GRK site β2AR 
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dephosphorylation rates at the membrane to be ~0.04/min per method described in 
2.1.1. 
To investigate the effects of membrane dephosphorylation and phosphorylated 
receptor recycling I created six different models (Figure 3.9A-F) that vary different 
reactions as described in the footnote of Table 3.1. In Figure 3.9A I modelled our 
default reaction topology that allowed for both dephosphorylation of the receptor at the 
plasma membrane and phosphorylated receptor recycling. I contrasted this with Figure 
3.9F where I modelled a reaction topology that did not allow for both plasma 
membrane dephosphorylation and recycling of phosphorylated receptor. This was in 
keeping with the prevalent view around early 2000s (Krupnick and Benovic 1998; 
Billington and Penn 2003). I showed that under these conditions the system failed to 
achieve more than 50% β2AR dephosphorylation which was discordant with our 
experimental measurements (Tran, Friedman et al. 2007). Increasing the cytosolic 
dephosphorylation rate did not help in rescuing the simulated dephosphorylation 
curves. Thus through modeling I was able to show that the prevalent model of early 
2000s was not able to explain dephosphorylation measurements done in our lab. I 
further explored if random variations in β2AR dephosphorylation and recycling reaction 
topologies could explain our experimental results. Through my analyses using these 
models I clarified the necessity for β2AR dephosphorylation at the membrane and the 
recycling of the GRK phosphorylated receptor. 
I further used the models described in Chapter 3 to explore the effects of various 
frequencies of agonist treatment since under physiological conditions based on the 
target tissue the β2AR “sees” different frequencies and amplitudes of stimuli. Synaptic 
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β2AR “sees” high norepinephrine concentrations in a pulsatile fashion (Trendelenburg, 
Gaiser et al. 1999; Stjarne 2000) due to the small synaptic volumes, rapid removal and 
reuptake of norepinephrine. In contrast to the synaptic stimuli, the bloodstream 
concentrations of agonist post epinephrine secretion from the adrenal gland are much 
lower but for relatively longer periods. The most exciting results from these 
computational analyses were that during pulsatile activation of the β2AR, the signalling 
machinery “remembered” prior exposure to an agonist and desensitised much more 
strongly on subsequent exposures (Figure 3.11A). This memory of prior stimuli could 
be attributed to the accumulation of the GRK phosphorylated β2AR due to slower 
dephosphorylation. In subsequent figures (Figure 3.12-3.13) I explored the basis of 
this cellular memory and showed (Figure 3.12B) that this memory was robust even 
after 2 hours of treatment. Thus this phenomenon could be responsible for the 
reduced drug efficacy on repeated use of short acting β-agonists. 
After exploring short acting β-agonists in chapter 3 in chapter 4 I developed models of 
salmeterol action, a long acting β-agonist used in combination with inhaled 
corticosteroids during maintenance therapy of asthma. Briefly, salmeterol action has 
been explained by three models. Salmeterol is lipohilic and reversibly incorporates in 
the plasma membrane, resulting in a partition of drugs between a membrane and an 
aqueous phase (Rhodes, Newton et al. 1992). Due to membrane partitioning of 
salmeterol, the membrane can act as a salmeterol reservoir and this forms the basis of 
the microkinetic model (MM) (Anderson, Linden et al. 1994) (Figure 4.2). Due to the 
high membrane partitioning of salmeterol and its slow rate of release from the 
membrane, t1/2 = 25 mins (synthetic membranes) – 3 hours (tracheal strips) (Rhodes, 
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Newton et al. 1992; Austin, Barton et al. 2003) it is posited that salmeterol reaches the 
receptor by lateral diffusion through the membrane (Anderson, Linden et al. 1994) 
since by the time salmeterol traverses the length of the airways to reach the target 
bronchii it would have  bound to the membrane on account of its lipophilicity. 
Per the exosite model (EM) (Figure 4.4) the saligenin head of salmeterol (Figure 1.2) 
and the hydrophobic phenylalkoxyalkyl side chain binds the β2AR at two spatially 
distinct sites. The site of saligenin head binding is identified as the active site and the 
site of hydrophobic phenylalkoxyalkyl side chain binding is called an exosite. In the 
exosite model tethering of the phenylalkoxyalkyl chain to the exosite is quasi-
irreversible while the binding of the saligenin head to the active site is rapidly 
reversible. This model also allows agonist or antagonist binding to the active site when 
the exosite is occupied by salmeterol’s hydrophobic tail (Figure 6.1). To allow the 
flipping in and out of the saligenin head from the active site, the exosite has been 
posited to be in the central core of the β2AR (Jack 1991). Both site directed 
mutagenesis studies involving replacement of β2AR central domains with β1AR 
(Green, Spasoff et al. 1996; Isogaya, Yamagiwa et al. 1998) and photoaffinity labeling 
with [125I]iodoazido-salmeterol (Rong, Arbabian et al. 1999) lend credence to the idea 
that the exosite is further into the transmembrane domains toward the cytosol than the 
active site. 
The rebinding model posits that a high local concentration of salmeterol is 
maintained on account of rapid rebinding (Szczuka, Wennerberg et al. 2009). This 
model wouldn’t be able to explain the reassertion phenomenon when a competing 
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ligand is present without invoking another mechanism to retain salmeterol in the 
vicinity of the receptor.  
Given the importance of salmeterol in treating asthma and COPD I developed 
phenomenological models to describe the effects of membrane retention of salmeterol, 
exosite binding or a composite of the two (combined model - CM). I then coupled 
these models to an adaptation of the GRK-mediated β2AR regulation model 
developed in Chapter 3 and then tested them to see if properties of salmeterol long 
action and reassertion still held true. Using these models I show (Figure 4.10A) that 
none of the three currently accepted models can sufficiently explain the long action of 
salmeterol or significantly reduced β2AR internalisation (Figure 4.10B) on treatment 
with saturating concentrations of salmeterol. It becomes necessary to invoke 
decreased arrestin affinity for salmeterol bound β2AR complex in order to simulate 
experimentally measured salmeterol-induced β2AR internalisation (Vayttaden, 
Friedman et al. 2010) and to rescue loss of long action to explain the long action of 
salmeterol (Figure 4.10C).  
In Chapter 5 I described an alpha version of the unified model of GRK-/PKA-/PDE-
mediated β2AR regulation. This model explores the effect of variation in receptor 
number (Figure 5.6). Once validated, this model will be an important tool to study the 
effects of various beta agonists on GRK- and PKA-mediated β2AR regulation in 
HASMs where the low receptor number makes phosphorylation experiments difficult. 
This model can eventually be used to discover the relative contribution of PKA, GRK, 
PDE, arrestin and internalisation to the total β2AR desensitisation on treatment with 
various beta agonists. This information in turn would be valuable in deciding what 
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desensitisation modules are best targeted pharmacologically for most effective use of 
individual beta agonists. 
A well tested comprehensive model of β2AR regulation would aid in: (i) understanding 
tissue specific mechanistic differences in β2AR response; (ii) in-silico estimation of 
tachyphylaxis associated with prolonged use of different β2AR agonists; (iii) 
hypothesis testing and in-silico prediction of experimental results. Some of the future 
work planned to understand β2AR regulation is described below. 
6.1. Salmeterol Models 
The salmeterol models presented in Chapter 4 deals only with GRK-mediated 
β2AR regulation. Since the GRK-mediated β2AR phosphorylation profile at 
saturating salmeterol concentrations are similar to that obtained with about 50 nM 
isoproterenol, it is expected that PKA- and PDE-modules would be significant 
players in β2AR regulation. I need to expand the combined model (Model 9) 
representing salmeterol exosite, microkinetic and rebinding effects to include PKA- 
and PDE-mediated β2AR regulation. 
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Figure 6.1 Model of Salmeterol Bitopic Action. 
Grey cylinders = β2AR; white triangle = empty active site; white circle = empty exosite; green 
triangle = active site occupied by isoproterenol; red triangle = active site occupied by 
salmeterol; red circle = exosite occupied by salmeterol. A = naïve β2AR; B = salmeterol bound 
to an exosite on the β2AR; C = salmeterol bound to the active site on the β2AR; D = 
salmeterol bound to both the active- and exo-site on the β2AR; E = isoproterenol bound to the 
active site on the β2AR; F = β2AR having isoproterenol bound to the active site and salmeterol 
to the exosite. 
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Salmeterol is a bitopic ligand since it binds the β2AR both at an active site and an 
exosite (Johnson, Butchers et al. 1993; Green, Spasoff et al. 1996; Isogaya, 
Yamagiwa et al. 1998; Rong, Arbabian et al. 1999). In Figure 6.1 I have shown the 
minimum number of β2AR states to accommodate isoproterenol and salmeterol 
binding per the exosite model. In the interest of simplification, in the models 
simulated in Chapter 4 I’ve ignored a β2AR state that has salmeterol bound only to 
the active site with an empty exosite (state D in Figure 6.1) since I expect all 
exosite to be occupied by salmeterol when β2AR is treated with saturating 
concentrations of salmeterol for long periods of time. The number of β2AR states 
now increases exponentially while allowing for GRK- and PKA-mediated β2AR 
phosphorylation, arrestin binding and internalisation of the β2AR.  Thus a unified 
GRK-/PKA-/PDE-mediated β2AR regulation model that simulates salmeterol 
exosite, microkinetic and rebinding effects is not easily tractable on account of an 
exponential increase in receptor species. Such a model is best attempted after the 
unified GRK-/PKA-/PDE-mediated β2AR regulation model for monotopic ligands as 
described in Chapter 5 is well validated and constrained. Since salmeterol 
treatment is for longer durations and it brings about negligible β2AR internalisation 
I’d have to incorporate additional reactions to capture the β2AR degradation 
kinetics.  
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6.2. GRK-/PKA-/PDE-Mediated Regulation 
The model of GRK-/PKA-/PDE-mediated regulation of β2AR signalling described in 
Chapter 5 has 167 reactions. There are a few quality control measures that need to 
be taken. I need to do a stoichiometric state analysis to calculate mass 
conservation. Since my model is implemented in COPASI I’ll be using the 
Householder reduction method (Householder 1958; Vallabhajosyula, Chickarmane 
et al. 2006). The model also needs to be subjected to sensitivity analysis similar to 
analysis done in Figures 2.5-6 and for cAMP profile. The results of the 
stoichiometric state analysis and sensitivity analysis will help determine if reactions 
need to be pruned.  
Currently I have only done a rudimentary phenomenological validation of the 
model. I need to extend the model validation to a more exhaustive set of time 
course profiles that cover PKA- and GRK-mediated β2AR phosphorylation, cAMP 
profile (± PDE inhibitors ± propranolol), β2AR trafficking (internalisation and 
recycling), and β2AR activity (desensitisation and resensitisation) for different 
monotopic agonists and concentrations. Once the model has been well constrained 
through experimental validation, stoichiometric state analysis and sensitivity 
analysis I will use the model to predict the percent contribution of each regulatory 
module to total β2AR desensitisation.  
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6.3. β2AR and Pro-Inflammatory Signalling Pathway Crosstalk 
Currently little is known about how salmeterol-mediated β2AR desensitisation 
pathways are altered with co-treatment of corticosteroids or under conditions of 
inflammation. The effect of corticosteroid and pro-inflammation mediated signalling 
on agonist induced β2AR desensitisation is important given that LABAs such as 
salmeterol are used clinically in asthmatic patients as a chronic medication in 
combination with inhaled corticosteroids. Recently, the Penn group has published 
data regarding the effect of PKA on the HASM transcriptome. They determined 
transcriptional changes using mRNA array technology following the introduction of 
a genetic inhibitor of PKA (GFP-PKI) under pro-inflammatory conditions and in the 
presence or absence of corticosteroids. A major finding of this study was that PKA 
is a critical modulator of the transcriptional changes induced by pro-inflammatory 
cytokines, particularly with regard to their promitogenic effects (Misior, Deshpande 
et al. 2009). They have also shown that corticosteroids can suppress β agonist-
induced PKA activity thus inhibiting the mitogenic effects of cytokines (Misior, Yan 
et al. 2008)  and that the anti-mitogenic effects of β-agonists (including salmeterol) 
are mediated by PKA (Yan, Deshpande et al. 2011). Modelling the crosstalk 
between salmeterol-mediated β2AR regulatory pathways and pro-inflammatory 
signalling pathways will have to be complemented with experiments. Salmeterol-
mediated β2AR desensitisation will have to be measured in the presence of 
corticosteroid like fluticasone propionate in both naïve cells as well as under 
cytokine-mediated inflammatory conditions, to mimic signaling in the asthmatic 
airway. The application of these results to my quantitative model will provide a 
180 
 
more complete picture of how β2AR signaling functions in disease states and an 
improved understanding of β agonist mediated crosstalk with pro-inflammatory 
pathways. 
  
181 
 
7. Bibliography 
Abramson, M. J., J. Walters, et al. (2003). "Adverse effects of beta-agonists: are 
they clinically relevant?" Am J Respir Med 2(4): 287-297. 
Ahn, S., C. D. Nelson, et al. (2003). "Desensitization, internalization, and signaling 
functions of beta-arrestins demonstrated by RNA interference." Proc Natl Acad Sci 
U S A 100(4): 1740-1744. 
Ahn, S., S. K. Shenoy, et al. (2004). "Differential kinetic and spatial patterns of 
beta-arrestin and G protein-mediated ERK activation by the angiotensin II 
receptor." J Biol Chem 279(34): 35518-35525. 
Anderson, G. P. (1993). "Long acting inhaled beta-adrenoceptor agonists the 
comparative pharmacology of formoterol and salmeterol." Agents Actions Suppl 43: 
253-269. 
Anderson, G. P. (2006). "Current issues with beta2-adrenoceptor agonists: 
pharmacology and molecular and cellular mechanisms." Clin Rev Allergy Immunol 
31(2-3): 119-130. 
Anderson, G. P., A. Linden, et al. (1994). "Why are long-acting beta-adrenoceptor 
agonists long-acting?" Eur Respir J 7(3): 569-578. 
Attwood, T. K. and J. B. Findlay (1994). "Fingerprinting G-protein-coupled 
receptors." Protein Eng 7(2): 195-203. 
182 
 
Austin, R. P., P. Barton, et al. (2003). "QSAR and the rational design of long-acting 
dual D2-receptor/beta 2-adrenoceptor agonists." J Med Chem 46(15): 3210-3220. 
Azzi, M., P. G. Charest, et al. (2003). "Beta-arrestin-mediated activation of MAPK 
by inverse agonists reveals distinct active conformations for G protein-coupled 
receptors." Proc Natl Acad Sci U S A 100(20): 11406-11411. 
Ball, D. I., R. T. Brittain, et al. (1991). "Salmeterol, a novel, long-acting beta 2-
adrenoceptor agonist: characterization of pharmacological activity in vitro and in 
vivo." Br J Pharmacol 104(3): 665-671. 
Barak, L. S., M. Tiberi, et al. (1994). "A highly conserved tyrosine residue in G 
protein-coupled receptors is required for agonist-mediated beta 2-adrenergic 
receptor sequestration." J Biol Chem 269(4): 2790-2795. 
Barber, R., T. J. Goka, et al. (1992). "Positively cooperative cAMP 
phosphodiesterase attenuates cellular cAMP responses." Second Messengers 
Phosphoproteins 14(1-2): 77-97. 
Barlic, J., J. D. Andrews, et al. (2000). "Regulation of tyrosine kinase activation and 
granule release through beta-arrestin by CXCRI." Nat Immunol 1(3): 227-233. 
Beach, J. R., C. L. Young, et al. (1992). "A comparison of the speeds of action of 
salmeterol and salbutamol in reversing methacholine-induced bronchoconstriction." 
Pulm Pharmacol 5(2): 133-135. 
Beaulieu, J. M., S. Marion, et al. (2008). "A beta-arrestin 2 signaling complex 
mediates lithium action on behavior." Cell 132(1): 125-136. 
183 
 
Beaulieu, J. M., T. D. Sotnikova, et al. (2005). "An Akt/beta-arrestin 2/PP2A 
signaling complex mediates dopaminergic neurotransmission and behavior." Cell 
122(2): 261-273. 
Benovic, J. L., H. Kuhn, et al. (1987). "Functional desensitization of the isolated 
beta-adrenergic receptor by the beta-adrenergic receptor kinase: potential role of 
an analog of the retinal protein arrestin (48-kDa protein)." Proc Natl Acad Sci U S A 
84(24): 8879-8882. 
Benovic, J. L., L. J. Pike, et al. (1985). "Phosphorylation of the mammalian beta-
adrenergic receptor by cyclic AMP-dependent protein kinase. Regulation of the rate 
of receptor phosphorylation and dephosphorylation by agonist occupancy and 
effects on coupling of the receptor to the stimulatory guanine nucleotide regulatory 
protein." J Biol Chem 260(11): 7094-7101. 
Benovic, J. L., R. H. Strasser, et al. (1986). "Beta-adrenergic receptor kinase: 
identification of a novel protein kinase that phosphorylates the agonist-occupied 
form of the receptor." Proc Natl Acad Sci U S A 83(9): 2797-2801. 
Berg, K. A., S. Maayani, et al. (1998). "Effector pathway-dependent relative efficacy 
at serotonin type 2A and 2C receptors: evidence for agonist-directed trafficking of 
receptor stimulus." Mol Pharmacol 54(1): 94-104. 
Bhalla, U. S. (2002). "Use of Kinetikit and GENESIS for modeling signaling 
pathways." Methods Enzymol 345: 3-23. 
184 
 
Bhattacharya, M., P. H. Anborgh, et al. (2002). "Beta-arrestins regulate a Ral-GDS 
Ral effector pathway that mediates cytoskeletal reorganization." Nat Cell Biol 4(8): 
547-555. 
Billington, C. K., S. K. Joseph, et al. (1999). "Modulation of human airway smooth 
muscle proliferation by type 3 phosphodiesterase inhibition." Am J Physiol 276(3 Pt 
1): L412-419. 
Billington, C. K., I. R. Le Jeune, et al. (2008). "A major functional role for 
phosphodiesterase 4D5 in human airway smooth muscle cells." Am J Respir Cell 
Mol Biol 38(1): 1-7. 
Billington, C. K. and R. B. Penn (2003). "Signaling and regulation of G protein-
coupled receptors in airway smooth muscle." Respir Res 4: 2. 
Bingham, J., S. Sudarsanam, et al. (2006). "Profiling human phosphodiesterase 
genes and splice isoforms." Biochem Biophys Res Commun 350(1): 25-32. 
Bjarnadottir, T. K., D. E. Gloriam, et al. (2006). "Comprehensive repertoire and 
phylogenetic analysis of the G protein-coupled receptors in human and mouse." 
Genomics 88(3): 263-273. 
Black, J. L., B. G. Oliver, et al. (2009). "Molecular mechanisms of combination 
therapy with inhaled corticosteroids and long-acting beta-agonists." Chest 136(4): 
1095-1100. 
Bockaert, J. and J. P. Pin (1999). "Molecular tinkering of G protein-coupled 
receptors: an evolutionary success." EMBO J 18(7): 1723-1729. 
185 
 
Bohn, L. M., R. J. Lefkowitz, et al. (2002). "Differential mechanisms of morphine 
antinociceptive tolerance revealed in (beta)arrestin-2 knock-out mice." J Neurosci 
22(23): 10494-10500. 
Bohn, L. M., R. J. Lefkowitz, et al. (1999). "Enhanced morphine analgesia in mice 
lacking beta-arrestin 2." Science 286(5449): 2495-2498. 
Bolger, G. B., A. McCahill, et al. (2003). "The unique amino-terminal region of the 
PDE4D5 cAMP phosphodiesterase isoform confers preferential interaction with 
beta-arrestins." J Biol Chem 278(49): 49230-49238. 
Boswell-Smith, V., M. Cazzola, et al. (2006). "Are phosphodiesterase 4 inhibitors 
just more theophylline?" J Allergy Clin Immunol 117(6): 1237-1243. 
Bouvier, M., W. P. Hausdorff, et al. (1988). "Removal of phosphorylation sites from 
the beta 2-adrenergic receptor delays onset of agonist-promoted desensitization." 
Nature 333(6171): 370-373. 
Bower, J. M. and D. Beeman (2007). "Constructing realistic neural simulations with 
GENESIS." Methods Mol Biol 401: 103-125. 
Bresnahan, S. J., J. L. Borowitz, et al. (1975). "Some steric factors affecting 
smooth muscle relaxation by cAMP analogs." Arch Int Pharmacodyn Ther 218(2): 
180-185. 
Brindley, D. N. and D. W. Waggoner (1996). "Phosphatidate phosphohydrolase 
and signal transduction." Chem Phys Lipids 80(1-2): 45-57. 
186 
 
Broadley, K. J. (1999). "Review of mechanisms involved in the apparent differential 
desensitization of beta1- and beta2-adrenoceptor-mediated functional responses." 
J Auton Pharmacol 19(6): 335-345. 
Brondello, J. M., A. Brunet, et al. (1997). "The dual specificity mitogen-activated 
protein kinase phosphatase-1 and -2 are induced by the p42/p44MAPK cascade." J 
Biol Chem 272(2): 1368-1376. 
Bruynzeel, P. L. (1984). "Changes in the beta-adrenergic system due to beta-
adrenergic therapy: clinical consequences." Eur J Respir Dis Suppl 135: 62-71. 
Bruynzeel, P. L., H. Meurs, et al. (1985). "Some fundamental points concerning the 
clinical aspects of desensitization." Bull Eur Physiopathol Respir 21(5): 45s-52s. 
Camps, M., A. Carozzi, et al. (1992). "Isozyme-selective stimulation of 
phospholipase C-beta 2 by G protein beta gamma-subunits." Nature 360(6405): 
684-686. 
Cazzola, M., S. Picciolo, et al. (2011). "Roflumilast in chronic obstructive pulmonary 
disease: evidence from large trials." Expert Opin Pharmacother 11(3): 441-449. 
Celli, B. R. and W. MacNee (2004). "Standards for the diagnosis and treatment of 
patients with COPD: a summary of the ATS/ERS position paper." Eur Respir J 
23(6): 932-946. 
Cherezov, V., D. M. Rosenbaum, et al. (2007). "High-resolution crystal structure of 
an engineered human beta2-adrenergic G protein-coupled receptor." Science 
318(5854): 1258-1265. 
187 
 
Chong, J., P. Poole, et al. (2011). "Phosphodiesterase 4 inhibitors for chronic 
obstructive pulmonary disease." Cochrane Database Syst Rev(5): CD002309. 
Choo-Kang, Y. F., W. T. Simpson, et al. (1969). "Controlled comparison of the 
bronchodilator effects of three beta-adrenergic stimulant drugs administered by 
inhalation to patients with asthma." Br Med J 2(5652): 287-289. 
Clark, R. B., C. Allal, et al. (1996). "Stable activation and desensitization of beta 2-
adrenergic receptor stimulation of adenylyl cyclase by salmeterol: evidence for 
quasi-irreversible binding to an exosite." Mol Pharmacol 49(1): 182-189. 
Clark, R. B., J. Friedman, et al. (1987). "Beta-adrenergic receptor desensitization of 
wild-type but not cyc lymphoma cells unmasked by submillimolar Mg2+." FASEB J 
1(4): 289-297. 
Clark, R. B. and B. J. Knoll (2002). "Measurement of receptor desensitization and 
internalization in intact cells." Methods Enzymol 343: 506-529. 
Clark, R. B., B. J. Knoll, et al. (1999). "Partial agonists and G protein-coupled 
receptor desensitization." Trends Pharmacol Sci 20(7): 279-286. 
Clark, R. B., M. W. Kunkel, et al. (1988). "Activation of cAMP-dependent protein 
kinase is required for heterologous desensitization of adenylyl cyclase in S49 wild-
type lymphoma cells." Proc Natl Acad Sci U S A 85(5): 1442-1446. 
Conner, D. A., M. A. Mathier, et al. (1997). "beta-Arrestin1 knockout mice appear 
normal but demonstrate altered cardiac responses to beta-adrenergic stimulation." 
Circ Res 81(6): 1021-1026. 
188 
 
Connors, A. F., Jr., N. V. Dawson, et al. (1996). "Outcomes following acute 
exacerbation of severe chronic obstructive lung disease. The SUPPORT 
investigators (Study to Understand Prognoses and Preferences for Outcomes and 
Risks of Treatments)." Am J Respir Crit Care Med 154(4 Pt 1): 959-967. 
Conti, M., W. Richter, et al. (2003). "Cyclic AMP-specific PDE4 
phosphodiesterases as critical components of cyclic AMP signaling." J Biol Chem 
278(8): 5493-5496. 
Conway, B. R., L. K. Minor, et al. (1999). "Quantification of G-Protein Coupled 
Receptor Internatilization Using G-Protein Coupled Receptor-Green Fluorescent 
Protein Conjugates with the ArrayScantrade mark High-Content Screening 
System." J Biomol Screen 4(2): 75-86. 
Cooper, P., R. Kurten, et al. (2011). "Formoterol and salmeterol induce a similar 
degree of beta(2) -adrenoceptor tolerance in human small airways but via different 
mechanisms." Br J Pharmacol 163(3): 521-532. 
Cowie, R. L., L. P. Boulet, et al. (2007). "Tolerability of a salmeterol 
xinafoate/fluticasone propionate hydrofluoroalkane metered-dose inhaler in 
adolescent and adult patients with persistent asthma: a 52-week, open-label, 
stratified, parallel-group, multicenter study." Clin Ther 29(7): 1390-1402. 
Davis, C. and M. E. Conolly (1980). "Tachyphylaxis to beta-adrenoceptor agonists 
in human bronchial smooth muscle: studies in vitro." Br J Clin Pharmacol 10(5): 
417-423. 
189 
 
DeFea, K. A., Z. D. Vaughn, et al. (2000). "The proliferative and antiapoptotic 
effects of substance P are facilitated by formation of a beta -arrestin-dependent 
scaffolding complex." Proc Natl Acad Sci U S A 97(20): 11086-11091. 
DeFea, K. A., J. Zalevsky, et al. (2000). "beta-arrestin-dependent endocytosis of 
proteinase-activated receptor 2 is required for intracellular targeting of activated 
ERK1/2." J Cell Biol 148(6): 1267-1281. 
Deshpande, D. A. and R. B. Penn (2006). "Targeting G protein-coupled receptor 
signaling in asthma." Cell Signal 18(12): 2105-2120. 
Devanathan, S., Z. Yao, et al. (2004). "Plasmon-waveguide resonance studies of 
ligand binding to the human beta 2-adrenergic receptor." Biochemistry 43(11): 
3280-3288. 
Donohue, J. F. (2004). "Therapeutic responses in asthma and COPD. 
Bronchodilators." Chest 126(2 Suppl): 125S-137S; discussion 159S-161S. 
Doskeland, S. O. and D. Ogreid (1984). "Characterization of the interchain and 
intrachain interactions between the binding sites of the free regulatory moiety of 
protein kinase I." J Biol Chem 259(4): 2291-2301. 
Drake, M. T., J. D. Violin, et al. (2008). "beta-arrestin-biased agonism at the beta2-
adrenergic receptor." J Biol Chem 283(9): 5669-5676. 
Duringer, C., G. Grundstrom, et al. (2009). "Agonist-specific patterns of beta 2-
adrenoceptor responses in human airway cells during prolonged exposure." Br J 
Pharmacol 158(1): 169-179. 
190 
 
Ferguson, S. S., W. E. Downey, 3rd, et al. (1996). "Role of beta-arrestin in 
mediating agonist-promoted G protein-coupled receptor internalization." Science 
271(5247): 363-366. 
Flower, D. R. (1999). "Modelling G-protein-coupled receptors for drug design." 
Biochim Biophys Acta 1422(3): 207-234. 
Francis, S. H., B. D. Noblett, et al. (1988). "Relaxation of vascular and tracheal 
smooth muscle by cyclic nucleotide analogs that preferentially activate purified 
cGMP-dependent protein kinase." Mol Pharmacol 34(4): 506-517. 
Gardella, T. J., M. D. Luck, et al. (1996). "Inverse agonism of amino-terminally 
truncated parathyroid hormone (PTH) and PTH-related peptide (PTHrP) analogs 
revealed with constitutively active mutant PTH/PTHrP receptors." Endocrinology 
137(9): 3936-3941. 
Gardner, B., Z. F. Liu, et al. (2001). "The role of phosphorylation/dephosphorylation 
in agonist-induced desensitization of D1 dopamine receptor function: evidence for 
a novel pathway for receptor dephosphorylation." Mol Pharmacol 59(2): 310-321. 
Gesty-Palmer, D., M. Chen, et al. (2006). "Distinct beta-arrestin- and G protein-
dependent pathways for parathyroid hormone receptor-stimulated ERK1/2 
activation." J Biol Chem 281(16): 10856-10864. 
Gesty-Palmer, D., H. El Shewy, et al. (2005). "beta-Arrestin 2 expression 
determines the transcriptional response to lysophosphatidic acid stimulation in 
murine embryo fibroblasts." J Biol Chem 280(37): 32157-32167. 
191 
 
Gesty-Palmer, D. and L. M. Luttrell (2008). "Heptahelical terpsichory. Who calls the 
tune?" J Recept Signal Transduct Res 28(1-2): 39-58. 
Giembycz, M. A. and J. Diamond (1990). "Partial characterization of cyclic AMP-
dependent protein kinases in guinea-pig lung employing the synthetic heptapeptide 
substrate, kemptide. In vitro sensitivity of the soluble enzyme to isoprenaline, 
forskolin, methacholine and leukotriene D4." Biochem Pharmacol 39(8): 1297-
1312. 
Gilman, A. G. (1987). "G proteins: transducers of receptor-generated signals." 
Annu Rev Biochem 56: 615-649. 
GlaxoSmithKline. (2008). "Advair Hfa (fluticasone propionate and salmeterol 
xinafoate)  Aerosol, Metered   
[GlaxoSmithKline] "   Retrieved Sept 28, 2011, 2011, from 
http://dailymed.nlm.nih.gov/dailymed/archives/fdaDrugInfo.cfm?archiveid=8926. 
Goldberg, N. D., R. F. O'Dea, et al. (1973). "Cyclic GMP." Adv Cyclic Nucleotide 
Res 3: 155-223. 
Green, S. A., A. P. Spasoff, et al. (1996). "Sustained activation of a G protein-
coupled receptor via "anchored" agonist binding. Molecular localization of the 
salmeterol exosite within the 2-adrenergic receptor." J Biol Chem 271(39): 24029-
24035. 
Guldberg, C. M. (1864). ""Concerning the Laws of Chemical Affinity"." 
Forhandlinger i Videnskabs-Selskabet i Christiania  
192 
 
Gurevich, V. V. and J. L. Benovic (1993). "Visual arrestin interaction with 
rhodopsin. Sequential multisite binding ensures strict selectivity toward light-
activated phosphorylated rhodopsin." J Biol Chem 268(16): 11628-11638. 
Gurevich, V. V., S. B. Dion, et al. (1995). "Arrestin interactions with G protein-
coupled receptors. Direct binding studies of wild type and mutant arrestins with 
rhodopsin, beta 2-adrenergic, and m2 muscarinic cholinergic receptors." J Biol 
Chem 270(2): 720-731. 
Gurevich, V. V., R. Pals-Rylaarsdam, et al. (1997). "Agonist-receptor-arrestin, an 
alternative ternary complex with high agonist affinity." J Biol Chem 272(46): 28849-
28852. 
Hansen, G., S. Jin, et al. (2000). "Absence of muscarinic cholinergic airway 
responses in mice deficient in the cyclic nucleotide phosphodiesterase PDE4D." 
Proc Natl Acad Sci U S A 97(12): 6751-6756. 
Hanson, S. M. and V. V. Gurevich (2006). "The differential engagement of arrestin 
surface charges by the various functional forms of the receptor." J Biol Chem 
281(6): 3458-3462. 
Hardman, J. G., G. A. Robison, et al. (1971). "Cyclic nucleotides." Annu Rev 
Physiol 33: 311-336. 
Harris, A. L., M. J. Connell, et al. (1989). "Role of low Km cyclic AMP 
phosphodiesterase inhibition in tracheal relaxation and bronchodilation in the 
guinea pig." J Pharmacol Exp Ther 251(1): 199-206. 
193 
 
Hausdorff, W. P., M. Bouvier, et al. (1989). "Phosphorylation sites on two domains 
of the beta 2-adrenergic receptor are involved in distinct pathways of receptor 
desensitization." J Biol Chem 264(21): 12657-12665. 
Heaslip, R. J., F. R. Giesa, et al. (1987). "Co-regulation of tracheal tone by cyclic 
AMP- and cyclic GMP-dependent mechanisms." J Pharmacol Exp Ther 243(3): 
1018-1026. 
Hertel, C. and J. P. Perkins (1984). "Receptor-specific mechanisms of 
desensitization of beta-adrenergic receptor function." Mol Cell Endocrinol 37(3): 
245-256. 
Hirsch, J. A., C. Schubert, et al. (1999). "The 2.8 A crystal structure of visual 
arrestin: a model for arrestin's regulation." Cell 97(2): 257-269. 
Holgate, S. T., C. J. Baldwin, et al. (1977). "beta-adrenergic agonist resistance in 
normal human airways." Lancet 2(8034): 375-377. 
Holloway, A. C., H. Qian, et al. (2002). "Side-chain substitutions within angiotensin 
II reveal different requirements for signaling, internalization, and phosphorylation of 
type 1A angiotensin receptors." Mol Pharmacol 61(4): 768-777. 
Hoops, S., S. Sahle, et al. (2006). "COPASI--a COmplex PAthway SImulator." 
Bioinformatics 22(24): 3067-3074. 
Householder, A. S. (1958). "Unitary Triangularization of a Nonsymmetric Matrix." 
Journal of the ACM 5(4). 
194 
 
Houslay, M. D., G. S. Baillie, et al. (2007). "cAMP-Specific phosphodiesterase-4 
enzymes in the cardiovascular system: a molecular toolbox for generating 
compartmentalized cAMP signaling." Circ Res 100(7): 950-966. 
Hu, A., G. Nino, et al. (2008). "Prolonged heterologous beta2-adrenoceptor 
desensitization promotes proasthmatic airway smooth muscle function via 
PKA/ERK1/2-mediated phosphodiesterase-4 induction." Am J Physiol Lung Cell 
Mol Physiol 294(6): L1055-1067. 
Huang, J., Y. Sun, et al. (2004). "Distinct roles for Src tyrosine kinase in beta2-
adrenergic receptor signaling to MAPK and in receptor internalization." J Biol Chem 
279(20): 21637-21642. 
Isogaya, M., Y. Yamagiwa, et al. (1998). "Identification of a key amino acid of the 
beta2-adrenergic receptor for high affinity binding of salmeterol." Mol Pharmacol 
54(4): 616-622. 
Iyer, V., T. M. Tran, et al. (2006). "Differential phosphorylation and 
dephosphorylation of beta2-adrenoceptor sites Ser262 and Ser355,356." Br J 
Pharmacol 147(3): 249-259. 
Jack, D. (1991). "The 1990 Lilly Prize Lecture. A way of looking at agonism and 
antagonism: lessons from salbutamol, salmeterol and other beta-adrenoceptor 
agonists." Br J Clin Pharmacol 31(5): 501-514. 
195 
 
Janssen, L. J., T. Tazzeo, et al. (2004). "KCl evokes contraction of airway smooth 
muscle via activation of RhoA and Rho-kinase." Am J Physiol Lung Cell Mol 
Physiol 287(4): L852-858. 
January, B., A. Seibold, et al. (1997). "beta2-adrenergic receptor desensitization, 
internalization, and phosphorylation in response to full and partial agonists." J Biol 
Chem 272(38): 23871-23879. 
Jelsema, C. L. and J. Axelrod (1987). "Stimulation of phospholipase A2 activity in 
bovine rod outer segments by the beta gamma subunits of transducin and its 
inhibition by the alpha subunit." Proc Natl Acad Sci U S A 84(11): 3623-3627. 
Johnson, M., P. R. Butchers, et al. (1993). "The pharmacology of salmeterol." Life 
Sci 52(26): 2131-2143. 
Johnston, C. A. and D. P. Siderovski (2007). "Receptor-mediated activation of 
heterotrimeric G-proteins: current structural insights." Mol Pharmacol 72(2): 219-
230. 
Jones, B. W. and P. M. Hinkle (2005). "Beta-arrestin mediates desensitization and 
internalization but does not affect dephosphorylation of the thyrotropin-releasing 
hormone receptor." J Biol Chem 280(46): 38346-38354. 
Jones, T. R., L. Charette, et al. (1993). "Interaction of iberiotoxin with beta-
adrenoceptor agonists and sodium nitroprusside on guinea pig trachea." J Appl 
Physiol 74(4): 1879-1884. 
196 
 
Joost, P. and A. Methner (2002). "Phylogenetic analysis of 277 human G-protein-
coupled receptors as a tool for the prediction of orphan receptor ligands." Genome 
Biol 3(11): RESEARCH0063. 
Katsuki, S. and F. Murad (1977). "Regulation of adenosine cyclic 3',5'-
monophosphate and guanosine cyclic 3',5'-monophosphate levels and contractility 
in bovine tracheal smooth muscle." Mol Pharmacol 13(2): 330-341. 
Keighley, J. F. (1966). "Iatrogenic asthma associated with adrenergic aerosols." 
Ann Intern Med 65(5): 985-995. 
Keith, D. E., S. R. Murray, et al. (1996). "Morphine activates opioid receptors 
without causing their rapid internalization." J Biol Chem 271(32): 19021-19024. 
Kelly, E. (2006). "G-protein-coupled receptor dephosphorylation at the cell surface." 
Br J Pharmacol 147(3): 235-236. 
Kenakin, T. (2002). "Drug efficacy at G protein-coupled receptors." Annu Rev 
Pharmacol Toxicol 42: 349-379. 
Kobilka, B. K., C. MacGregor, et al. (1987). "Functional activity and regulation of 
human beta 2-adrenergic receptors expressed in Xenopus oocytes." J Biol Chem 
262(32): 15796-15802. 
Koenig, J. A. and J. M. Edwardson (1997). "Endocytosis and recycling of G protein-
coupled receptors." Trends Pharmacol Sci 18(8): 276-287. 
Kolakowski, L. F., Jr. (1994). "GCRDb: a G-protein-coupled receptor database." 
Receptors Channels 2(1): 1-7. 
197 
 
Komori, N., S. D. Cain, et al. (1998). "Differential expression of alternative splice 
variants of beta-arrestin-1 and -2 in rat central nervous system and peripheral 
tissues." Eur J Neurosci 10(8): 2607-2616. 
Krasel, C., M. Bunemann, et al. (2005). "Beta-arrestin binding to the beta2-
adrenergic receptor requires both receptor phosphorylation and receptor 
activation." J Biol Chem 280(10): 9528-9535. 
Kristiansen, K. (2004). "Molecular mechanisms of ligand binding, signaling, and 
regulation within the superfamily of G-protein-coupled receptors: molecular 
modeling and mutagenesis approaches to receptor structure and function." 
Pharmacol Ther 103(1): 21-80. 
Krueger, K. M., Y. Daaka, et al. (1997). "The role of sequestration in G protein-
coupled receptor resensitization. Regulation of beta2-adrenergic receptor 
dephosphorylation by vesicular acidification." J Biol Chem 272(1): 5-8. 
Krupnick, J. G. and J. L. Benovic (1998). "The role of receptor kinases and 
arrestins in G protein-coupled receptor regulation." Annu Rev Pharmacol Toxicol 
38: 289-319. 
Kurrasch-Orbaugh, D. M., V. J. Watts, et al. (2003). "Serotonin 5-
hydroxytryptamine 2A receptor-coupled phospholipase C and phospholipase A2 
signaling pathways have different receptor reserves." J Pharmacol Exp Ther 
304(1): 229-237. 
198 
 
Lapetina, E. G. and R. H. Michell (1973). "A membrane-bound activity catalysing 
phosphatidylinositol breakdown to 1,2-diacylglycerol, D-myoinositol 1:2-cyclic 
phosphate an D-myoinositol 1-phosphate. Properties and subcellular distribution in 
rat cerebral cortex." Biochem J 131(3): 433-442. 
Le Jeune, I. R., M. Shepherd, et al. (2002). "Cyclic AMP-dependent transcriptional 
up-regulation of phosphodiesterase 4D5 in human airway smooth muscle cells. 
Identification and characterization of a novel PDE4D5 promoter." J Biol Chem 
277(39): 35980-35989. 
Liang, W., Q. Hoang, et al. (2008). "Accelerated dephosphorylation of the beta2-
adrenergic receptor by mutation of the C-terminal lysines: effects on ubiquitination, 
intracellular trafficking, and degradation." Biochemistry 47(45): 11750-11762. 
Lim, S., A. Jatakanon, et al. (2000). "Comparison of high dose inhaled steroids, low 
dose inhaled steroids plus low dose theophylline, and low dose inhaled steroids 
alone in chronic asthma in general practice." Thorax 55(10): 837-841. 
Lin, F. T., W. Chen, et al. (2002). "Phosphorylation of beta-arrestin2 regulates its 
function in internalization of beta(2)-adrenergic receptors." Biochemistry 41(34): 
10692-10699. 
Lin, F. T., K. M. Krueger, et al. (1997). "Clathrin-mediated endocytosis of the beta-
adrenergic receptor is regulated by phosphorylation/dephosphorylation of beta-
arrestin1." J Biol Chem 272(49): 31051-31057. 
199 
 
Liu, G., J. Shi, et al. (2004). "Assembly of a Ca2+-dependent BK channel signaling 
complex by binding to beta2 adrenergic receptor." EMBO J 23(11): 2196-2205. 
Lohse, M. J., S. Andexinger, et al. (1992). "Receptor-specific desensitization with 
purified proteins. Kinase dependence and receptor specificity of beta-arrestin and 
arrestin in the beta 2-adrenergic receptor and rhodopsin systems." J Biol Chem 
267(12): 8558-8564. 
Lohse, M. J., J. L. Benovic, et al. (1990). "Multiple pathways of rapid beta 2-
adrenergic receptor desensitization. Delineation with specific inhibitors." J Biol 
Chem 265(6): 3202-3211. 
Lohse, M. J., J. L. Benovic, et al. (1990). "beta-Arrestin: a protein that regulates 
beta-adrenergic receptor function." Science 248(4962): 1547-1550. 
Lohse, M. J., R. J. Lefkowitz, et al. (1989). "Inhibition of beta-adrenergic receptor 
kinase prevents rapid homologous desensitization of beta 2-adrenergic receptors." 
Proc Natl Acad Sci U S A 86(9): 3011-3015. 
Lombardi, D., B. Cuenoud, et al. (2009). "Lipid membrane interactions of 
indacaterol and salmeterol: do they influence their pharmacological properties?" 
Eur J Pharm Sci 38(5): 533-547. 
Loza, M. J. and R. B. Penn (2010). "Regulation of T cells in airway disease by 
beta-agonist." Front Biosci (Schol Ed) 2: 969-979. 
Luo, J., J. M. Busillo, et al. (2008). "M3 muscarinic acetylcholine receptor-mediated 
signaling is regulated by distinct mechanisms." Mol Pharmacol 74(2): 338-347. 
200 
 
Luttrell, L. M., S. S. Ferguson, et al. (1999). "Beta-arrestin-dependent formation of 
beta2 adrenergic receptor-Src protein kinase complexes." Science 283(5402): 655-
661. 
Luttrell, L. M. and T. P. Kenakin (2011). "Refining efficacy: allosterism and bias in g 
protein-coupled receptor signaling." Methods Mol Biol 756: 3-35. 
Luttrell, L. M., F. L. Roudabush, et al. (2001). "Activation and targeting of 
extracellular signal-regulated kinases by beta-arrestin scaffolds." Proc Natl Acad 
Sci U S A 98(5): 2449-2454. 
Markham, A. and B. Jarvis (2000). "Inhaled salmeterol/fluticasone propionate 
combination: a review of its use in persistent asthma." Drugs 60(5): 1207-1233. 
Maudsley, S., B. Martin, et al. (2005). "The origins of diversity and specificity in g 
protein-coupled receptor signaling." J Pharmacol Exp Ther 314(2): 485-494. 
McCrea, K. E. and S. J. Hill (1993). "Salmeterol, a long-acting beta 2-adrenoceptor 
agonist mediating cyclic AMP accumulation in a neuronal cell line." Br J Pharmacol 
110(2): 619-626. 
McCrea, K. E. and S. J. Hill (1996). "Comparison of duration of agonist action at 
beta 1- and beta 2- adrenoceptors in C6 glioma cells: evidence that the long 
duration of action of salmeterol is specific to the beta 2-adrenoceptor." Mol 
Pharmacol 49(5): 927-937. 
201 
 
McDonald, N. A., C. M. Henstridge, et al. (2007). "An essential role for constitutive 
endocytosis, but not activity, in the axonal targeting of the CB1 cannabinoid 
receptor." Mol Pharmacol 71(4): 976-984. 
McDonald, P. H., C. W. Chow, et al. (2000). "Beta-arrestin 2: a receptor-regulated 
MAPK scaffold for the activation of JNK3." Science 290(5496): 1574-1577. 
McKeage, K. and S. J. Keam (2009). "Salmeterol/fluticasone propionate: a review 
of its use in asthma." Drugs 69(13): 1799-1828. 
Mehats, C., S. L. Jin, et al. (2003). "PDE4D plays a critical role in the control of 
airway smooth muscle contraction." FASEB J 17(13): 1831-1841. 
Menard, L., S. S. Ferguson, et al. (1997). "Synergistic regulation of beta2-
adrenergic receptor sequestration: intracellular complement of beta-adrenergic 
receptor kinase and beta-arrestin determine kinetics of internalization." Mol 
Pharmacol 51(5): 800-808. 
Milano, S. K., Y. M. Kim, et al. (2006). "Nonvisual arrestin oligomerization and 
cellular localization are regulated by inositol hexakisphosphate binding." J Biol 
Chem 281(14): 9812-9823. 
Misior, A. M., D. A. Deshpande, et al. (2009). "Glucocorticoid- and protein kinase 
A-dependent transcriptome regulation in airway smooth muscle." Am J Respir Cell 
Mol Biol 41(1): 24-39. 
202 
 
Misior, A. M., H. Yan, et al. (2008). "Mitogenic effects of cytokines on smooth 
muscle are critically dependent on protein kinase A and are unmasked by steroids 
and cyclooxygenase inhibitors." Mol Pharmacol 73(2): 566-574. 
Mohammad, S., G. Baldini, et al. (2007). "Constitutive traffic of melanocortin-4 
receptor in Neuro2A cells and immortalized hypothalamic neurons." J Biol Chem 
282(7): 4963-4974. 
Moore, C. A., S. K. Milano, et al. (2007). "Regulation of receptor trafficking by 
GRKs and arrestins." Annu Rev Physiol 69: 451-482. 
Moore, R. H., E. E. Millman, et al. (2007). "Salmeterol stimulation dissociates 
beta2-adrenergic receptor phosphorylation and internalization." Am J Respir Cell 
Mol Biol 36(2): 254-261. 
Morrison, D. L., J. S. Sanghera, et al. (1996). "Phosphorylation and activation of 
smooth muscle myosin light chain kinase by MAP kinase and cyclin-dependent 
kinase-1." Biochem Cell Biol 74(4): 549-557. 
Morrison, K. J., R. H. Moore, et al. (1996). "Repetitive endocytosis and recycling of 
the beta 2-adrenergic receptor during agonist-induced steady state redistribution." 
Mol Pharmacol 50(3): 692-699. 
Mueller, H., H. J. Motulsky, et al. (1988). "The potency and kinetics of the beta-
adrenergic receptors on human neutrophils." Mol Pharmacol 34(3): 347-353. 
203 
 
Napoli, S. A., C. A. Gruetter, et al. (1980). "Relaxation of bovine coronary arterial 
smooth muscle by cyclic GMP, cyclic AMP and analogs." J Pharmacol Exp Ther 
212(3): 469-473. 
Nelson, C. D., S. J. Perry, et al. (2007). "Targeting of diacylglycerol degradation to 
M1 muscarinic receptors by beta-arrestins." Science 315(5812): 663-666. 
Nelson, H. S. (2001). "Advair: combination treatment with fluticasone 
propionate/salmeterol in the treatment of asthma." J Allergy Clin Immunol 107(2): 
398-416. 
Nelson, H. S., S. T. Weiss, et al. (2006). "The Salmeterol Multicenter Asthma 
Research Trial: a comparison of usual pharmacotherapy for asthma or usual 
pharmacotherapy plus salmeterol." Chest 129(1): 15-26. 
Nials, A. T., D. I. Ball, et al. (1994). "Formoterol on airway smooth muscle and 
human lung mast cells: a comparison with salbutamol and salmeterol." Eur J 
Pharmacol 251(2-3): 127-135. 
Nials, A. T., R. A. Coleman, et al. (1993). "Effects of beta-adrenoceptor agonists in 
human bronchial smooth muscle." Br J Pharmacol 110(3): 1112-1116. 
Nino, G., A. Hu, et al. (2009). "Mechanism regulating proasthmatic effects of 
prolonged homologous beta2-adrenergic receptor desensitization in airway smooth 
muscle." Am J Physiol Lung Cell Mol Physiol 297(4): L746-757. 
204 
 
Nobles, K. N., K. Xiao, et al. (2011). "Distinct Phosphorylation Sites on the {beta}2-
Adrenergic Receptor Establish a Barcode That Encodes Differential Functions of 
{beta}-Arrestin." Sci Signal 4(185): ra51. 
Oakley, R. H., S. A. Laporte, et al. (2000). "Differential affinities of visual arrestin, 
beta arrestin1, and beta arrestin2 for G protein-coupled receptors delineate two 
major classes of receptors." J Biol Chem 275(22): 17201-17210. 
Overington, J. P., B. Al-Lazikani, et al. (2006). "How many drug targets are there?" 
Nat Rev Drug Discov 5(12): 993-996. 
Palczewski, K. (1997). "GTP-binding-protein-coupled receptor kinases--two 
mechanistic models." Eur J Biochem 248(2): 261-269. 
Palczewski, K., T. Kumasaka, et al. (2000). "Crystal structure of rhodopsin: A G 
protein-coupled receptor." Science 289(5480): 739-745. 
Palmqvist, M., G. Persson, et al. (1997). "Inhaled dry-powder formoterol and 
salmeterol in asthmatic patients: onset of action, duration of effect and potency." 
Eur Respir J 10(11): 2484-2489. 
Pan, L., E. V. Gurevich, et al. (2003). "The nature of the arrestin x receptor 
complex determines the ultimate fate of the internalized receptor." J Biol Chem 
278(13): 11623-11632. 
Paterson, J. W., R. J. Evans, et al. (1971). "SElectivity of broncholidlator action of 
salbutamol in asthmatic patients." Br J Dis Chest 65(1): 21-38. 
205 
 
Penela, P., C. Ribas, et al. (2003). "Mechanisms of regulation of the expression 
and function of G protein-coupled receptor kinases." Cell Signal 15(11): 973-981. 
Perry, S. J., G. S. Baillie, et al. (2002). "Targeting of cyclic AMP degradation to 
beta 2-adrenergic receptors by beta-arrestins." Science 298(5594): 834-836. 
Pierce, K. L., L. M. Luttrell, et al. (2001). "New mechanisms in heptahelical receptor 
signaling to mitogen activated protein kinase cascades." Oncogene 20(13): 1532-
1539. 
Pierce, K. L., S. Maudsley, et al. (2000). "Role of endocytosis in the activation of 
the extracellular signal-regulated kinase cascade by sequestering and 
nonsequestering G protein-coupled receptors." Proc Natl Acad Sci U S A 97(4): 
1489-1494. 
Pippig, S., S. Andexinger, et al. (1995). "Sequestration and recycling of beta 2-
adrenergic receptors permit receptor resensitization." Mol Pharmacol 47(4): 666-
676. 
Pontier, S. M., Y. Percherancier, et al. (2008). "Cholesterol-dependent separation 
of the beta2-adrenergic receptor from its partners determines signaling efficacy: 
insight into nanoscale organization of signal transduction." J Biol Chem 283(36): 
24659-24672. 
Price, D. M., C. L. Chik, et al. (2004). "Mitogen-activated protein kinase 
phosphatase-1 (MKP-1): >100-fold nocturnal and norepinephrine-induced changes 
in the rat pineal gland." FEBS Lett 577(1-2): 220-226. 
206 
 
Prichard, B. N. and B. Tomlinson (1986). "The additional properties of beta 
adrenoceptor blocking drugs." J Cardiovasc Pharmacol 8 Suppl 4: S1-15. 
Qian, Y., E. Naline, et al. (1993). "Effects of rolipram and siguazodan on the human 
isolated bronchus and their interaction with isoprenaline and sodium nitroprusside." 
Br J Pharmacol 109(3): 774-778. 
Rabe, K. F. (2011). "Update on roflumilast, a phosphodiesterase 4 inhibitor for the 
treatment of chronic obstructive pulmonary disease." Br J Pharmacol 163(1): 53-
67. 
Rall, T. W. and E. W. Sutherland (1962). "Adenyl cyclase. II. The enzymatically 
catalyzed formation of adenosine 3',5'-phosphate and inorganic pyrophosphate 
from adenosine triphosphate." J Biol Chem 237: 1228-1232. 
Rasmussen, S. G., H. J. Choi, et al. (2007). "Crystal structure of the human beta2 
adrenergic G-protein-coupled receptor." Nature 450(7168): 383-387. 
Reiner, S., M. Ambrosio, et al. (2010). "Differential signaling of the endogenous 
agonists at the beta2-adrenergic receptor." J Biol Chem 285(46): 36188-36198. 
Reiter, E. and R. J. Lefkowitz (2006). "GRKs and beta-arrestins: roles in receptor 
silencing, trafficking and signaling." Trends Endocrinol Metab 17(4): 159-165. 
Rennard, S. I. (2004). "Treatment of stable chronic obstructive pulmonary disease." 
Lancet 364(9436): 791-802. 
Rhodes, D. G., R. Newton, et al. (1992). "Equilibrium and kinetic studies of the 
interactions of salmeterol with membrane bilayers." Mol Pharmacol 42(4): 596-602. 
207 
 
Rinard, G. A., A. R. Rubinfeld, et al. (1979). "Depressed cyclic AMP levels in 
airways smooth muscle from asthmatic dogs." Proc Natl Acad Sci U S A 76(3): 
1472-1476. 
Rong, Y., M. Arbabian, et al. (1999). "Probing the salmeterol binding site on the 
beta 2-adrenergic receptor using a novel photoaffinity ligand, 
[(125)I]iodoazidosalmeterol." Biochemistry 38(35): 11278-11286. 
Rosenbaum, D. M., V. Cherezov, et al. (2007). "GPCR engineering yields high-
resolution structural insights into beta2-adrenergic receptor function." Science 
318(5854): 1266-1273. 
Roth, N. S., P. T. Campbell, et al. (1991). "Comparative rates of desensitization of 
beta-adrenergic receptors by the beta-adrenergic receptor kinase and the cyclic 
AMP-dependent protein kinase." Proc Natl Acad Sci U S A 88(14): 6201-6204. 
Saucerman, J. J., L. L. Brunton, et al. (2003). "Modeling beta-adrenergic control of 
cardiac myocyte contractility in silico." J Biol Chem 278(48): 47997-48003. 
Scarselli, M. and J. G. Donaldson (2009). "Constitutive internalization of G protein-
coupled receptors and G proteins via clathrin-independent endocytosis." J Biol 
Chem 284(6): 3577-3585. 
Schramm, C. M., S. T. Chuang, et al. (1995). "cAMP generation inhibits inositol 
1,4,5-trisphosphate binding in rabbit tracheal smooth muscle." Am J Physiol 269(5 
Pt 1): L715-719. 
208 
 
Schutter, E. d. (2001). Computational neuroscience : realistic modeling for 
experimentalists. Boca Raton, Fla., CRC Press. 
Sears, M. R. (2002). "Adverse effects of beta-agonists." J Allergy Clin Immunol 
110(6 Suppl): S322-328. 
Seibold, A., B. G. January, et al. (1998). "Desensitization of beta2-adrenergic 
receptors with mutations of the proposed G protein-coupled receptor kinase 
phosphorylation sites." J Biol Chem 273(13): 7637-7642. 
Seibold, A., B. Williams, et al. (2000). "Localization of the sites mediating 
desensitization of the beta(2)-adrenergic receptor by the GRK pathway." Mol 
Pharmacol 58(5): 1162-1173. 
Shenoy, S. K., M. T. Drake, et al. (2006). "beta-arrestin-dependent, G protein-
independent ERK1/2 activation by the beta2 adrenergic receptor." J Biol Chem 
281(2): 1261-1273. 
Shenoy, S. K., P. H. McDonald, et al. (2001). "Regulation of receptor fate by 
ubiquitination of activated beta 2-adrenergic receptor and beta-arrestin." Science 
294(5545): 1307-1313. 
Sher, E. and F. Clementi (1985). "Correlation between agonist potency, 
desensitization and internalization of beta adrenergic receptors in a muscle cell 
line." Pharmacol Res Commun 17(12): 1095-1108. 
Sibley, D. R., J. L. Benovic, et al. (1987). "Regulation of transmembrane signaling 
by receptor phosphorylation." Cell 48(6): 913-922. 
209 
 
Sibley, D. R., R. H. Strasser, et al. (1986). "Phosphorylation/dephosphorylation of 
the beta-adrenergic receptor regulates its functional coupling to adenylate cyclase 
and subcellular distribution." Proc Natl Acad Sci U S A 83(24): 9408-9412. 
Sitkauskiene, B. and R. Sakalauskas (2005). "The role of beta(2)-adrenergic 
receptors in inflammation and allergy." Curr Drug Targets Inflamm Allergy 4(2): 
157-162. 
Sneddon, W. B., C. E. Magyar, et al. (2004). "Ligand-selective dissociation of 
activation and internalization of the parathyroid hormone (PTH) receptor: 
conditional efficacy of PTH peptide fragments." Endocrinology 145(6): 2815-2823. 
Soderling, S. H. and J. A. Beavo (2000). "Regulation of cAMP and cGMP signaling: 
new phosphodiesterases and new functions." Curr Opin Cell Biol 12(2): 174-179. 
Song, X., S. Coffa, et al. (2009). "How does arrestin assemble MAPKs into a 
signaling complex?" J Biol Chem 284(1): 685-695. 
Spencer, C. M. and B. Jarvis (1999). "Salmeterol/fluticasone propionate 
combination." Drugs 57(6): 933-940; discussion 941-933. 
Spina, D. (2008). "PDE4 inhibitors: current status." Br J Pharmacol 155(3): 308-
315. 
Stadel, J. M., P. Nambi, et al. (1983). "Catecholamine-induced desensitization of 
turkey erythrocyte adenylate cyclase is associated with phosphorylation of the 
beta-adrenergic receptor." Proc Natl Acad Sci U S A 80(11): 3173-3177. 
210 
 
Stjarne, L. (2000). "Do sympathetic nerves release noradrenaline in "quanta"?" J 
Auton Nerv Syst 81(1-3): 236-243. 
Sullivan, P., S. Bekir, et al. (1994). "Anti-inflammatory effects of low-dose oral 
theophylline in atopic asthma." Lancet 343(8904): 1006-1008. 
Sutherland, E. W., T. W. Rall, et al. (1962). "Adenyl cylase. I. Distribution, 
preparation, and properties." J Biol Chem 237: 1220-1227. 
Sutherland, E. W. and G. A. Robison (1966). "The role of cyclic-3',5'-AMP in 
responses to catecholamines and other hormones." Pharmacol Rev 18(1): 145-
161. 
Szczuka, A., M. Wennerberg, et al. (2009). "Molecular mechanisms for the 
persistent bronchodilatory effect of the beta 2-adrenoceptor agonist salmeterol." Br 
J Pharmacol 158(1): 183-194. 
Tang, W. J. and A. G. Gilman (1991). "Type-specific regulation of adenylyl cyclase 
by G protein beta gamma subunits." Science 254(5037): 1500-1503. 
Tian, L., L. S. Coghill, et al. (2004). "Distinct stoichiometry of BKCa channel 
tetramer phosphorylation specifies channel activation and inhibition by cAMP-
dependent protein kinase." Proc Natl Acad Sci U S A 101(32): 11897-11902. 
Tohgo, A., K. L. Pierce, et al. (2002). "beta-Arrestin scaffolding of the ERK cascade 
enhances cytosolic ERK activity but inhibits ERK-mediated transcription following 
angiotensin AT1a receptor stimulation." J Biol Chem 277(11): 9429-9436. 
211 
 
Tolkovsky, A. M. and A. Levitzki (1981). "Theories and predictions of models 
describing sequential interactions between the receptor, the GTP regulatory unit, 
and the catalytic unit of hormone dependent adenylate cyclases." J Cyclic 
Nucleotide Res 7(3): 139-150. 
Torphy, T. J., W. B. Freese, et al. (1982). "Cyclic nucleotide-dependent protein 
kinases in airway smooth muscle." J Biol Chem 257(19): 11609-11616. 
Torphy, T. J., B. J. Undem, et al. (1993). "Identification, characterization and 
functional role of phosphodiesterase isozymes in human airway smooth muscle." J 
Pharmacol Exp Ther 265(3): 1213-1223. 
Torphy, T. J., H. L. Zhou, et al. (1991). "Role of cyclic nucleotide 
phosphodiesterase isozymes in intact canine trachealis." Mol Pharmacol 39(3): 
376-384. 
Touretzky, D. S. (1989). Advances in neural information processing systems. San 
Mateo, CA, Morgan Kaufmann Publishers: v. 
Tran, T. M., J. Friedman, et al. (2007). "Characterization of beta2-adrenergic 
receptor dephosphorylation: Comparison with the rate of resensitization." Mol 
Pharmacol 71(1): 47-60. 
Tran, T. M., J. Friedman, et al. (2004). "Characterization of agonist stimulation of 
cAMP-dependent protein kinase and G protein-coupled receptor kinase 
phosphorylation of the beta2-adrenergic receptor using phosphoserine-specific 
antibodies." Mol Pharmacol 65(1): 196-206. 
212 
 
Tran, T. M., R. Jorgensen, et al. (2007). "Phosphorylation of the beta2-adrenergic 
receptor in plasma membranes by intrinsic GRK5." Biochemistry 46(50): 14438-
14449. 
Trendelenburg, A. U., E. G. Gaiser, et al. (1999). "Mouse postganglionic 
sympathetic neurons: primary culturing and noradrenaline release." J Neurochem 
73(4): 1431-1438. 
Trester-Zedlitz, M., A. Burlingame, et al. (2005). "Mass spectrometric analysis of 
agonist effects on posttranslational modifications of the beta-2 adrenoceptor in 
mammalian cells." Biochemistry 44(16): 6133-6143. 
Vallabhajosyula, R. R., V. Chickarmane, et al. (2006). "Conservation analysis of 
large biochemical networks." Bioinformatics 22(3): 346-353. 
Van Metre, T. E., Jr. (1969). "Adverse effects of inhalation of excessive amounts of 
nebulized isoproterenol in status asthmaticus." J Allergy 43(2): 101-113. 
Vaughan, D. J., E. E. Millman, et al. (2006). "Role of the G protein-coupled receptor 
kinase site serine cluster in beta2-adrenergic receptor internalization, 
desensitization, and beta-arrestin translocation." J Biol Chem 281(11): 7684-7692. 
Vayttaden, S. J. and U. S. Bhalla (2004). "Developing complex signaling models 
using GENESIS/Kinetikit." Sci STKE 2004(219): pl4. 
Vayttaden, S. J., J. Friedman, et al. (2010). "Quantitative modeling of GRK-
mediated beta2AR regulation." PLoS Comput Biol 6(1): e1000647. 
213 
 
Violin, J. D., L. M. DiPilato, et al. (2008). "beta2-adrenergic receptor signaling and 
desensitization elucidated by quantitative modeling of real time cAMP dynamics." J 
Biol Chem 283(5): 2949-2961. 
Violin, J. D. and R. J. Lefkowitz (2007). "Beta-arrestin-biased ligands at seven-
transmembrane receptors." Trends Pharmacol Sci 28(8): 416-422. 
Violin, J. D., X. R. Ren, et al. (2006). "G-protein-coupled receptor kinase specificity 
for beta-arrestin recruitment to the beta2-adrenergic receptor revealed by 
fluorescence resonance energy transfer." J Biol Chem 281(29): 20577-20588. 
Vishnivetskiy, S. A., J. A. Hirsch, et al. (2002). "Transition of arrestin into the active 
receptor-binding state requires an extended interdomain hinge." J Biol Chem 
277(46): 43961-43967. 
Vishnivetskiy, S. A., C. L. Paz, et al. (1999). "How does arrestin respond to the 
phosphorylated state of rhodopsin?" J Biol Chem 274(17): 11451-11454. 
Vishnivetskiy, S. A., C. Schubert, et al. (2000). "An additional phosphate-binding 
element in arrestin molecule. Implications for the mechanism of arrestin activation." 
J Biol Chem 275(52): 41049-41057. 
Vroling, B., M. Sanders, et al. (2011). "GPCRDB: information system for G protein-
coupled receptors." Nucleic Acids Res 39(Database issue): D309-319. 
Waage, P. (1864). ""Experiments for Determining the Affinity Law"." Forhandlinger i 
Videnskabs-Selskabet i Christiania. 
214 
 
Waage, P. and C. M. Guldberg (1864). ""Studies Concerning Affinity"." 
Forhandlinger: Videnskabs-Selskabet i Christiana  
Waage, P. and C. M. Guldberg. (2000 (Translation)). "Studies Concerning Affinity." 
2011, from http://chimie.scola.ac-
paris.fr/sitedechimie/hist_chi/text_origin/guldberg_waage/Concerning-Affinity.htm. 
Wei, H., S. Ahn, et al. (2004). "Stable interaction between beta-arrestin 2 and 
angiotensin type 1A receptor is required for beta-arrestin 2-mediated activation of 
extracellular signal-regulated kinases 1 and 2." J Biol Chem 279(46): 48255-48261. 
Wei, H., S. Ahn, et al. (2003). "Independent beta-arrestin 2 and G protein-mediated 
pathways for angiotensin II activation of extracellular signal-regulated kinases 1 
and 2." Proc Natl Acad Sci U S A 100(19): 10782-10787. 
Weinberger, M. and L. Hendeles (1996). "Theophylline in asthma." N Engl J Med 
334(21): 1380-1388. 
Whaley, B. S., N. Yuan, et al. (1994). "Differential expression of the beta-
adrenergic receptor modifies agonist stimulation of adenylyl cyclase: a quantitative 
evaluation." Mol Pharmacol 45(3): 481-489. 
Whistler, J. L. and M. von Zastrow (1998). "Morphine-activated opioid receptors 
elude desensitization by beta-arrestin." Proc Natl Acad Sci U S A 95(17): 9914-
9919. 
215 
 
Williams, B. R., R. Barber, et al. (2000). "Kinetic analysis of agonist-induced down-
regulation of the beta(2)-adrenergic receptor in BEAS-2B cells reveals high- and 
low-affinity components." Mol Pharmacol 58(2): 421-430. 
Wisler, J. W., S. M. DeWire, et al. (2007). "A unique mechanism of beta-blocker 
action: carvedilol stimulates beta-arrestin signaling." Proc Natl Acad Sci U S A 
104(42): 16657-16662. 
Witherow, D. S., T. R. Garrison, et al. (2004). "beta-Arrestin inhibits NF-kappaB 
activity by means of its interaction with the NF-kappaB inhibitor IkappaBalpha." 
Proc Natl Acad Sci U S A 101(23): 8603-8607. 
Wong, S. K. and C. K. Buckner (1978). "Studies on beta-adrenoceptors mediating 
changes in mechanical events and adenosine 3',5'-monophosphate levels. Guinea-
pig trachea." Eur J Pharmacol 47(3): 273-280. 
Woo, A. Y., T. B. Wang, et al. (2009). "Stereochemistry of an agonist determines 
coupling preference of beta2-adrenoceptor to different G proteins in 
cardiomyocytes." Mol Pharmacol 75(1): 158-165. 
Wooldridge, A. A., J. A. MacDonald, et al. (2004). "Smooth muscle phosphatase is 
regulated in vivo by exclusion of phosphorylation of threonine 696 of MYPT1 by 
phosphorylation of Serine 695 in response to cyclic nucleotides." J Biol Chem 
279(33): 34496-34504. 
Xin, W., T. M. Tran, et al. (2008). "Roles of GRK and PDE4 activities in the 
regulation of beta2 adrenergic signaling." J Gen Physiol 131(4): 349-364. 
216 
 
Xu, T. R., G. S. Baillie, et al. (2008). "Mutations of beta-arrestin 2 that limit self-
association also interfere with interactions with the beta2-adrenoceptor and the 
ERK1/2 MAPKs: implications for beta2-adrenoceptor signalling via the ERK1/2 
MAPKs." Biochem J 413(1): 51-60. 
Yan, H., D. A. Deshpande, et al. (2011). "Anti-mitogenic effects of beta-agonists 
and PGE2 on airway smooth muscle are PKA dependent." FASEB J 25(1): 389-
397. 
Yu, S. S., R. J. Lefkowitz, et al. (1993). "Beta-adrenergic receptor sequestration. A 
potential mechanism of receptor resensitization." J Biol Chem 268(1): 337-341. 
Yuan, N., J. Friedman, et al. (1994). "cAMP-dependent protein kinase and protein 
kinase C consensus site mutations of the beta-adrenergic receptor. Effect on 
desensitization and stimulation of adenylylcyclase." J Biol Chem 269(37): 23032-
23038. 
Zhang, J., L. S. Barak, et al. (1997). "A central role for beta-arrestins and clathrin-
coated vesicle-mediated endocytosis in beta2-adrenergic receptor resensitization. 
Differential regulation of receptor resensitization in two distinct cell types." J Biol 
Chem 272(43): 27005-27014. 
Zhou, H. L., S. J. Newsholme, et al. (1992). "Agonist-related differences in the 
relationship between cAMP content and protein kinase activity in canine 
trachealis." J Pharmacol Exp Ther 261(3): 1260-1267. 
217 
 
Zhou, X. B., C. Arntz, et al. (2001). "A molecular switch for specific stimulation of 
the BKCa channel by cGMP and cAMP kinase." J Biol Chem 276(46): 43239-
43245. 
 
 
  
218 
 
Vita 
 
Sharat received his Bachelor of Science in 1999 from the University of Mangalore, 
India and his Master of Science in 2001 from Kerala University, India.  He joined the 
Graduate School of Biomedical Sciences at the University of Texas Health Science 
Center at Houston in the Fall of 2005. Sharat joined the Cell and Regulatory Biology 
program and will graduate with his Doctorate of Philosophy in December of 2011. 
 
 
